Any feedback?
Information on EC 2.7.12.2 - mitogen-activated protein kinase kinase
for references in articles please use BRENDA:EC2.7.12.2Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
EC Tree
2.7.12.2 mitogen-activated protein kinase kinaseIUBMB Comments
This enzyme is a dual-specific protein kinase and requires mitogen-activated protein kinase kinase kinase (MAPKKK) for activation. It is required for activation of EC 2.7.11.24, mitogen-activated protein kinase. Phosphorylation of MEK1 by Raf involves phosphorylation of two serine residues . Mitogen-activated protein kinase (MAPK) signal transduction pathways are among the most widespread mechanisms of cellular regulation. Mammalian MAPK pathways can be recruited by a wide variety of stimuli including hormones (e.g. insulin and growth hormone), mitogens (e.g. epidermal growth factor and platelet-derived growth factor), vasoactive peptides (e.g. angiotensin-II and endothelin), inflammatory cytokines of the tumour necrosis factor (TNF) family and environmental stresses such as osmotic shock, ionizing radiation and ischaemic injury.
Specify your search results
Word Map
- 2.7.12.2
- mapks
- c-jun
- 3-kinase
- endothelial
- phosphatidylinositol
- mek1
- pkc
- necrosis
- agonist
- melanoma
- metastasis
- camp
- sirnas
- egf
- raf-1
- bcl-2
- cyclins
- c-fos
-
dominant-negative
- erk2
- rapamycin
-
stress-activated
-
phorbol
- wortmannin
- caspase-3
- nf-kappab
- phosphoinositide
- mtor
- trametinib
- creb
-
kinase-dependent
-
platelet-derived
- pertussis
-
mek-erk
-
brafv600e
-
ras-mediated
-
p21ras
- agriculture
- p38alpha
- elk-1
-
ras-induced
-
dual-specificity
-
extracellular-regulated
-
signal-related
-
p90rsk
-
ras-dependent
- drug development
- rsk
- medicine
- analysis
-
braf-mutant
-
egf-induced
- phospho-erk
-
erk-dependent
The expected taxonomic range for this enzyme is: Eukaryota, Bacteria, Archaea
Reaction Schemes
+
a [protein]-(L-serine/L-threonine)
=
+
a [protein]-(L-serine/L-threonine) phosphate
Synonyms
mek/erk, mitogen-activated protein kinase kinase, map kinase kinase, mapkk, mek-1, extracellular-signal-regulated kinase, mapk/erk kinase, map2k4, erk 1, mitogen-activated protein kinase kinase 1, 
more
topPlease wait a moment until the data is sorted. This message will disappear when the data is sorted.
SYNONYM 
ORGANISM
UNIPROT
COMMENTARY 
LITERATURE
dual specificity mitogen-activated protein kinase kinase 4
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SYSTEMATIC NAME
IUBMB Comments
ATP:protein phosphotransferase (MAPKKK-activated)
This enzyme is a dual-specific protein kinase and requires mitogen-activated protein kinase kinase kinase (MAPKKK) for activation. It is required for activation of EC 2.7.11.24, mitogen-activated protein kinase. Phosphorylation of MEK1 by Raf involves phosphorylation of two serine residues [5]. Mitogen-activated protein kinase (MAPK) signal transduction pathways are among the most widespread mechanisms of cellular regulation. Mammalian MAPK pathways can be recruited by a wide variety of stimuli including hormones (e.g. insulin and growth hormone), mitogens (e.g. epidermal growth factor and platelet-derived growth factor), vasoactive peptides (e.g. angiotensin-II and endothelin), inflammatory cytokines of the tumour necrosis factor (TNF) family and environmental stresses such as osmotic shock, ionizing radiation and ischaemic injury.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
CAS REGISTRY NUMBER
COMMENTARY
142805-58-1
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SUBSTRATE
PRODUCT
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate)
(Substrate)
LITERATURE
(Substrate)
(Substrate)
COMMENTARY
(Product)
(Product)
LITERATURE
(Product)
(Product)
Reversibility
r=reversible
ir=irreversible
?=not specified
r=reversible
ir=irreversible
?=not specified
ATP + JNK
ADP + phospho-JNK
the enzyme is involved in stress-activated MAP kinase pathways, tumorigenesis, and cancer, physiologic effects, overview
-
-
?
ATP + JNK
ADP + phospho-JNK
substrate of MKK4 and MKK7 in a synergistic manner
-
-
?
ATP + p38
ADP + phospho-p38
the enzyme is involved in stress-activated MAP kinase pathways, tumorigenesis, and cancer, physiologic effects, overview
-
-
?
ATP + protein
ADP + phosphoprotein
enzyme is involved in independent human MAP-kinase signal transduction pathway
-
-
?
ATP + protein
ADP + phosphoprotein
MKK4 may participate in a tumor suppressive signaling pathway distinct from DPC4, p16, p53, and BRCA2. The enzyme is a component of a stress and cytokine-induced signal transduction pathway involving MAPK proteins, additional role for MKK4 in tumor suppression
-
-
?
additional information
?
-
-
pro-oncogenic role of mitogen-activated protein kinase kinase 4 in cancer, overview
-
-
?
additional information
?
-
pro-oncogenic role of mitogen-activated protein kinase kinase 4 in cancer, overview
-
-
?
additional information
?
-
pro-oncogenic role of mitogen-activated protein kinase kinase 4 in cancer, overview
-
-
?
additional information
?
-
-
substrate binding via the D-domain of the MKK
-
-
?
additional information
?
-
substrate binding via the D-domain of the MKK
-
-
?
additional information
?
-
substrate binding via the D-domain of the MKK
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
NATURAL SUBSTRATE
NATURAL PRODUCT
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate)
(Substrate)
LITERATURE
(Substrate)
(Substrate)
COMMENTARY
(Product)
(Product)
LITERATURE
(Product)
(Product)
REVERSIBILITY
r=reversible
ir=irreversible
?=not specified
r=reversible
ir=irreversible
?=not specified
ATP + JNK
ADP + phospho-JNK
the enzyme is involved in stress-activated MAP kinase pathways, tumorigenesis, and cancer, physiologic effects, overview
-
-
?
ATP + p38
ADP + phospho-p38
the enzyme is involved in stress-activated MAP kinase pathways, tumorigenesis, and cancer, physiologic effects, overview
-
-
?
ATP + protein
ADP + phosphoprotein
enzyme is involved in independent human MAP-kinase signal transduction pathway
-
-
?
ATP + protein
ADP + phosphoprotein
MKK4 may participate in a tumor suppressive signaling pathway distinct from DPC4, p16, p53, and BRCA2. The enzyme is a component of a stress and cytokine-induced signal transduction pathway involving MAPK proteins, additional role for MKK4 in tumor suppression
-
-
?
additional information
?
-
-
pro-oncogenic role of mitogen-activated protein kinase kinase 4 in cancer, overview
-
-
?
additional information
?
-
pro-oncogenic role of mitogen-activated protein kinase kinase 4 in cancer, overview
-
-
?
additional information
?
-
pro-oncogenic role of mitogen-activated protein kinase kinase 4 in cancer, overview
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
COFACTOR
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
ATP
upon ATP-binding, the transient conformation adopted the configuration of typical kinase folding. In the absence of ATP-binding, the transient state of apo npMAP2K4 may shift to a state of aggregation via non-particular hydrophobic interactions as a result of the exposed hydrophobic residues
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
METALS and IONS
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
Mg2+
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
ZINC00142380
i.e. 1-methyl-1H-indole-2-carboxylic acid, inhibitor obtained from virtual screening
ZINC00167997
i.e. 2-[(2-carboxyethyl)amino]benzoic acid, inhibitor obtained from virtual screening
ZINC00388545
i.e. 2,6-dihydroxybenzoic acid, inhibitor obtained from virtual screening
ZINC00389778
i.e. 2,4,6-trihydroxybenzoic acid, inhibitor obtained from virtual screening
ZINC00391412
i.e. 2,6-dihydroxy-4-methylbenzoic acid, inhibitor obtained from virtual screening
ZINC01641166
i.e. 2,4,5-trihydroxybenzoic acid, inhibitor obtained from virtual screening
ZINC02349698
i.e. 7-chloro-1H-indole-2-carboxylic acid, inhibitor obtained from virtual screening
ZINC06091752
i.e. 2,3,6-trihydroxybenzoic acid, inhibitor obtained from virtual screening
ZINC13526482
i.e. 2,5-dihydroxy-4-methylbenzoic acid, inhibitor obtained from virtual screening
ZINC14817730
i.e. (2,4,6-trihydroxyphenyl)acetic acid, inhibitor obtained from virtual screening
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
ACTIVATING COMPOUND
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
additional information
-
MKKs are activated by phopshorylation through MKKKs, activation mechanism of MKK4 involving MEKK1, overview
-
additional information
MKKs are activated by phopshorylation through MKKKs, activation mechanism of MKK4 involving MEKK1, overview
-
additional information
MKKs are activated by phopshorylation through MKKKs, activation mechanism of MKK4 involving MEKK1, overview
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Achondroplasia
C-type natriuretic Peptide plasma levels are elevated in subjects with achondroplasia, hypochondroplasia, and thanatophoric dysplasia.
Acidosis
Acidosis Promotes Bcl-2 Family-mediated Evasion of Apoptosis: INVOLVEMENT OF ACID-SENSING G PROTEIN-COUPLED RECEPTOR GPR65 SIGNALING TO MEK/ERK.
Acneiform Eruptions
A retrospective chart review on oral retinoids as a treatment for epidermal growth factor receptor inhibitor- and mitogen-activated protein kinase kinase inhibitor-induced acneiform eruptions.
Acute Kidney Injury
MEK inhibitor, U0126, attenuates cisplatin-induced renal injury by decreasing inflammation and apoptosis.
Acute Lung Injury
Discovery of pan-ErbB inhibitors protecting from SARS-CoV-2 replication, inflammation, and lung injury by a drug repurposing screen.
Acute Lung Injury
Protective effects of luteolin against lipopolysaccharide-induced acute lung injury involves inhibition of MEK/ERK and PI3K/Akt pathways in neutrophils.
Adenocarcinoma
A chemical genomics-aggrephagy integrated method studying functional analysis of autophagy inducers.
Adenocarcinoma
A subset of metastatic pancreatic ductal adenocarcinomas depends quantitatively on oncogenic Kras/Mek/Erk-induced hyperactive mTOR signalling.
Adenocarcinoma
BKCa participates in E2 inducing endometrial adenocarcinoma by activating MEK/ERK pathway.
Adenocarcinoma
Claudin-4, mitogen-activated protein kinase kinase 4, and stratifin are markers of gastric adenocarcinoma precursor lesions.
Adenocarcinoma
Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling.
Adenocarcinoma
Effects of 3-Tetrazolyl Methyl-3-Hydroxy-Oxindole Hybrid (THOH) on Cell Proliferation, Apoptosis, and G2/M Cell Cycle Arrest Occurs by Targeting Platelet-Derived Growth Factor D (PDGF-D) and the MEK/ERK Signaling Pathway in Human Lung Cell Lines SK-LU-1, A549, and A-427.
Adenocarcinoma
Expression of EGFR, HER2, Phosphorylated ERK and Phosphorylated MEK in Colonic Neoplasms of Familial Adenomatous Polyposis Patients.
Adenocarcinoma
Extracellular regulated kinase (ERK)-dependent regulation of sialomucin complex/rat Muc4 in mammary epithelial cells.
Adenocarcinoma
HAVCR1 Affects the MEK/ERK Pathway in Gastric Adenocarcinomas and Influences Tumor Progression and Patient Outcome.
Adenocarcinoma
Mammary Precancerous Stem and Non-Stem Cells Evolve into Cancers of Distinct Subtypes.
Adenocarcinoma of Lung
Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium.
Adenocarcinoma of Lung
Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer.
Adenocarcinoma of Lung
Dioscin overcome TKI resistance in EGFR-mutated lung adenocarcinoma cells via down-regulation of tyrosine phosphatase SHP2 expression.
Adenocarcinoma of Lung
Downregulation of estrogen receptor ? inhibits lung adenocarcinoma cell growth.
Adenocarcinoma of Lung
Hit identification of SMYD3 enzyme inhibitors using structure-based pharmacophore modeling.
Adenocarcinoma of Lung
Hypoxic tumor-derived exosomal miR-31-5p promotes lung adenocarcinoma metastasis by negatively regulating SATB2-reversed EMT and activating MEK/ERK signaling.
Adenocarcinoma of Lung
KCNN4 promotes the progression of lung adenocarcinoma by activating the AKT and ERK signaling pathways.
Adenocarcinoma of Lung
Luteolin exerts pro-apoptotic effect and anti-migration effects on A549 lung adenocarcinoma cells through the activation of MEK/ERK signaling pathway.
Adenocarcinoma of Lung
Map2k4 functions as a tumor suppressor in lung adenocarcinoma and inhibits tumor cell invasion by decreasing peroxisome proliferator-activated receptor ?2 expression.
Adenocarcinoma of Lung
Olean-28,13b-olide 2 plays a role in cisplatin-mediated apoptosis and reverses cisplatin resistance in human lung cancer through multiple signaling pathways.
Adenoma
Antitumor activity of the MEK inhibitor trametinib on intestinal polyp formation in Apc(?716) mice involves stromal COX-2.
Adenoma
Expression of EGFR, HER2, Phosphorylated ERK and Phosphorylated MEK in Colonic Neoplasms of Familial Adenomatous Polyposis Patients.
Adenoma
Lipopolysaccharides Enhance Epithelial Hyperplasia and Tubular Adenoma in Intestine-Specific Expression of krasV12 in Transgenic Zebrafish.
Adenoma
STRAP is a Critical Mediator of APC Mutation-Induced Intestinal Tumorigenesis through a Feed-Forward Mechanism.
Adenoma
Whole-exome sequencing identified mutational profiles of high-grade colon adenomas.
Adenomatous Polyposis Coli
Antitumor activity of the MEK inhibitor trametinib on intestinal polyp formation in Apc(?716) mice involves stromal COX-2.
Adenomatous Polyposis Coli
Hotspot Mutations Detectable by Next-generation Sequencing in Exhaled Breath Condensates from Patients with Lung Cancer.
Albuminuria
Inhibition of the ERK1/2-mTORC1 axis ameliorates proteinuria and the fibrogenic action of transforming growth factor-? in Adriamycin-induced glomerulosclerosis.
Alzheimer Disease
An early dysregulation of FAK and MEK/ERK signaling pathways precedes the ?-amyloid deposition in the olfactory bulb of APP/PS1 mouse model of Alzheimer's disease.
Alzheimer Disease
Increased expression and subcellular translocation of the mitogen activated protein kinase kinase and mitogen-activated protein kinase in Alzheimer's disease.
Anthrax
Anthrax lethal factor causes proteolytic inactivation of mitogen-activated protein kinase kinase.
Anthrax
Anthrax Lethal Toxin Increases Superoxide Production in Murine Neutrophils via Differential Effects on MAPK Signaling Pathways.
Anthrax
Apoptosis and melanogenesis in human melanoma cells induced by anthrax lethal factor inactivation of mitogen-activated protein kinase kinase.
Anthrax
Chemical genetic screening identifies critical pathways in anthrax lethal toxin-induced pathogenesis.
Anthrax
Cross-Reactivity of Anthrax and C2 Toxin: Protective Antigen Promotes the Uptake of Botulinum C2I Toxin into Human Endothelial Cells.
Anthrax
Detection and quantification of anthrax lethal factor in serum by mass spectrometry.
Anthrax
Highly predictive support vector machine (SVM) models for anthrax toxin lethal factor (LF) inhibitors.
Anthrax
Identification of exosite-targeting inhibitors of anthrax lethal factor by high-throughput screening.
Anthrax
Mitochondrial Impairment is a Critical Event in Anthrax Lethal Toxin-Induced Cytolysis of Murine Macrophages.
Anthrax
Susceptibility of mitogen-activated protein kinase kinase family members to proteolysis by anthrax lethal factor.
Arrhythmias, Cardiac
Antiarrhythmogenic effect of reconstituted high-density lipoprotein against ischemia/reperfusion in rats.
Arthritis
High-resolution structure discloses the potential for allosteric regulation of mitogen-activated protein kinase kinase 7.
Arthritis
MEK/ERK pathway inhibitors as a treatment for inflammatory arthritis might result in the development of lupus: comment on the article by Thiel et al.
Arthritis
Mitogen-activated protein kinase kinase 3 is a pivotal pathway regulating p38 activation in inflammatory arthritis.
Arthritis
Murine Lyme arthritis development mediated by p38 mitogen-activated protein kinase activity.
Arthritis
Regulation of inflammatory arthritis by the upstream kinase mitogen activated protein kinase kinase 7 in the c-Jun N-Terminal kinase pathway.
Arthritis
Role of MAPK kinase 6 in arthritis: distinct mechanism of action in inflammation and cytokine expression.
Arthritis, Experimental
Central role of the MEK/ERK MAP kinase pathway in a mouse model of rheumatoid arthritis: potential proinflammatory mechanisms.
Arthritis, Rheumatoid
Central role of the MEK/ERK MAP kinase pathway in a mouse model of rheumatoid arthritis: potential proinflammatory mechanisms.
Arthritis, Rheumatoid
Egr-1 inhibits the expression of extracellular matrix genes in chondrocytes by TNFalpha-induced MEK/ERK signalling.
Arthritis, Rheumatoid
Gene-gene interaction and RNA splicing profiles of MAP2K4 gene in rheumatoid arthritis.
Arthritis, Rheumatoid
Regulation of c-Jun N-terminal kinase by MEKK-2 and mitogen-activated protein kinase kinase kinases in rheumatoid arthritis.
Ascorbic Acid Deficiency
Dietary vitamin C deficiency depresses the growth, head kidney and spleen immunity and structural integrity by regulating NF-?B, TOR, Nrf2, apoptosis and MLCK signaling in young grass carp (Ctenopharyngodon idella).
Asthma
Anti-inflammatory effects of mitogen-activated protein kinase kinase inhibitor U0126 in an asthma mouse model.
Asthma
Rhinovirus-induced MMP-9 expression is dependent on Fra-1, which is modulated by formoterol and dexamethasone.
Asthma
Role of miR-27a in the regulation of cellular function via the inhibition of MAP2K4 in patients with asthma.
Astrocytoma
Fragile X mental retardation protein promotes astrocytoma proliferation via the MEK/ERK signaling pathway.
Astrocytoma
Phosphatidylinositol 3'-kinase and MAPK/ERK kinase 1/2 differentially regulate expression of vascular endothelial growth factor in human malignant astrocytoma cells.
Atherosclerosis
Identification of 4-hydroxy-2-nonenal-histidine adducts that serve as ligands for human lectin-like oxidized LDL receptor-1.
Atherosclerosis
Inhibition of ERK1/2 and activation of LXR synergistically reduce atherosclerotic lesions in ApoE-deficient mice.
Bacterial Infections
A non-redundant role for Drosophila Mkk4 and hemipterous/Mkk7 in TAK1-mediated activation of JNK.
Bacterial Infections
Anthrax toxin component, Protective Antigen, protects insects from bacterial infections.
Bone Diseases, Metabolic
Identification of Differential Genes Expression Profiles and Pathways of Bone Marrow Mesenchymal Stem Cells of Adolescent Idiopathic Scoliosis Patients by Microarray and Integrated Gene Network Analysis.
Bone Resorption
Calcium-containing crystals enhance receptor activator of nuclear factor ?B ligand/macrophage colony-stimulating factor-mediated osteoclastogenesis via extracellular-signal-regulated kinase and p38 pathways.
Brain Injuries
Enhanced expressions of microvascular smooth muscle receptors after focal cerebral ischemia occur via the MAPK MEK/ERK pathway.
Brain Injuries
Intravenous administration of MEK inhibitor U0126 affords brain protection against forebrain ischemia and focal cerebral ischemia.
Brain Injuries, Traumatic
Activation of Sphingosine 1-Phosphate Receptor 1 Enhances Hippocampus Neurogenesis in a Rat Model of Traumatic Brain Injury: An Involvement of MEK/Erk Signaling Pathway.
Brain Ischemia
Activated mitogen-activated protein kinase kinase 7 redistributes to the cytosol and binds to Jun N-terminal kinase-interacting protein 1 involving oxidative stress during early reperfusion in rat hippocampal CA1 region.
Brain Ischemia
Activation of Akt/FoxO and inactivation of MEK/ERK pathways contribute to induction of neuroprotection against transient global cerebral ischemia by delayed hypoxic postconditioning in adult rats.
Brain Ischemia
Alterations in the Cerebral Microvascular Proteome Expression Profile After Transient Global Cerebral Ischemia in Rat.
Brain Ischemia
Analysis of Association between MAP2K4 Gene Polymorphism rs3826392 and IL-1b Serum Level in Southern Chinese Han Ischemic Stroke Patients.
Brain Ischemia
Cerebral ischemia induces microvascular pro-inflammatory cytokine expression via the MEK/ERK pathway.
Brain Ischemia
Delayed activation and regulation of MKK7 in hippocampal CA1 region following global cerebral ischemia in rats.
Brain Ischemia
Elevated expression of miR-302 cluster improves traumatic brain injury by inhibiting phosphorylation of connexin43 via ERK signaling.
Brain Ischemia
Enhanced cerebrovascular expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 via the MEK/ERK pathway during cerebral ischemia in the rat.
Brain Ischemia
Enhanced expressions of microvascular smooth muscle receptors after focal cerebral ischemia occur via the MAPK MEK/ERK pathway.
Brain Ischemia
Hypoxic Preconditioning Attenuates Neuronal Cell Death by Preventing MEK/ERK Signaling Pathway Activation after Transient Global Cerebral Ischemia in Adult Rats.
Brain Ischemia
Inhibition of MEK/ERK 1/2 pathway reduces pro-inflammatory cytokine interleukin-1 expression in focal cerebral ischemia.
Brain Ischemia
MEK1 protein kinase inhibition protects against damage resulting from focal cerebral ischemia.
Brain Ischemia
microRNA-21 Confers Neuroprotection Against Cerebral Ischemia-Reperfusion Injury and Alleviates Blood-Brain Barrier Disruption in Rats via the MAPK Signaling Pathway.
Brain Ischemia
Neuroprotective effects of Tongxinluo on focal cerebral ischemia and reperfusion injury in rats associated with the activation of the MEK1/2/ERK1/2/p90RSK signaling pathway.
Brain Ischemia
Protein phosphatase 2A-negative regulation of the protective signaling pathway of Ca2+/CaM-dependent ERK activation in cerebral ischemia.
Brain Ischemia
Similar time-course of interleukin-1 beta production and extracellular-signal-regulated kinase (ERK) activation in permanent focal brain ischemic injury.
Brain Ischemia
The role of tumor necrosis factor-alpha and TNF-alpha receptors in cerebral arteries following cerebral ischemia in rat.
Brain Neoplasms
Analytical approach to characterize the intratumoral pharmacokinetics and pharmacodynamics of gefitinib in a glioblastoma model.
Brain Neoplasms
Combined kinase inhibitors of MEK1/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer.
Brain Neoplasms
Induction of transforming growth factor-beta1 by basic fibroblast growth factor in rat C6 glioma cells and astrocytes is mediated by MEK/ERK signaling and AP-1 activation.
Brain Neoplasms
Regorafenib: Antitumor Activity upon Mono and Combination Therapy in Preclinical Pediatric Malignancy Models.
Breast Neoplasms
Activation of c-Src/HER1/STAT5b and HER1/ERK1/2 Signaling Pathways and Cell Migration by Hexachlorobenzene in MDA-MB-231 Human Breast Cancer Cell Line.
Breast Neoplasms
Activation of MAP kinase by muscarinic cholinergic receptors induces cell proliferation and protein synthesis in human breast cancer cells.
Breast Neoplasms
Alpha-eleostearic acid suppresses proliferation of MCF-7 breast cancer cells via activation of PPARgamma and inhibition of ERK 1 / 2.
Breast Neoplasms
Anti-proliferative actions of N'-desmethylsorafenib in human breast cancer cells.
Breast Neoplasms
Artemisia absinthium (AA): a novel potential complementary and alternative medicine for breast cancer.
Breast Neoplasms
Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition.
Breast Neoplasms
Clustering of monosialyl-Gb5 initiates downstream signalling events leading to invasion of MCF-7 breast cancer cells.
Breast Neoplasms
Cross-talk between Endoplasmic Reticulum (ER) Stress and the MEK/ERK Pathway Potentiates Apoptosis in Human Triple Negative Breast Carcinoma Cells: ROLE OF A DIHYDROPYRIMIDONE, NIFETEPIMINE.
Breast Neoplasms
Delayed activation of extracellular-signal-regulated kinase 1/2 is involved in genistein- and equol-induced cell proliferation and estrogen-receptor-alpha-mediated transcription in MCF-7 breast cancer cells.
Breast Neoplasms
Distinct mechanisms mediate the initial and sustained phases of cell migration in epidermal growth factor receptor-overexpressing cells.
Breast Neoplasms
Dual Inhibition of Key Proliferation Signaling Pathways in Triple-Negative Breast Cancer Cells by a Novel Derivative of Taiwanin A.
Breast Neoplasms
Elevated expression of erbB3 confers paclitaxel resistance in erbB2-overexpressing breast cancer cells via upregulation of Survivin.
Breast Neoplasms
Epithelial mesenchymal transition and resistance in endocrine-related cancers.
Breast Neoplasms
FAM53A Affects Breast Cancer Cell Proliferation, Migration, and Invasion in a p53-Dependent Manner.
Breast Neoplasms
Fibroblast growth factor 8 induced downregulation of thrombospondin 1 is mediated by the MEK/ERK and PI3K pathways in breast cancer cells.
Breast Neoplasms
Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.
Breast Neoplasms
Identification and validation of genes with expression patterns inverse to multiple metastasis suppressor genes in breast cancer cell lines.
Breast Neoplasms
In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models.
Breast Neoplasms
Induction of apoptosis in MCF-7 and MDA-MB-231 breast cancer cells by Oligonol is mediated by Bcl-2 family regulation and MEK/ERK signaling.
Breast Neoplasms
Inhibition of either phosphatidylinositol 3-kinase/Akt or the mitogen/extracellular-regulated kinase, MEK/ERK, signaling pathways suppress growth of breast cancer cell lines, but MEK/ERK signaling is critical for cell survival.
Breast Neoplasms
Inhibition of extracellular signal regulated kinase (ERK) leads to apoptosis inducing factor (AIF) mediated apoptosis in epithelial breast cancer cells: the lack of effect of ERK in p53 mediated copper induced apoptosis.
Breast Neoplasms
Inhibition of mitogen-activated protein kinase kinase enhances apoptosis induced by arsenic trioxide in human breast cancer MCF-7 cells.
Breast Neoplasms
Inhibition of mitogen-activated protein kinase kinase selectively inhibits cell proliferation in human breast cancer cells displaying enhanced insulin-like growth factor I-mediated mitogen-activated protein kinase activation.
Breast Neoplasms
Inhibition of mitogen-activated protein kinase signaling pathway sensitizes breast cancer cells to endoplasmic reticulum stress-induced apoptosis.
Breast Neoplasms
Interleukin-34-CSF1R Signaling Axis Promotes Epithelial Cell Transformation and Breast Tumorigenesis.
Breast Neoplasms
Low molecular proanthocyanidin dietary biofactor Oligonol: Its modulation of oxidative stress, bioefficacy, neuroprotection, food application and chemoprevention potentials.
Breast Neoplasms
Male breast cancer precursor lesions: analysis of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program.
Breast Neoplasms
MAP kinase/estrogen receptor cross-talk enhances estrogen-mediated signaling and tumor growth but does not confer tamoxifen resistance.
Breast Neoplasms
MAP2K4 interacts with Vimentin to activate the PI3K/AKT pathway and promotes breast cancer pathogenesis.
Breast Neoplasms
MAPK kinase 3 is a tumor suppressor with reduced copy number in breast cancer.
Breast Neoplasms
MEK inhibition leads to lysosome-mediated Na+/I- symporter protein degradation in human breast cancer cells.
Breast Neoplasms
MEK inhibition prevents tumour-shed transforming growth factor-?-induced T-regulatory cell augmentation in tumour milieu.
Breast Neoplasms
Metalloprotease-dependent activation of EGFR modulates CD44(+)/CD24(-) populations in triple negative breast cancer cells through the MEK/ERK pathway.
Breast Neoplasms
Methylglyoxal, a glycolysis metabolite, triggers metastasis through MEK/ERK/SMAD1 pathway activation in breast cancer.
Breast Neoplasms
MicroRNA-1 regulates the growth and chemosensitivity of breast cancer cells by targeting MEK/ERK pathway.
Breast Neoplasms
MiR-96-5p promotes breast cancer migration by activating MEK/ERK signaling.
Breast Neoplasms
Mitogen-activated protein kinase kinase 3 induces cell cycle arrest via p38 activation mediated Bmi-1 downregulation in hepatocellular carcinoma.
Breast Neoplasms
Naturally occurring Girinimbine alkaloid inhibits the proliferation, migration, and invasion of human breast cancer cells via induction of apoptosis and inhibition of MEK/ERK and STAT3 signalling pathways.
Breast Neoplasms
Oncostatin M-induced growth inhibition and morphological changes of MDA-MB231 breast cancer cells are abolished by blocking the MEK/ERK signaling pathway.
Breast Neoplasms
Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase.
Breast Neoplasms
P-REX1 creates a positive feedback loop to activate growth factor receptor, PI3K/AKT and MEK/ERK signaling in breast cancer.
Breast Neoplasms
p38 isoforms have opposite effects on AP-1-dependent transcription through regulation of c-Jun. The determinant roles of the isoforms in the p38 MAPK signal specificity.
Breast Neoplasms
PDGF regulated migration of mesenchymal stem cells towards malignancy acts via the PI3K signaling pathway.
Breast Neoplasms
PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1.
Breast Neoplasms
Pifithrin-?, an inhibitor of p53 transactivation, up-regulates COX-2 expression through an MAPK-dependent pathway.
Breast Neoplasms
Proteome profiling of immortalization-to-senescence transition of human breast epithelial cells identified MAP2K3 as a senescence-promoting protein which is downregulated in human breast cancer.
Breast Neoplasms
PTEN sensitizes MDA-MB-468 cells to inhibition of MEK/Erk signaling for the blockade of cell proliferation.
Breast Neoplasms
Retinoids interfere with the AP1 signalling pathway in human breast cancer cells.
Breast Neoplasms
Shionone suppresses the growth, migration and invasion of human breast cancer cells via induction of apoptosis and inhibition of MEK/ERK and STAT3 signalling pathways.
Breast Neoplasms
Specific amino acid deficiency alters the expression of genes in human melanoma and other tumor cell lines.
Breast Neoplasms
Splicing factor hnRNPA2B1 contributes to tumorigenic potential of breast cancer cells through STAT3 and ERK1/2 signaling pathway.
Breast Neoplasms
Synergistic anti-angiogenic treatment effects by dual FGFR1 and VEGFR1 inhibition in FGFR1-amplified breast cancer.
Breast Neoplasms
The Histone Deacetylase Inhibitor JAHA Down-Regulates pERK and Global DNA Methylation in MDA-MB231 Breast Cancer Cells.
Breast Neoplasms
The novel long noncoding RNA AU021063, induced by IL-6/Arid5a signaling, exacerbates breast cancer invasion and metastasis by stabilizing Trib3 and activating the Mek/Erk pathway.
Breast Neoplasms
The requirement of SEPT2 and SEPT7 for migration and invasion in human breast cancer via MEK/ERK activation.
Breast Neoplasms
The synthetic ?-nitrostyrene derivative CYT-Rx20 induces breast cancer cell death and autophagy via ROS-mediated MEK/ERK pathway.
Breast Neoplasms
Therapeutic sensitivity to Rac GTPase inhibition requires consequential suppression of mTORC1, AKT, and MEK signaling in breast cancer.
Breast Neoplasms
Three-dimensional overlay culture models of human breast cancer reveal a critical sensitivity to mitogen-activated protein kinase kinase inhibitors.
Breast Neoplasms
Unmet needs in ovarian cancer: dividing histologic subtypes to exploit novel targets and pathways.
Breast Neoplasms
[Expressions of MAP2K4 and estrogen receptor and their clinical significance in invasive breast cancer].
Carcinogenesis
3-Nitrobenzanthrone promotes malignant transformation in human lung epithelial cells through the epiregulin-signaling pathway.
Carcinogenesis
A functional variant (-1304T>G) in the MKK4 promoter contributes to a decreased risk of lung cancer by increasing the promoter activity.
Carcinogenesis
Advanced pharmacological therapies for neurofibromatosis type 1-related tumors.
Carcinogenesis
CInQ-03, a novel allosteric MEK inhibitor, suppresses cancer growth in vitro and in vivo.
Carcinogenesis
Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation.
Carcinogenesis
Detection of novel copy number variants in uterine leiomyomas using high-resolution SNP arrays.
Carcinogenesis
Differential Activation of ERK Signaling in HPV-Related Oropharyngeal Squamous Cell Carcinoma.
Carcinogenesis
Downregulation of uPAR inhibits migration, invasion, proliferation, FAK/PI3K/Akt signaling and induces senescence in papillary thyroid carcinoma cells.
Carcinogenesis
Essential, non-redundant roles of B-Raf and Raf-1 in Ras-driven skin tumorigenesis.
Carcinogenesis
Evaluation of the association between the -1304T>G polymorphism in the promoter of the MKK4 gene and the risk of colorectal cancer: a PRISMA-compliant meta-analysis.
Carcinogenesis
Flavonoids as Protein Kinase Inhibitors for Cancer Chemoprevention: Direct Binding and Molecular Modeling.
Carcinogenesis
Functional variant (-1304T>G) in the MKK4 promoter is associated with decreased risk of acute myeloid leukemia in a southern Chinese population.
Carcinogenesis
Gene expression profiles in liver of mouse after chronic exposure to drinking water.
Carcinogenesis
Hematopoietic cell kinase enhances osteosarcoma development via the MEK/ERK pathway.
Carcinogenesis
In vivo effect of alpha-bisabolol, a nontoxic sesquiterpene alcohol, on the induction of spontaneous mammary tumors in HER-2/neu transgenic mice.
Carcinogenesis
Inhibition of MAP kinase kinase causes morphological reversion and dissociation between soft agar growth and in vivo tumorigenesis in angiosarcoma cells.
Carcinogenesis
Integrative pan-cancer analysis of MEK1 aberrations and the potential clinical implications.
Carcinogenesis
Interleukin-34-CSF1R Signaling Axis Promotes Epithelial Cell Transformation and Breast Tumorigenesis.
Carcinogenesis
K27-linked ubiquitination of BRAF by ITCH engages cytokine response to maintain MEK-ERK signaling.
Carcinogenesis
Lgr4 is crucial for skin carcinogenesis by regulating MEK/ERK and Wnt/?-catenin signaling pathways.
Carcinogenesis
Map2k4 functions as a tumor suppressor in lung adenocarcinoma and inhibits tumor cell invasion by decreasing peroxisome proliferator-activated receptor ?2 expression.
Carcinogenesis
MEK2 is a critical modulating mechanism to down-regulate GCIP stability and function in cancer cells.
Carcinogenesis
Nanosized Modification Strategies for Improving the Antitumor Efficacy of MEK Inhibitors.
Carcinogenesis
Novel tumor-suppressor function of KLF4 in pediatric T-cell acute lymphoblastic leukemia.
Carcinogenesis
REX-1 Represses RASSF1a and Activates the MEK/ERK Pathway to Promote Tumorigenesis in Prostate Cancer.
Carcinogenesis
Steady-State Levels of Phosphorylated Mitogen-Activated Protein Kinase Kinase 1/2 Determined by Mortalin/HSPA9 and Protein Phosphatase 1 Alpha in KRAS and BRAF Tumor Cells.
Carcinogenesis
Synthesis, anticancer activity, and molecular modeling of 1,4-naphthoquinones that inhibit MKK7 and Cdc25.
Carcinogenesis
TGF? engages MEK/ERK to differentially regulate benign and malignant pancreas cell function.
Carcinogenesis
The Association Between -1304T>G Polymorphism in the Promoter of Mitogen-Activated Protein Kinase Kinase 4 Gene and the Risk of Cervical Cancer in Chinese Population.
Carcinogenesis
The DNA replication regulator MCM6: An emerging cancer biomarker and target.
Carcinogenesis
The miR-19b-3p-MAP2K3-STAT3 feedback loop regulates cell proliferation and invasion in esophageal squamous cell carcinoma.
Carcinogenesis
Upregulation of MEK5 by Stat3 promotes breast cancer cell invasion and metastasis.
Carcinogenesis
Von Hippel-Lindau tumor suppressor gene loss in renal cell carcinoma promotes oncogenic epidermal growth factor receptor signaling via Akt-1 and MEK-1.
Carcinoma
A long-term surviving patient with recurrent low-grade serous ovarian carcinoma treated with the MEK1/2 inhibitor, selumetinib.
Carcinoma
Activation of the mitogen-activated protein kinase kinase/extracellular signal-regulated kinase pathway overcomes cisplatin resistance in ovarian carcinoma cells.
Carcinoma
CCNY Accelerates Cylcin E Expression to Regulate the Proliferation of Laryngeal Carcinoma Cells via MEK/ERK Signaling Pathway.
Carcinoma
Correction: ZHX2 drives cell growth and migration via activating MEK/ERK signal and induces Sunitinib resistance by regulating the autophagy in clear cell Renal Cell Carcinoma.
Carcinoma
Cyr61 promotes CD204 expression and the migration of macrophages via MEK/ERK pathway in esophageal squamous cell carcinoma.
Carcinoma
Differential expression of phosphorylated MEK and ERK correlates with aggressive BCC subtypes.
Carcinoma
Editorial comment on: Von Hippel-Lindau tumor suppressor gene loss in renal cell carcinoma promotes oncogenic epidermal growth factor receptor signaling via Akt-1 and MEK-1.
Carcinoma
Effect of PD 098059, a specific inhibitor of mitogen-activated protein kinase kinase, on urokinase expression and in vitro invasion.
Carcinoma
Functional consequences of mutations in a putative Akt phosphorylation motif of B-raf in human cancers.
Carcinoma
Genistein inhibits the proliferation, migration and invasion of the squamous cell carcinoma cells via inhibition of MEK/ERK and JNK signalling pathways.
Carcinoma
Inhibition of Pancreatic Carcinoma Growth Through Enhancing ?-3 Epoxy Polyunsaturated Fatty Acid Profile by Inhibition of Soluble Epoxide Hydrolase.
Carcinoma
Inhibitors of Ras/Raf-1 interaction identified by two-hybrid screening revert Ras-dependent transformation phenotypes in human cancer cells.
Carcinoma
Kinase domain mutation of MAP2K4 is rare in gastric, colorectal and lung carcinomas.
Carcinoma
Mammary Precancerous Stem and Non-Stem Cells Evolve into Cancers of Distinct Subtypes.
Carcinoma
MEK Inhibitor PD-0325901 Overcomes Resistance to PI3K/mTOR Inhibitor PF-5212384 and Potentiates Antitumor Effects in Human Head and Neck Squamous Cell Carcinoma.
Carcinoma
MicroRNA-802 plays a tumour suppressive role in tongue squamous cell carcinoma through directly targeting MAP2K4.
Carcinoma
Mitogen activated protein kinase kinase kinase 3 (MAP3K3/MEKK3) overexpression is an early event in esophageal tumorigenesis and is a predictor of poor disease prognosis.
Carcinoma
Mitogen-activated protein kinase kinase 4 (MKK4) acts as a metastasis suppressor gene in human ovarian carcinoma.
Carcinoma
Overexpression of integrin ?v facilitates proliferation and invasion of oral squamous cell carcinoma cells via MEK/ERK signaling pathway that is activated by interaction of integrin ?v?8 with type ? collagen.
Carcinoma
Overexpression of mitogen-activated protein kinase kinase 4 and nuclear factor-kappaB in laryngeal squamous cell carcinoma: a potential indicator for poor prognosis.
Carcinoma
Purpurogallin is a novel mitogen-activated protein kinase kinase 1/2 inhibitor that suppresses esophageal squamous cell carcinoma growth in vitro and in vivo.
Carcinoma
Simultaneous inhibition of the mitogen-activated protein kinase kinase and phosphatidylinositol 3'-kinase pathways enhances sensitivity to paclitaxel in ovarian carcinoma.
Carcinoma
The Dilemma of HER2 Double-equivocal Breast Carcinomas: Genomic Profiling and Implications for Treatment.
Carcinoma
Upregulation of lncRNA ADAMTS9-AS2 Promotes Salivary Adenoid Cystic Carcinoma Metastasis via PI3K/Akt and MEK/Erk Signaling.
Carcinoma
Vitamin D(3)-induced apoptosis of murine squamous cell carcinoma cells. Selective induction of caspase-dependent MEK cleavage and up-regulation of MEKK-1.
Carcinoma
Von Hippel-Lindau tumor suppressor gene loss in renal cell carcinoma promotes oncogenic epidermal growth factor receptor signaling via Akt-1 and MEK-1.
Carcinoma
ZHX2 drives cell growth and migration via activating MEK/ERK signal and induces Sunitinib resistance by regulating the autophagy in clear cell Renal Cell Carcinoma.
Carcinoma
[Effect of enhancer of zeste homolog 2 inhibitor GSK126 on the proliferation and apoptosis of tongue squamous cell carcinoma].
Carcinoma
[Expression of MEK/ERK signal pathways in renal cell carcinoma with bone metastasis].
Carcinoma
[The relationship between expression of mitogen-activated protein kinase kinase 4 and metastasis in oral squamous cell carcinoma].
Carcinoma in Situ
Prolonged survival and delayed progression of pancreatic intraepithelial neoplasia in LSL-KrasG12D/+;Pdx-1-Cre mice by vitamin E ?-tocotrienol.
Carcinoma, Adenoid Cystic
Upregulation of lncRNA ADAMTS9-AS2 Promotes Salivary Adenoid Cystic Carcinoma Metastasis via PI3K/Akt and MEK/Erk Signaling.
Carcinoma, Basal Cell
Differential expression of phosphorylated MEK and ERK correlates with aggressive BCC subtypes.
Carcinoma, Ductal
Male breast cancer precursor lesions: analysis of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program.
Carcinoma, Hepatocellular
?-Bufarenogin, a novel anti-tumor compound, suppresses liver cancer growth by inhibiting receptor tyrosine kinase-mediated signaling.
Carcinoma, Hepatocellular
Activation of MEK/ERK and PI3K/Akt pathways by fibronectin requires integrin alphav-mediated ADAM activity in hepatocellular carcinoma: A novel functional target for gefitinib.
Carcinoma, Hepatocellular
Allosteric MEK1/2 inhibitor refametinib (BAY 86-9766) in combination with sorafenib exhibits antitumor activity in preclinical murine and rat models of hepatocellular carcinoma.
Carcinoma, Hepatocellular
Autophagy-related gene 7 (Atg7) and reactive oxygen species (ROS)/ extracellular-signal-regulated kinase (ERK) regulate tetrandrine-induced autophagy in human hepatocellular carcinoma.
Carcinoma, Hepatocellular
Cellular mechanisms of hepatocyte growth factor-mediated urokinase plasminogen activator secretion by MAPK signaling in hepatocellular carcinoma.
Carcinoma, Hepatocellular
CircRNA CDR1as/miR-1287/Raf1 Axis Modulates Hepatocellular Carcinoma Progression Through MEK/ERK Pathway.
Carcinoma, Hepatocellular
Cross-talk between PI3K/Akt and MEK/ERK pathways mediates endoplasmic reticulum stress-induced cell cycle progression and cell death in human hepatocellular carcinoma cells.
Carcinoma, Hepatocellular
Effect of halofuginone on the inhibition of proliferation and invasion of hepatocellular carcinoma HepG2 cell line.
Carcinoma, Hepatocellular
Epidermal growth factor upregulates the expression of A20 in hepatic cells via the MEK1/MSK1/p-p65 (Ser276) signaling pathway.
Carcinoma, Hepatocellular
FAM83D activates the MEK/ERK signaling pathway and promotes cell proliferation in hepatocellular carcinoma.
Carcinoma, Hepatocellular
HSCs-derived COMP drives hepatocellular carcinoma progression by activating MEK/ERK and PI3K/AKT signaling pathways.
Carcinoma, Hepatocellular
Inhibition of MEK/ERK activation attenuates autophagy and potentiates pemetrexed-induced activity against HepG2 hepatocellular carcinoma cells.
Carcinoma, Hepatocellular
Insulin Dependant Gene Expression of Heat Shock Protein 60 in H4IIE Hepatoma Cells.
Carcinoma, Hepatocellular
Interstitial Fluid Flow Increases Hepatocellular Carcinoma Cell Invasion through CXCR4/CXCL12 and MEK/ERK Signaling.
Carcinoma, Hepatocellular
Involvement of the p38 mitogen-activated protein kinase cascade in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Kinesin family member 2C promotes hepatocellular carcinoma growth and metastasis via activating MEK/ERK pathway.
Carcinoma, Hepatocellular
LDLR inhibition promotes hepatocellular carcinoma proliferation and metastasis by elevating intracellular cholesterol synthesis through the MEK/ERK signaling pathway.
Carcinoma, Hepatocellular
lncRNA DRHC inhibits proliferation and invasion in hepatocellular carcinoma via c-Myb-regulated MEK/ERK signaling.
Carcinoma, Hepatocellular
LncRNA HOXA-AS3 Sponges miR-29c to Facilitate Cell Proliferation, Metastasis, and EMT Process and Activate the MEK/ERK Signaling Pathway in Hepatocellular Carcinoma.
Carcinoma, Hepatocellular
MCM6 promotes metastasis of hepatocellular carcinoma via MEK/ERK pathway and serves as a novel serum biomarker for early recurrence.
Carcinoma, Hepatocellular
MEK/ERK pathway is positively involved in hypoxia-induced vasculogenic mimicry formation in hepatocellular carcinoma which is regulated negatively by protein kinase A.
Carcinoma, Hepatocellular
MEK/ERK signaling is a critical mediator for integrin-induced cell scattering in highly metastatic hepatocellular carcinoma cells.
Carcinoma, Hepatocellular
MEK/ERK-dependent uPAR expression is required for motility via phosphorylation of P70S6K in human hepatocarcinoma cells.
Carcinoma, Hepatocellular
Mitogen-activated protein kinase kinase 3 induces cell cycle arrest via p38 activation mediated Bmi-1 downregulation in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Modulation of YrdC promotes hepatocellular carcinoma progression via MEK/ERK signaling pathway.
Carcinoma, Hepatocellular
NO donor inhibits proliferation and induces apoptosis by targeting PI3K/AKT/mTOR and MEK/ERK pathways in hepatocellular carcinoma cells.
Carcinoma, Hepatocellular
Potentiation of the antitumor effects of both selective cyclooxygenase-1 and cyclooxygenase-2 inhibitors in human hepatic cancer cells by inhibition of the MEK/ERK pathway.
Carcinoma, Hepatocellular
Protein kinase C alpha trigger Ras and Raf-independent MEK/ERK activation for TPA-induced growth inhibition of human hepatoma cell HepG2.
Carcinoma, Hepatocellular
Radiosensitivity enhancement of human hepatocellular carcinoma cell line SMMC-7721 by sorafenib through the MEK/ERK signal pathway.
Carcinoma, Hepatocellular
Recent developments with immunotherapy for hepatocellular carcinoma.
Carcinoma, Hepatocellular
Receptor for activated C kinase 1 promotes hepatocellular carcinoma growth by enhancing mitogen-activated protein kinase kinase 7 activity.
Carcinoma, Hepatocellular
Resistance to MEK inhibitors correlates with upregulation of the MEK/ERK pathway in hepatocellular carcinoma cells.
Carcinoma, Hepatocellular
Serine protease inhibitor Kazal type 1 (SPINK1) downregulates E-cadherin and induces EMT of hepatoma cells to promote hepatocellular carcinoma metastasis via the MEK/ERK signaling pathway.
Carcinoma, Hepatocellular
SERPINA11 Inhibits Metastasis in Hepatocellular Carcinoma by Suppressing MEK/ERK Signaling Pathway.
Carcinoma, Hepatocellular
Silencing of long noncoding RNA HOXD-AS1 inhibits proliferation, cell cycle progression, migration and invasion of hepatocellular carcinoma cells through MEK/ERK pathway.
Carcinoma, Hepatocellular
Stereoisomeric guaiacylglycerol-?-coniferyl aldehyde ether induces distinctive apoptosis by downregulation of MEK/ERK pathway in hepatocellular carcinoma cells.
Carcinoma, Hepatocellular
STYK1 promotes epithelial-mesenchymal transition and tumor metastasis in human hepatocellular carcinoma through MEK/ERK and PI3K/AKT signaling.
Carcinoma, Hepatocellular
Targeting mitogen-activated protein kinase kinase with the inhibitor PD0325901 decreases hepatocellular carcinoma growth in vitro and in mouse model systems.
Carcinoma, Hepatocellular
The Activation of MEK/ERK Signaling Pathway by Bone Morphogenetic Protein 4 to Increase Hepatocellular Carcinoma Cell Proliferation and Migration.
Carcinoma, Hepatocellular
[Cross-talk between PI3K/Akt and MEK/ERK pathways regulates human hepatocellular carcinoma cell cycle progression under endoplasmic reticulum stress].
Carcinoma, Intraductal, Noninfiltrating
Breast ductal carcinoma in situ carry mutational driver events representative of invasive breast cancer.
Carcinoma, Intraductal, Noninfiltrating
Male breast cancer precursor lesions: analysis of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program.
Carcinoma, Non-Small-Cell Lung
Aldehyde Dehydrogenase 1 (ALDH1) Promotes the Toxicity of TRAIL in Non-Small Cell Lung Cancer Cells via Post-Transcriptional Regulation of MEK-1 Expression.
Carcinoma, Non-Small-Cell Lung
Blockade of ?7 nicotinic acetylcholine receptors inhibit nicotine-induced tumor growth and vimentin expression in non-small cell lung cancer through MEK/ERK signaling way.
Carcinoma, Non-Small-Cell Lung
Blocking the PI3K/AKT and MEK/ERK signaling pathways can overcome gefitinib-resistance in non-small cell lung cancer cell lines.
Carcinoma, Non-Small-Cell Lung
Combination therapies with mitogen-activated protein kinase kinase inhibitors and immune checkpoint inhibitors in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Concurrent inhibition of ErbB family and MEK/ERK kinases to suppress non-small cell lung cancer proliferation.
Carcinoma, Non-Small-Cell Lung
Enhanced G1 arrest and apoptosis via MDM4/MDM2 double knockdown and MEK inhibition in wild-type TP53 colon and gastric cancer cells with aberrant KRAS signaling.
Carcinoma, Non-Small-Cell Lung
Enhancing therapeutic efficacy of the MEK inhibitor, MEK162, by blocking autophagy or inhibiting PI3K/Akt signaling in human lung cancer cells.
Carcinoma, Non-Small-Cell Lung
Functional consequences of mutations in a putative Akt phosphorylation motif of B-raf in human cancers.
Carcinoma, Non-Small-Cell Lung
Gastrointestinal perforation following dabrafenib and trametinib administration in non-small cell lung carcinoma with BRAF V600E mutation: a case report and literature review.
Carcinoma, Non-Small-Cell Lung
Gefitinib-Resistance Is Related to BIM Expression in Non-Small Cell Lung Cancer Cell Lines.
Carcinoma, Non-Small-Cell Lung
Inhibition of histamine receptor H3 suppresses the growth and metastasis of human non-small cell lung cancer cells via inhibiting PI3K/Akt/mTOR and MEK/ERK signaling pathways and blocking EMT.
Carcinoma, Non-Small-Cell Lung
KRAS mutant lung cancer cells are differentially responsive to MEK inhibitor due to AKT or STAT3 activation: implication for combinatorial approach.
Carcinoma, Non-Small-Cell Lung
Loss of MKK3 and MK2 Copy Numbers in Non-Small Cell Lung Cancer.
Carcinoma, Non-Small-Cell Lung
MiR-199a-5p suppresses non-small cell lung cancer via targeting MAP3K11.
Carcinoma, Non-Small-Cell Lung
Mitogen-activated protein kinase kinase-4 promotes cell survival by decreasing PTEN expression through an NF kappa B-dependent pathway.
Carcinoma, Non-Small-Cell Lung
PAQR3 suppresses the growth of non-small cell lung cancer cells via modulation of EGFR-mediated autophagy.
Carcinoma, Non-Small-Cell Lung
Population Pharmacokinetic and Exposure-Response Analysis of Selumetinib and Its N-desmethyl Metabolite in Patients With Non-Small Cell Lung Cancer.
Carcinoma, Non-Small-Cell Lung
Silibinin Inhibits NSCLC Metastasis by Targeting the EGFR/LOX Pathway.
Carcinoma, Non-Small-Cell Lung
The antitumor effect of hinesol, extract from Atractylodes lancea (Thunb.) DC. by proliferation, inhibition, and apoptosis induction via MEK/ERK and NF-?B pathway in non-small cell lung cancer cell lines A549 and NCI-H1299.
Carcinoma, Renal Cell
Alpha-Mangostin Suppresses the Metastasis of Human Renal Carcinoma Cells by Targeting MEK/ERK Expression and MMP-9 Transcription Activity.
Carcinoma, Renal Cell
Aqueous Extracts of Toona sinensis Leaves Inhibit Renal Carcinoma Cell Growth and Migration Through JAK2/stat3, Akt, MEK/ERK, and mTOR/HIF-2? Pathways.
Carcinoma, Renal Cell
Correction: ZHX2 drives cell growth and migration via activating MEK/ERK signal and induces Sunitinib resistance by regulating the autophagy in clear cell Renal Cell Carcinoma.
Carcinoma, Renal Cell
Editorial comment on: Von Hippel-Lindau tumor suppressor gene loss in renal cell carcinoma promotes oncogenic epidermal growth factor receptor signaling via Akt-1 and MEK-1.
Carcinoma, Renal Cell
Von Hippel-Lindau tumor suppressor gene loss in renal cell carcinoma promotes oncogenic epidermal growth factor receptor signaling via Akt-1 and MEK-1.
Carcinoma, Renal Cell
ZHX2 drives cell growth and migration via activating MEK/ERK signal and induces Sunitinib resistance by regulating the autophagy in clear cell Renal Cell Carcinoma.
Carcinoma, Renal Cell
[Expression of MEK/ERK signal pathways in renal cell carcinoma with bone metastasis].
Carcinoma, Squamous Cell
Effect of PD 098059, a specific inhibitor of mitogen-activated protein kinase kinase, on urokinase expression and in vitro invasion.
Carcinoma, Squamous Cell
Genistein inhibits the proliferation, migration and invasion of the squamous cell carcinoma cells via inhibition of MEK/ERK and JNK signalling pathways.
Carcinoma, Squamous Cell
MEK Inhibitor PD-0325901 Overcomes Resistance to PI3K/mTOR Inhibitor PF-5212384 and Potentiates Antitumor Effects in Human Head and Neck Squamous Cell Carcinoma.
Carcinoma, Squamous Cell
MicroRNA-802 plays a tumour suppressive role in tongue squamous cell carcinoma through directly targeting MAP2K4.
Carcinoma, Squamous Cell
Migration induced by epidermal and hepatocyte growth factors in oral squamous carcinoma cells in vitro: role of MEK/ERK, p38 and PI-3 kinase/Akt.
Carcinoma, Squamous Cell
Retracted: Xanthoxyletin Inhibits Proliferation of Human Oral Squamous Carcinoma Cells and Induces Apoptosis, Autophagy, and Cell Cycle Arrest by Modulation of the MEK/ERK Signaling Pathway.
Carcinoma, Squamous Cell
Vitamin D(3)-induced apoptosis of murine squamous cell carcinoma cells. Selective induction of caspase-dependent MEK cleavage and up-regulation of MEKK-1.
Carcinoma, Squamous Cell
Xanthoxyletin Inhibits Proliferation of Human Oral Squamous Carcinoma Cells and Induces Apoptosis, Autophagy, and Cell Cycle Arrest by Modulation of the MEK/ERK Signaling Pathway.
Carcinoma, Squamous Cell
[Effect of enhancer of zeste homolog 2 inhibitor GSK126 on the proliferation and apoptosis of tongue squamous cell carcinoma].
Cardiomegaly
Angiotensin II-induced cardiac hypertrophy is associated with different mitogen-activated protein kinase activation in normotensive and hypertensive mice.
Cardiomegaly
Angiotensin-Converting Enzyme 3 (ACE3) Protects Against Pressure Overload-Induced Cardiac Hypertrophy.
Cardiomegaly
Baicalein protects against cardiac hypertrophy through blocking MEK-ERK1/2 signaling.
Cardiomegaly
Caffeic acid phenethyl ester attenuates pathological cardiac hypertrophy by regulation of MEK/ERK signaling pathway in vivo and vitro.
Cardiomegaly
Cardiac hypertrophy induced by mitogen-activated protein kinase kinase 7, a specific activator for c-Jun NH2-terminal kinase in ventricular muscle cells.
Cardiomegaly
Caspase recruitment domain 6 protects against cardiac hypertrophy in response to pressure overload.
Cardiomegaly
GADD45B inhibits MKK7-induced cardiac hypertrophy and the polymorphisms of GADD45B is associated with inter-ventricular septum hypertrophy.
Cardiomegaly
Growth Arrest-Specific 6 Exacerbates Pressure Overload-Induced Cardiac Hypertrophy.
Cardiomegaly
High-resolution structure discloses the potential for allosteric regulation of mitogen-activated protein kinase kinase 7.
Cardiomegaly
Interleukin 6 is not necessary for STAT3 phosphorylation and myocardial hypertrophy following short term beta-adrenergic stimulation.
Cardiomegaly
Mechanical stress activates protein kinase cascade of phosphorylation in neonatal rat cardiac myocytes.
Cardiomegaly
Opposing effects of Jun kinase and p38 mitogen-activated protein kinases on cardiomyocyte hypertrophy.
Cardiomegaly
Rapamycin Inhibits Cardiac Hypertrophy by Promoting Autophagy via the MEK/ERK/Beclin-1 Pathway.
Cardiomegaly
Rat parathyroid hormone 1-34 signals through the MEK/ERK pathway to induce cardiac hypertrophy.
Cardiomegaly
Zebrafish heart failure models for the evaluation of chemical probes and drugs.
Cardiomegaly
[Parathyroid hormone 1-34 induce cardiac myocytes hypertrophy via extracellular regulated protein kinase 1/2 pathway]
Cardiomyopathies
Mitogen-activated protein kinase kinase 1/2 inhibition and angiotensin II converting inhibition in mice with cardiomyopathy caused by lamin A/C gene mutation.
Cardiomyopathies
Type 5 Adenylyl Cyclase Increases Oxidative Stress by Transcriptional Regulation of MnSOD via the SIRT1/FoxO3a Pathway.
Cardiomyopathy, Hypertrophic
Inducible Pluripotent Stem Cell-Derived Cardiomyocytes Reveal Aberrant Extracellular Regulated Kinase 5 and Mitogen-Activated Protein Kinase Kinase 1/2 Signaling Concomitantly Promote Hypertrophic Cardiomyopathy in RAF1-Associated Noonan Syndrome.
Cardiotoxicity
Ageing alters the severity of Sunitinib-induced cardiotoxicity: Investigating the mitogen activated kinase kinase 7 pathway association.
Cardiotoxicity
Involvement of mitogen activated kinase kinase 7 intracellular signalling pathway in Sunitinib-induced cardiotoxicity.
Cardiotoxicity
The epigallocatechin gallate derivative Y6 reduces the cardiotoxicity and enhances the efficacy of daunorubicin against human hepatocellular carcinoma by inhibiting carbonyl reductase 1 expression.
Cell Transformation, Neoplastic
Cocoa procyanidins suppress transformation by inhibiting mitogen-activated protein kinase kinase.
Central Serous Chorioretinopathy
Clinical and Morphologic Characteristics of Extracellular Signal-Regulated Kinase Inhibitor-Associated Retinopathy.
Cerebral Infarction
microRNA-21 Confers Neuroprotection Against Cerebral Ischemia-Reperfusion Injury and Alleviates Blood-Brain Barrier Disruption in Rats via the MAPK Signaling Pathway.
Cerebral Infarction
PI3K/Akt and ERK1/2 pathways are responsible for sodium butyrateinduced inhibition of neuronal apoptosis in rats with cerebral infarction.
Cholangiocarcinoma
MiR-192-5p regulates the proliferation and apoptosis of cholangiocarcinoma cells by activating MEK/ERK pathway.
Cholera
Protein kinase A antagonizes platelet-derived growth factor-induced signaling by mitogen-activated protein kinase in human arterial smooth muscle cells.
Chondrosarcoma
Glial cell-derived neurotrophic factor increases migration of human chondrosarcoma cells via ERK and NF-kappaB pathways.
Chondrosarcoma
Involvement of integrin up-regulation in RANKL/RANK pathway of chondrosarcomas migration.
Chondrosarcoma
SDF-1/CXCR4 signaling up-regulates survivin to regulate human sacral chondrosarcoma cell cycle and epithelial-mesenchymal transition via ERK and PI3K/AKT pathway.
Chondrosarcoma
TGF-beta-induced expression of tissue inhibitor of metalloproteinases-3 gene in chondrocytes is mediated by extracellular signal-regulated kinase pathway and Sp1 transcription factor.
Chordoma
The FGFR/MEK/ERK/brachyury pathway is critical for chordoma cell growth and survival.
Choriocarcinoma
Neutral endopeptidase/CD10 expression during phorbol ester-induced differentiation of choriocarcinoma cells through the protein kinase C- and extracellular signal-regulated kinase-dependent signalling pathway.
Choroidal Neovascularization
Role of PI3K/Akt and MEK/ERK in mediating hypoxia-induced expression of HIF-1alpha and VEGF in laser-induced rat choroidal neovascularization.
Classical Swine Fever
Mitogen-activated Protein Kinase Kinase 2 (MEK2), a Novel E2-interacting Protein, Promotes the Growth of Classical Swine Fever Virus via Attenuation of the JAK-STAT Signaling Pathway.
Coinfection
Noonan syndrome mutation Q79R in Shp2 increases proliferation of valve primordia mesenchymal cells via extracellular signal-regulated kinase 1/2 signaling.
Colitis
Dietary oligosaccharides attenuate DSS-induced colitis in mice, induce PGlyRP3 expression, and inhibit NF-?B and MEK/ERK signaling.
Colitis
Raf protects against colitis by promoting mouse colon epithelial cell survival through NF-kappaB.
Colitis
Randomised clinical trial: Efficacy and safety of Qing-Chang-Hua-Shi granules in a multicenter, randomized, and double-blind clinical trial of patients with moderately active ulcerative colitis.
Colitis
Retraction notice to "Dietary oligosaccharides attenuate DSS-induced colitis in mice, induce PGlyRP3 expression, and inhibit NF-?B and MEK/ERK signaling" [Cell. Immunol. 354 (2020) 104144].
Colitis
SGK1 inhibits cellular apoptosis and promotes proliferation via the MEK/ERK/p53 pathway in colitis.
Colitis, Ulcerative
Qing Chang Hua Shi granule ameliorate inflammation in experimental rats and cell model of ulcerative colitis through MEK/ERK signaling pathway.
Colonic Neoplasms
Activation of ERK signaling and induction of colon cancer cell death by piperlongumine.
Colonic Neoplasms
Activin and TGF? use diverging mitogenic signaling in advanced colon cancer.
Colonic Neoplasms
Antitumor activity of the MEK inhibitor trametinib on intestinal polyp formation in Apc(?716) mice involves stromal COX-2.
Colonic Neoplasms
Berbamine exerts anticancer effects on human colon cancer cells via induction of autophagy and apoptosis, inhibition of cell migration and MEK/ERK signalling pathway.
Colonic Neoplasms
Ca(2+)/calmodulin-dependent protein kinase II promotes cell cycle progression by directly activating MEK1 and subsequently modulating p27 phosphorylation.
Colonic Neoplasms
Combination of CYP inhibitor with MEK/ERK inhibitor enhances the inhibitory effect on ERK in BRAF mutant colon cancer cells.
Colonic Neoplasms
Dihydroartemisinin increases apoptosis of colon cancer cells through targeting Janus kinase 2/signal transducer and activator of transcription 3 signaling.
Colonic Neoplasms
FABP7 promotes cell proliferation and survival in colon cancer through MEK/ERK signaling pathway.
Colonic Neoplasms
Inhibition of extracellular signal-regulated kinase 1/2 phosphorylation and induction of apoptosis by sulindac metabolites.
Colonic Neoplasms
Inhibition of extracellular-signal regulated kinases 1/2 is required for apoptosis of human colon cancer cells in vitro by sulindac metabolites.
Colonic Neoplasms
Matrine triggers colon cancer cell apoptosis and G0/G1 cell cycle arrest via mediation of microRNA-22.
Colonic Neoplasms
MEK Inhibitor Suppresses Expression of the miR-17-92 Cluster with G1-Phase Arrest in HT-29 Human Colon Cancer Cells and MIA PaCa-2 Pancreatic Cancer Cells.
Colonic Neoplasms
MicroRNA-335 targets the MEK/ERK pathway to regulate the proliferation and metastasis of colon cancer.
Colonic Neoplasms
Oncogenic Ras upregulates NADPH oxidase 1 gene expression through MEK-ERK-dependent phosphorylation of GATA-6.
Colonic Neoplasms
Quantitative Size-Based Analysis of Tumor Spheroids and Responses to Therapeutics.
Colonic Neoplasms
The molecular chaperone Cosmc enhances malignant behaviors of colon cancer cells via activation of Akt and ERK.
Colonic Neoplasms
Verticillin A increases the BIMEL/MCL-1 ratio to overcome ABT-737-resistance in human colon cancer cells by targeting the MEK/ERK pathway.
Colonic Neoplasms
Xanthohumol chalcone acts as a powerful inhibitor of carcinogenesis in drug-resistant human colon carcinoma and these effects are mediated via G2/M phase cell cycle arrest, activation of apoptotic pathways, caspase activation and targeting Ras /MEK/ERK pathway.
Colorectal Neoplasms
Bidirectional signals transduced by TOPK-ERK interaction increase tumorigenesis of HCT116 colorectal cancer cells.
Colorectal Neoplasms
Cetuximab improves AZD6244 antitumor activity in colorectal cancer HT29 cells in vitro and in nude mice by attenuating HER3/Akt pathway activation.
Colorectal Neoplasms
Combination of CYP inhibitor with MEK/ERK inhibitor enhances the inhibitory effect on ERK in BRAF mutant colon cancer cells.
Colorectal Neoplasms
Development and External Validation of a Novel Immune Checkpoint-Related Gene Signature for Prediction of Overall Survival in Hepatocellular Carcinoma.
Colorectal Neoplasms
Effect of KRAS exon 2 mutations on antitumor activity of afatinib and gefitinib.
Colorectal Neoplasms
HMGB1-mediated autophagy modulates sensitivity of colorectal cancer cells to oxaliplatin via MEK/ERK signaling pathway.
Colorectal Neoplasms
Identification of Y-box binding protein 1 as a core regulator of MEK/ERK pathway-dependent gene signatures in colorectal cancer cells.
Colorectal Neoplasms
Inducing effects of hepatocyte growth factor on the expression of vascular endothelial growth factor in human colorectal carcinoma cells through MEK and PI3K signaling pathways.
Colorectal Neoplasms
Inhibition of extracellular-signal regulated kinases 1/2 is required for apoptosis of human colon cancer cells in vitro by sulindac metabolites.
Colorectal Neoplasms
Inhibition of MEK sensitizes paclitaxel-induced apoptosis of human colorectal cancer cells by downregulation of GRP78.
Colorectal Neoplasms
km23-1/DYNLRB1 regulation of MEK/ERK signaling and R-Ras in invasive human colorectal cancer cells.
Colorectal Neoplasms
LIM and SH3 protein 1 knockdown suppresses proliferation and metastasis of colorectal carcinoma cells via inhibition of the mitogen-activated protein kinase signaling pathway.
Colorectal Neoplasms
MEK162 Enhances Antitumor Activity of 5-Fluorouracil and Trifluridine in KRAS-mutated Human Colorectal Cancer Cell Lines.
Colorectal Neoplasms
Nanocomplexes loaded with miR-128-3p for enhancing chemotherapy effect of colorectal cancer through dual-targeting silence the activity of PI3K/AKT and MEK/ERK pathway.
Colorectal Neoplasms
Oncogenic K-ras activates p38 to maintain colorectal cancer cell proliferation during MEK inhibition.
Colorectal Neoplasms
PAR4 overexpression promotes colorectal cancer cell proliferation and migration.
Colorectal Neoplasms
Primary and acquired resistance of colorectal cancer cells to anti-EGFR antibodies converge on MEK/ERK pathway activation and can be overcome by combined MEK/EGFR inhibition.
Colorectal Neoplasms
Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers.
Colorectal Neoplasms
Resistance to 3-HTMC-induced apoptosis through activation of PI3K/Akt, MEK/ERK and p38/COX-2/PGE2 pathways in human HT-29 and HCT116 colorectal cancer cells.
Colorectal Neoplasms
Silencing of linc00337 inhibits proliferation, cell cycle progression, migration, and invasion of colorectal cancer cells through the MEK/ERK pathway.
Colorectal Neoplasms
Simultaneous targeting of EGFR and mTOR inhibits the growth of colorectal carcinoma cells.
Colorectal Neoplasms
Targeting CDK1 and MEK/ERK Overcomes Apoptotic Resistance in BRAF-Mutant Human Colorectal Cancer.
Colorectal Neoplasms
The MEK/ERK pathway mediates COX-2-selective NSAID-induced apoptosis and induced COX-2 protein expression in colorectal carcinoma cells.
Colorectal Neoplasms
The molecular chaperone Cosmc enhances malignant behaviors of colon cancer cells via activation of Akt and ERK.
Colorectal Neoplasms
The Mutant KRAS Gene Up-regulates BCL-XL Protein via STAT3 to Confer Apoptosis Resistance That Is Reversed by BIM Protein Induction and BCL-XL Antagonism.
Colorectal Neoplasms
The preclinical evaluation of the dual mTORC1/2 inhibitor INK-128 as a potential anti-colorectal cancer agent.
Coronary Occlusion
AMPK is critical for mitochondrial function during reperfusion after myocardial ischemia.
Costello Syndrome
Retinoblastoma protein modulates the inverse relationship between cellular proliferation and elastogenesis.
Cysts
Cyclic AMP activates B-Raf and ERK in cyst epithelial cells from autosomal-dominant polycystic kidneys.
Cysts
Hyperactivity of Mek in TNS1 knockouts leads to potential treatments for cystic kidney diseases.
Dehydration
Rice calcium/calmodulin-dependent protein kinase directly phosphorylates a mitogen-activated protein kinase kinase to regulate abscisic acid responses.
Dehydration
Wwox Deficiency Causes Downregulation of Prosurvival ERK Signaling and Abnormal Homeostatic Responses in Mouse Skin.
Dengue
The dengue virus envelope protein induced PAI-1 gene expression via MEK/ERK pathways.
Diabetes Mellitus
Bioactive compounds in plant materials for the prevention of diabetesand obesity.
Diabetes Mellitus
Injury-induced activation of ERK 1/2 in the sciatic nerve of healthy and diabetic rats.
Diabetes Mellitus, Type 1
GLP-2 restores impairments in spatial working memory and hippocampal LTD via the MEK/ERK pathway in juvenile-onset diabetes rats.
Diabetes Mellitus, Type 1
The MAPK kinase kinase-1 is essential for stress-induced pancreatic islet cell death.
Diabetes Mellitus, Type 2
Bioactive compounds in plant materials for the prevention of diabetesand obesity.
Diabetes Mellitus, Type 2
Inhibition of MEK1 Signaling Pathway in the Liver Ameliorates Insulin Resistance.
Diabetic Nephropathies
Induction of B1 receptors in streptozotocin diabetic rats: possible involvement in the control of hyperglycemia-induced glomerular Erk 1 and 2 phosphorylation.
Diabetic Nephropathies
Inhibition of IGF-I-induced Erk 1 and 2 activation and mitogenesis in mesangial cells by bradykinin.
Diabetic Nephropathies
Knock-Down of Long Non-Coding RNA ANRIL Suppresses Mouse Mesangial Cell Proliferation, Fibrosis, Inflammation via Regulating Wnt/?-Catenin and MEK/ERK Pathways in Diabetic Nephropathy.
Diabetic Nephropathies
NOD2 promotes endothelial-to-mesenchymal transition of glomerular endothelial cells via MEK/ERK signaling pathway in diabetic nephropathy.
Diabetic Nephropathies
Up-regulation of miR-20a weakens inflammation and apoptosis in high-glucose-induced renal tubular cell mediating diabetic kidney disease by repressing CXCL8 expression.
Diffuse Intrinsic Pontine Glioma
Dual Inhibition of PI3K/AKT and MEK/ERK Pathways Induces Synergistic Antitumor Effects in Diffuse Intrinsic Pontine Glioma Cells.
Dwarfism
C-type natriuretic Peptide plasma levels are elevated in subjects with achondroplasia, hypochondroplasia, and thanatophoric dysplasia.
Encephalitis
EP4 Receptor-Associated Protein in Microglia Promotes Inflammation in the Brain.
Encephalitis
The small molecule AZD6244 inhibits dengue virus replication in vitro and protects against lethal challenge in a mouse model.
Encephalitis, Japanese
Pathogenicity and virulence of Japanese encephalitis virus: Neuroinflammation and neuronal cell damage.
Encephalitis, St. Louis
The small molecule AZD6244 inhibits dengue virus replication in vitro and protects against lethal challenge in a mouse model.
Endometrial Neoplasms
Estrogenic G protein-coupled receptor 30 signaling is involved in regulation of endometrial carcinoma by promoting proliferation, invasion potential, and interleukin-6 secretion via the MEK/ERK mitogen-activated protein kinase pathway.
Endometrial Neoplasms
Functional and Clinicopathological Analysis of Loss of MKK4 Expression in Endometrial Cancer.
Endometrial Neoplasms
Insulin promotes proliferation, survival, and invasion in endometrial carcinoma by activating the MEK/ERK pathway.
Endometrial Neoplasms
Sirtuin 2 promotes cell stemness and MEK/ERK signaling pathway while reduces chemosensitivity in endometrial cancer.
Endometrial Neoplasms
[Coexpression of MAP2K4 and vimentin proteins in human endometrial carcinoma and its clinicopathological significance].
Endometriosis
Differential expression of genes in eutopic and ectopic endometrium from patients with ovarian endometriosis.
Endometriosis
DNA microarray analysis of gene expression profiles in deep endometriosis using laser capture microdissection.
Endometriosis
miR-196a overexpression activates the MEK/ERK signal and represses the progesterone receptor and decidualization in eutopic endometrium from women with endometriosis.
Endometriosis
USP10 promotes proliferation and migration and inhibits apoptosis of endometrial stromal cells in endometriosis through activating the Raf-1/MEK/ERK pathway.
Endotoxemia
Activation of extracellular signal-regulated kinases, NF-kappa B, and cyclic adenosine 5'-monophosphate response element-binding protein in lung neutrophils occurs by differing mechanisms after hemorrhage or endotoxemia.
Esophageal Neoplasms
Enhancement of peripheral benzodiazepine receptor ligand-induced apoptosis and cell cycle arrest of esophageal cancer cells by simultaneous inhibition of MAPK/ERK kinase.
Esophageal Neoplasms
Overexpression of miR-199a-5p decreases esophageal cancer cell proliferation through repression of mitogen-activated protein kinase kinase kinase-11 (MAP3K11).
Esophageal Neoplasms
PAR-2 promotes invasion and migration of esophageal cancer cells by activating MEK/ERK and PI3K/Akt signaling pathway.
Esophageal Neoplasms
Sulforaphene inhibits esophageal cancer progression via suppressing SCD and CDH3 expression, and activating the GADD45B-MAP2K3-p38-p53 feedback loop.
Esophageal Neoplasms
Up-regulation of MicroRNA-133a Inhibits the MEK/ERK Signaling Pathway to Promote Cell Apoptosis and Enhance Radio-sensitivity by targeting EGFR in Esophageal Cancer in Vivo and in Vitro.
Esophageal Squamous Cell Carcinoma
Cyr61 promotes CD204 expression and the migration of macrophages via MEK/ERK pathway in esophageal squamous cell carcinoma.
Esophageal Squamous Cell Carcinoma
Mitogen activated protein kinase kinase kinase 3 (MAP3K3/MEKK3) overexpression is an early event in esophageal tumorigenesis and is a predictor of poor disease prognosis.
Esophageal Squamous Cell Carcinoma
Purpurogallin is a novel mitogen-activated protein kinase kinase 1/2 inhibitor that suppresses esophageal squamous cell carcinoma growth in vitro and in vivo.
Exanthema
Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails.
Fatty Liver
Activation of ERK1/2 Ameliorates Liver Steatosis in Leptin Receptor-Deficient (db/db) Mice via Stimulating ATG7-Dependent Autophagy.
Fibrosarcoma
Cellular cholesterol regulates MT1 MMP dependent activation of MMP 2 via MEK-1 in HT1080 fibrosarcoma cells.
Fibrosarcoma
Inhibitors of Ras/Raf-1 interaction identified by two-hybrid screening revert Ras-dependent transformation phenotypes in human cancer cells.
Fibrosarcoma
Mitogen-activated protein kinase kinase signaling promotes growth and vascularization of fibrosarcoma.
Fibrosarcoma
The long noncoding RNA MEG3 regulates Ras-MAPK pathway through RASA1 in trophoblast and is associated with unexplained recurrent spontaneous abortion.
Fibrosarcoma
TIMP-2 binding with cellular MT1-MMP stimulates invasion-promoting MEK/ERK signaling in cancer cells.
Gallbladder Neoplasms
A MEK inhibitor (U0126) markedly inhibits direct liver invasion of orthotopically inoculated human gallbladder cancer cells in nude mice.
Gallbladder Neoplasms
Anti-tumor Activity of Bufalin by Inhibiting c-MET Mediated MEK/ERK and PI3K/AKT Signaling Pathways in Gallbladder Cancer.
Gallbladder Neoplasms
Overexpressed microRNA-136 works as a cancer suppressor in gallbladder cancer through suppression of JNK signaling pathway via inhibition of MAP2K4.
Glioblastoma
Analytical approach to characterize the intratumoral pharmacokinetics and pharmacodynamics of gefitinib in a glioblastoma model.
Glioblastoma
Crosstalk Between the PI3K/mTOR and MEK/ERK Pathways Involved in the Maintenance of Self-Renewal and Tumorigenicity of Glioblastoma Stem-Like Cells.
Glioblastoma
FoxO3a Functions as a Key Integrator of Cellular Signals That Control Glioblastoma Stem-like Cell Differentiation and Tumorigenicity.
Glioblastoma
Histone deacetylase 1 promotes glioblastoma cell proliferation and invasion via activation of PI3K/AKT and MEK/ERK signaling pathways.
Glioblastoma
Hypoxia-induced acetylation of PAK1 enhances autophagy and promotes brain tumorigenesis via phosphorylating ATG5.
Glioblastoma
Inhibition of the PI3K but not the MEK/ERK pathway sensitizes human glioma cells to alkylating drugs.
Glioblastoma
Intronic miR-744 Inhibits Glioblastoma Migration by Functionally Antagonizing Its Host Gene MAP2K4.
Glioblastoma
Rehmannia glutinosa induces glial cell line-derived neurotrophic factor gene expression in astroglial cells via cPKC and ERK1/2 pathways independently.
Glioblastoma
Xyloketal B suppresses glioblastoma cell proliferation and migration in vitro through inhibiting TRPM7-regulated PI3K/Akt and MEK/ERK signaling pathways.
Glioma
Delta opioid activation of the mitogen-activated protein kinase cascade does not require transphosphorylation of receptor tyrosine kinases.
Glioma
Dual Inhibition of PI3K/AKT and MEK/ERK Pathways Induces Synergistic Antitumor Effects in Diffuse Intrinsic Pontine Glioma Cells.
Glioma
Glial cell line-derived neurotrophic factor induces cell migration and matrix metalloproteinase-13 expression in glioma cells.
Glioma
Globularifolin exerts anticancer effects on glioma U87 cells through inhibition of Akt/mTOR and MEK/ERK signaling pathways in vitro and inhibits tumor growth in vivo.
Glioma
Hypoxia-induced acetylation of PAK1 enhances autophagy and promotes brain tumorigenesis via phosphorylating ATG5.
Glioma
Increased sensitivity to the platelet-derived growth factor (PDGF) receptor inhibitor STI571 in chemoresistant glioma cells is associated with enhanced PDGF-BB-mediated signaling and STI571-induced Akt inactivation.
Glioma
Induction of transforming growth factor-beta1 by basic fibroblast growth factor in rat C6 glioma cells and astrocytes is mediated by MEK/ERK signaling and AP-1 activation.
Glioma
Inhibition of histamine receptor 3 suppresses glioblastoma tumor growth, invasion, and epithelial-to-mesenchymal transition.
Glioma
Inhibition of the PI3K but not the MEK/ERK pathway sensitizes human glioma cells to alkylating drugs.
Glioma
Interaction of hsa-miR-381 and glioma suppressor LRRC4 is involved in glioma growth.
Glioma
Knockdown of ER-?36 expression inhibits glioma proliferation, invasion and epithelial-to-mesenchymal transition.
Glioma
Licochalcone A inhibits the invasive potential of human glioma cells by targeting the MEK/ERK and ADAM9 signaling pathways.
Glioma
Long noncoding RNA HNF1A-AS1 regulates proliferation and apoptosis of glioma through activation of the JNK signaling pathway via miR-363-3p/MAP2K4.
Glioma
Long noncoding RNA-GAS5 attenuates progression of glioma by eliminating microRNA-10b and Sirtuin 1 in U251 and A172 cells.
Glioma
MAP-ing glioma invasion: mitogen-activated protein kinase kinase 3 and p38 drive glioma invasion and progression and predict patient survival.
Glioma
MEK-ERK-dependent multiple caspase activation by mitochondrial proapoptotic Bcl-2 family proteins is essential for heavy ion irradiation-induced glioma cell death.
Glioma
MEK2 is a prognostic marker and potential chemo-sensitizing target for glioma patients undergoing temozolomide treatment.
Glioma
MicroRNA-338-5p plays a tumor suppressor role in glioma through inhibition of the MAPK-signaling pathway by binding to FOXD1.
Glioma
Mitochondrial KATP Channels Control Glioma Radioresistance by Regulating ROS-Induced ERK Activation.
Glioma
Protein kinase C-mediated in vitro invasion of human glioma cells through extracellular-signal-regulated kinase and ornithine decarboxylase.
Glioma
Proteomic expression analysis and comparison of protein and mRNA expression profiles in human malignant gliomas.
Glioma
Ro31-8220 inhibits protein kinase C to block the phorbol ester-stimulated release of choline- and ethanolamine-metabolites from C6 glioma cells: p70 S6 kinase and MAPKAP kinase-1beta do not function downstream of PKC in activating PLD.
Glioma
Suppression of Rac activity induces apoptosis of human glioma cells but not normal human astrocytes.
Glioma
T11TS inhibits Angiopoietin-1/Tie-2 signaling, EGFR activation and Raf/MEK/ERK pathway in brain endothelial cells restraining angiogenesis in glioma model.
Glioma
The D Domain of LRRC4 anchors ERK1/2 in the cytoplasm and competitively inhibits MEK/ERK activation in glioma cells.
Glioma
The Use of MEK Inhibitors in Neurofibromatosis Type 1-Associated Tumors and Management of Toxicities.
Glioma
Transcriptional Repression of Mad-Max Complex by Human Umbilical Cord Blood Stem Cells Downregulates Extracellular Signal-Regulated Kinase in Glioblastoma.
Glioma
[Mig-7 gene silencing inhibits vasculogenic mimicry formation and invasion of glioma U251 cells in vitro by suppressing MEK/ERK signaling].
Glioma
[Retracted] Anticancer activity of caffeic acid n?butyl ester against A431 skin carcinoma cell line occurs via induction of apoptosis and inhibition of the mTOR/PI3K/AKT signaling pathway.
Glomerulonephritis, IGA
The IgA1 immune complex-mediated activation of the MAPK/ERK kinase pathway in mesangial cells is associated with glomerular damage in IgA nephropathy.
Heart Defects, Congenital
Functional evidence of mTOR? splice variant involvement in the pathogenesis of congenital heart defects.
Heart Failure
Type 5 Adenylyl Cyclase Increases Oxidative Stress by Transcriptional Regulation of MnSOD via the SIRT1/FoxO3a Pathway.
Heart Failure
Zebrafish heart failure models for the evaluation of chemical probes and drugs.
Hemangiosarcoma
Inhibition of MAP kinase kinase causes morphological reversion and dissociation between soft agar growth and in vivo tumorigenesis in angiosarcoma cells.
Hepatitis A
Knockdown of Mitogen-Activated Protein Kinase Kinase 3 Negatively Regulates Hepatitis A Virus Replication.
Hepatitis B
Hepatitis B virus core protein sensitizes hepatocytes to tumor necrosis factor-induced apoptosis by suppression of the phosphorylation of mitogen-activated protein kinase kinase 7.
Hepatitis C
Hepatitis C Virus Nonstructural 5A Protein Interacts with Abelson Interactor 1 and Modulates Epidermal Growth Factor-Mediated MEK/ERK Signaling Pathway.
Hepatitis C
Up-Regulation of Hepatitis C Virus Replication and Production by Inhibition of MEK/ERK Signaling.
Hepatoblastoma
Huaier Extract Induces Apoptosis in Hepatoblastoma Cells Via the MEK/ERK Signaling Pathway.
Herpes Simplex
Novel Agents in the Management of Pancreatic Adenocarcinoma: Phase I Studies. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011.
Herpes Zoster
Adrenomedullin stimulates DNA synthesis of rat adrenal zona glomerulosa cells through activation of the mitogen-activated protein kinase-dependent cascade.
Herpesviridae Infections
Modulation of Kaposi's sarcoma-associated herpesvirus infection and replication by MEK/ERK, JNK, and p38 multiple mitogen-activated protein kinase pathways during primary infection.
Herpesviridae Infections
Reactivation of Kaposi's sarcoma-associated herpesvirus from latency requires MEK/ERK, JNK and p38 multiple mitogen-activated protein kinase pathways.
Hodgkin Disease
B7-H1 expression is regulated by MEK/ERK signaling pathway in anaplastic large cell lymphoma and Hodgkin lymphoma.
Hodgkin Disease
MEK/ERK pathway is aberrantly active in Hodgkin disease: a signaling pathway shared by CD30, CD40, and RANK that regulates cell proliferation and survival.
Huntington Disease
A chemical genomics-aggrephagy integrated method studying functional analysis of autophagy inducers.
Hyperalgesia
Activation of spinal ERK signaling pathway contributes to pain-related responses induced by scorpion Buthus martensi Karch venom.
Hyperalgesia
Early intervention of ERK activation in the spinal cord can block initiation of peripheral nerve injury-induced neuropathic pain in rats.
Hyperalgesia
ERK MAP kinase activation in spinal cord regulates phosphorylation of Cdk5 at serine 159 and contributes to peripheral inflammation induced pain/hypersensitivity.
Hyperalgesia
Impaired Inflammatory Pain and Thermal Hyperalgesia in Mice Expressing Neuron-Specific Dominant Negative Mitogen Activated Protein Kinase Kinase (MEK).
Hyperalgesia
Low nociceptor GRK2 prolongs prostaglandin E2 hyperalgesia via biased cAMP signaling to Epac/Rap1, protein kinase Cepsilon, and MEK/ERK.
Hyperalgesia
Protease-activated receptor-2 in endosomes signals persistent pain of irritable bowel syndrome.
Hyperalgesia
Rational Basis for the Use of Bergamot Essential Oil in Complementary Medicine to Treat Chronic Pain.
Hyperalgesia
Second messengers mediating the expression of neuroplasticity in a model of chronic pain in the rat.
Hyperglycemia
High glucose exacerbates neuroinflammation and apoptosis at the intermediate stage after post-traumatic brain injury.
Hyperglycemia
Hyperglycemia acutely increases monocyte extracellular signal-regulated kinase activity in vivo in humans.
Hyperglycemia
Hyperglycemia reduces nitric oxide synthase and glycogen synthase activity in endothelial cells.
Hyperglycemia
Increase in cardiac M(2)-muscarinic receptor expression is regulated by GATA binding protein 4 (GATA-4) in streptozotocin-induced diabetic rats.
Hyperpigmentation
Inhibition of melanogenesis by Aster yomena callus pellet extract in melanoma cells and patients with skin pigmentation.
Hyperpigmentation
The Anti-Melanogenesis Effect of 3,4-Dihydroxybenzalacetone through Downregulation of Melanosome Maturation and Transportation in B16F10 and Human Epidermal Melanocytes.
Hypersensitivity
A Caenorhabditis elegans MAP kinase kinase, MEK-1, is involved in stress responses.
Hypersensitivity
Activation of spinal extracellular signaling-regulated kinases by intraplantar melittin injection.
Hypersensitivity
Crosstalk between protein kinase A and the HOG pathway under impaired biosynthesis of complex sphingolipids in budding yeast.
Hypersensitivity
Dexmedetomidine Relieves Acute Inflammatory Visceral Pain in Rats through the ERK Pathway, Toll-Like Receptor Signaling, and TRPV1 Channel.
Hypersensitivity
jkk-1 and mek-1 regulate body movement coordination and response to heavy metals through jnk-1 in Caenorhabditis elegans.
Hypertension
Angiotensin II activates extracellular signal-regulated kinase independently of receptor tyrosine kinases in renal smooth muscle cells: implications for blood pressure regulation.
Hypertension
Angiotensin II-Induced vascular remodeling and hypertension involves cathepsin L/V- MEK/ERK mediated mechanism.
Hypertension
Cross-talking between calcium and histamine in the expression of MAPKs in hypertensive vascular smooth muscle cells.
Hypertension
The promoting role of Cx43 on the proliferation and migration of arterial smooth muscle cells for angiotensin II-dependent hypertension.
Hypertension
TRPM7 channel inhibition exacerbates pulmonary arterial hypertension through MEK/ERK pathway.
Hypertension, Pulmonary
MAP kinase kinase kinase-2 (MEKK2) regulates hypertrophic remodeling of the right ventricle in hypoxia-induced pulmonary hypertension.
Hypertrophy, Left Ventricular
A combined linkage, microarray and exome analysis suggests MAP3K11 as a candidate gene for left ventricular hypertrophy.
Hypopigmentation
Inhibition of melanogenesis by gallic acid: possible involvement of the PI3K/Akt, MEK/ERK and Wnt/?-catenin signaling pathways in B16F10 cells.
Hypopigmentation
Partially purified components of Nardostachys chinensis suppress melanin synthesis through ERK and Akt signaling pathway with cAMP down-regulation in B16F10 cells.
Infarction, Middle Cerebral Artery
Similar time-course of interleukin-1 beta production and extracellular-signal-regulated kinase (ERK) activation in permanent focal brain ischemic injury.
Infections
A MAP Kinase Kinase Interacts with SymRK and Regulates Nodule Organogenesis in Lotus japonicus.
Infections
Activation of Aquaporin 5 by carcinogenic Helicobacter pylori infection promotes epithelial-mesenchymal transition via the MEK/ERK pathway.
Infections
Activation of ERK2 by respiratory syncytial virus in A549 cells is linked to the production of interleukin 8.
Infections
Activation of PI3K, Akt, and ERK during early rotavirus infection leads to V-ATPase-dependent endosomal acidification required for uncoating.
Infections
Berberine inhibits enterovirus 71 replication by downregulating the MEK/ERK signaling pathway and autophagy.
Infections
Ca(2+)-independent protein kinase C activity is required for alpha1-adrenergic-receptor-mediated regulation of ribosomal protein S6 kinases in adult cardiomyocytes.
Infections
Cardiac muscle cell hypertrophy and apoptosis induced by distinct members of the p38 mitogen-activated protein kinase family.
Infections
Cellular localization and role of kinase activity of PMK1 in Magnaporthe grisea.
Infections
CVB3 Nonstructural 2A Protein Modulates SREBP1a Signaling via the MEK/ERK Pathway.
Infections
Detection and quantification of anthrax lethal factor in serum by mass spectrometry.
Infections
Divergent requirements for the MAPK(ERK) signal transduction pathway during initial virus infection of quiescent primary B cells and disruption of Epstein-Barr virus latency by phorbol esters.
Infections
Drug-resistance in doxorubicin-resistant FL5.12 hematopoietic cells: elevated MDR1, drug efflux and side-population positive and decreased BCL2-family member expression.
Infections
Effect of Cryphonectria hypovirus 1 (CHV1) infection on Cpkk1, a mitogen-activated protein kinase kinase of the filamentous fungus Cryphonectria parasitica.
Infections
Exogenous gamma and alpha/beta interferon rescues human macrophages from cell death induced by Bacillus anthracis.
Infections
Functional Involvement of a Mitogen Activated Protein Kinase Module, OsMKK3-OsMPK7-OsWRK30 in Mediating Resistance against Xanthomonas oryzae in Rice.
Infections
Helicobacter pylori activate epidermal growth factor receptor- and phosphatidylinositol 3-OH kinase-dependent Akt and glycogen synthase kinase 3beta phosphorylation.
Infections
Helicobacter pylori induces Snail expression through ROS-mediated activation of Erk and inactivation of GSK-3? in human gastric cancer cells.
Infections
Identification of novel human kinases that suppress hepatitis C virus infection.
Infections
Induction of prostaglandin endoperoxide synthase 2 by mitogen-activated protein kinase cascades.
Infections
Investigation on the partial resistance of Cpkk2 knock out strain of Cryphonectria parasitica to Cryphonectria hypovirus 1 infection in presence of Geneticin and Geneticin resistance gene.
Infections
Isolation and expression analysis of an MAPKK gene from Fenneropenaeus chinensis in response to white spot syndrome virus infection.
Infections
Knockdown of Mitogen-Activated Protein Kinase Kinase 3 Negatively Regulates Hepatitis A Virus Replication.
Infections
Listeria monocytogenes infection of HeLa cells results in listeriolysin O-mediated transient activation of the Raf-MEK-MAP kinase pathway.
Infections
MAPK involvement in cytokine production in response to Corynebacterium pseudotuberculosis infection.
Infections
MEK/ERK signaling pathway is required for enterovirus 71 replication in immature dendritic cells.
Infections
Modulation of Kaposi's sarcoma-associated herpesvirus infection and replication by MEK/ERK, JNK, and p38 multiple mitogen-activated protein kinase pathways during primary infection.
Infections
Murine Lyme arthritis development mediated by p38 mitogen-activated protein kinase activity.
Infections
Newcastle Disease Virus Nonstructural V Protein Upregulates SOCS3 Expression to Facilitate Viral Replication Depending on the MEK/ERK Pathway.
Infections
Phosphatidylinositol 3-Kinase/Akt and MEK/ERK Signaling Pathways Facilitate Sapovirus Trafficking and Late Endosomal Acidification for Viral Uncoating in LLC-PK Cells.
Infections
Porphyromonas gingivalis activates NF?B and MAPK pathways in human oral epithelial cells.
Infections
Productive parvovirus B19 infection of primary human erythroid progenitor cells at hypoxia is regulated by STAT5A and MEK signaling but not HIF?.
Infections
Progressive Accumulation of Activated ERK2 within Highly Stable ORF45-Containing Nuclear Complexes Promotes Lytic Gammaherpesvirus Infection.
Infections
Reactivation of Kaposi's sarcoma-associated herpesvirus from latency requires MEK/ERK, JNK and p38 multiple mitogen-activated protein kinase pathways.
Infections
Shedding light on autophagy coordinating with cell wall integrity signaling to govern pathogenicity of Magnaporthe oryzae.
Infections
The interplay between Araçatuba virus and host signaling pathways: role of PI3K/Akt in viral replication.
Infections
The MAP Kinase Kinase Gene AbSte7 Regulates Multiple Aspects of Alternaria brassicicola Pathogenesis.
Infections
The protective role of microRNA-21 against coxsackievirus B3 infection through targeting the MAP2K3/P38 MAPK signaling pathway.
Infections
The RAS/Raf1/MEK/ERK signaling pathway facilitates VSV-mediated oncolysis: implication for the defective interferon response in cancer cells.
Infections
The RAS/Raf1/MEK/ERK Signaling Pathway Facilitates VSV-mediated Oncolysis: Implication for the Defective Interferon Response in Cancer Cells.
Infections
Transcriptome-based analysis of mitogen-activated protein kinase cascades in the rice response to Xanthomonas oryzae infection.
Insulin Resistance
Dihydromyricetin enhances glucose uptake by inhibition of MEK/ERK pathway and consequent down-regulation of phosphorylation of PPAR? in 3T3-L1 cells.
Insulin Resistance
Hepatic serum- and glucocorticoid-regulated protein kinase 1 (SGK1) regulates insulin sensitivity in mice via extracellular-signal-regulated kinase 1/2 (ERK1/2).
Insulin Resistance
In silico analysis of non-coding RNAs and putative target genes implicated in metabolic syndrome.
Insulin Resistance
Inhibition of MEK1 Signaling Pathway in the Liver Ameliorates Insulin Resistance.
Insulin Resistance
Pathways leading to phosphorylation of p450c17 and to the posttranslational regulation of androgen biosynthesis.
Insulin Resistance
Phosphorylation of Beta-3 adrenergic receptor at serine 247 by ERK MAP kinase drives lipolysis in obese adipocytes.
Insulin Resistance
Three mitogen-activated protein kinases inhibit insulin signaling by different mechanisms in 3T3-L1 adipocytes.
Intellectual Disability
Fragile X mental retardation protein promotes astrocytoma proliferation via the MEK/ERK signaling pathway.
Ischemic Stroke
Analysis of Association between MAP2K4 Gene Polymorphism rs3826392 and IL-1b Serum Level in Southern Chinese Han Ischemic Stroke Patients.
Keratoacanthoma
Keratoacanthoma, palmoplantar keratoderma developing in an advanced melanoma patient treated with vemurafenib regressed by blockade of mitogen-activated protein kinase kinase signaling.
Keratoderma, Palmoplantar
Keratoacanthoma, palmoplantar keratoderma developing in an advanced melanoma patient treated with vemurafenib regressed by blockade of mitogen-activated protein kinase kinase signaling.
Kidney Diseases, Cystic
Hyperactivity of Mek in TNS1 knockouts leads to potential treatments for cystic kidney diseases.
Kidney Neoplasms
Chelerythrine chloride induces apoptosis in renal cancer HEK-293 and SW-839 cell lines.
Laryngeal Neoplasms
A combined modality of carboplatin and photodynamic therapy suppresses epithelial-mesenchymal transition and matrix metalloproteinase-2 (MMP-2)/MMP-9 expression in HEp-2 human laryngeal cancer cells via ROS-mediated inhibition of MEK/ERK signalling pathway.
Laryngeal Neoplasms
Anticancer Activity of Mukonal Against Human Laryngeal Cancer Cells Involves Apoptosis, Cell Cycle Arrest, and Inhibition of PI3K/AKT and MEK/ERK Signalling Pathways.
Leiomyoma
Detection of novel copy number variants in uterine leiomyomas using high-resolution SNP arrays.
Leiomyosarcoma
Molecular profiling of soft tissue sarcomas using next-generation sequencing: a pilot study toward precision therapeutics.
Leishmaniasis, Cutaneous
Cellular and humoral responses against Leishmania virulence factors in healed Cutaneous Leishmaniasis and Mediterranean Visceral Leishmaniasis patients.
Leishmaniasis, Visceral
Cellular and humoral responses against Leishmania virulence factors in healed Cutaneous Leishmaniasis and Mediterranean Visceral Leishmaniasis patients.
Leukemia
2-Deoxy-D-glucose cooperates with arsenic trioxide to induce apoptosis in leukemia cells: involvement of IGF-1R-regulated Akt/mTOR, MEK/ERK and LKB-1/AMPK signaling pathways.
Leukemia
Activation of AP-1 is required for bufalin-induced apoptosis in human leukemia U937 cells.
Leukemia
Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies.
Leukemia
AMPK activators contribute to maintain naïve pluripotency in mouse embryonic stem cells.
Leukemia
Bcl-2 protein inhibits bufalin-induced apoptosis through inhibition of mitogen-activated protein kinase activation in human leukemia U937 cells.
Leukemia
Block of C/EBP{alpha} function by phosphorylation in acute myeloid leukemia with FLT3 activating mutations.
Leukemia
Blockade of MEK/ERK signaling enhances sunitinib-induced growth inhibition and apoptosis of leukemia cells possessing activating mutations of the FLT3 gene.
Leukemia
Cbl-b promotes chemotherapy-induced apoptosis in rat basophilic leukemia cells by suppressing PI3K/Akt activation and enhancing MEK/ERK activation.
Leukemia
Chemical Reversion of Conventional Human Pluripotent Stem Cells to a Naïve-like State with Improved Multilineage Differentiation Potency.
Leukemia
Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1/2 inactivation and the generation of ceramide and reactive oxygen species.
Leukemia
Coadministration of UCN-01 with MEK1/2 inhibitors potently induces apoptosis in BCR/ABL+ leukemia cells sensitive and resistant to ST1571.
Leukemia
Derivation of Embryonic Stem Cell Lines From Parthenogenetically Developing Rat Blastocysts.
Leukemia
Downregulating Notch counteracts KrasG12D-induced ERK activation and oxidative phosphorylation in myeloproliferative neoplasm.
Leukemia
Farnesyltransferase inhibitors interact synergistically with the Chk1 inhibitor UCN-01 to induce apoptosis in human leukemia cells through interruption of both Akt and MEK/ERK pathways and activation of SEK1/JNK.
Leukemia
FLT3-ITD Activates RSK1 to Enhance Proliferation and Survival of AML Cells by Activating mTORC1 and eIF4B Cooperatively with PIM or PI3K and by Inhibiting Bad and BIM.
Leukemia
Friedelin inhibits the growth and metastasis of human leukemia cells via modulation of MEK/ERK and PI3K/AKT signalling pathways.
Leukemia
GDNF-induced leukemia inhibitory factor can mediate differentiation via the MEK/ERK pathway in pheochromocytoma cells derived from nf1-heterozygous knockout mice.
Leukemia
HDAC3 as a molecular chaperone for shuttling phosphorylated TR2 to PML: a novel deacetylase activity-independent function of HDAC3.
Leukemia
HMGB1 promotes differentiation syndrome by inducing hyperinflammation via MEK/ERK signaling in acute promyelocytic leukemia cells.
Leukemia
Induction of differentiation-specific miRNAs in TPA-induced myeloid leukemia cells through MEK/ERK activation.
Leukemia
Inhibition of the MAP2K7-JNK pathway with 5Z-7-oxozeaenol induces apoptosis in T-cell acute lymphoblastic leukemia.
Leukemia
Interleukin-1beta can mediate growth arrest and differentiation via the leukemia inhibitory factor/JAK/STAT pathway in medullary thyroid carcinoma cells.
Leukemia
Interruption of the MEK/ERK signaling cascade promotes dihydroartemisinin-induced apoptosis in vitro and in vivo.
Leukemia
Involvement of protein kinase C during activation of the mitogen-activated protein kinase cascade by leukemia inhibitory factor. Evidence for participation of multiple signaling pathways.
Leukemia
Isoflavones regulate secretion of leukemia inhibitory factor and transforming growth factor {beta} and expression of glycodelin in human endometrial epithelial cells.
Leukemia
Jun N-terminal kinase pathway enhances signaling of monocytic differentiation of human leukemia cells induced by 1,25-dihydroxyvitamin D3.
Leukemia
Leukemia inhibitory factor activates cardiac L-Type Ca2+ channels via phosphorylation of serine 1829 in the rabbit Cav1.2 subunit.
Leukemia
Lithium chloride antileukemic activity in acute promyelocytic leukemia is GSK-3 and MEK/ERK dependent.
Leukemia
MEK blockade converts AML differentiating response to retinoids into extensive apoptosis.
Leukemia
Metformin induces differentiation in acute promyelocytic leukemia by activating the MEK/ERK signaling pathway.
Leukemia
MS-275, a novel histone deacetylase inhibitor with selectivity against HDAC1, induces degradation of FLT3 via inhibition of chaperone function of heat shock protein 90 in AML cells.
Leukemia
Normal hematopoiesis and neurofibromin-deficient myeloproliferative disease require Erk.
Leukemia
Novel tumor-suppressor function of KLF4 in pediatric T-cell acute lymphoblastic leukemia.
Leukemia
Pharmacologic inhibitors of extracellular signal-regulated kinase (ERKs) and c-Jun NH(2)-terminal kinase (JNK) decrease glutathione content and sensitize human promonocytic leukemia Cells to arsenic trioxide-induced apoptosis.
Leukemia
RAF-1/MEK/ERK pathway regulates ATRA-induced differentiation in acute promyelocytic leukemia cells through C/EBP?, C/EBP? and PU.1.
Leukemia
Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition.
Leukemia
Renal carcinogenesis in models of diabetes in rats: metabolic changes are closely related to neoplastic development.
Leukemia
Reprogramming of mouse somatic cells into pluripotent stem-like cells using a combination of small molecules.
Leukemia
Small-Molecule Induction of Canine Embryonic Stem Cells Toward Naïve Pluripotency.
Leukemia
Sorafenib inhibited cell growth through the MEK/ERK signaling pathway in acute promyelocytic leukemia cells.
Leukemia
Specific inhibition of basal mitogen-activated protein kinases and phosphatidylinositol 3 kinase activities in leukemia cells: a possible therapeutic role for the kinase inhibitors.
Leukemia
Staurosporine enhances ATRA-induced granulocytic differentiation in human leukemia U937 cells via the MEK/ERK signaling pathway.
Leukemia
Synergistic Interactions between DMAG and Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitors in Bcr/abl+ Leukemia Cells Sensitive and Resistant to Imatinib Mesylate.
Leukemia
The combination of UCN-01 and ATRA triggers differentiation in ATRA resistant acute promyelocytic leukemia cell lines via RAF-1 independent activation of MEK/ERK.
Leukemia
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) promotes mitochondrial dysfunction and apoptosis induced by 7-hydroxystaurosporine and mitogen-activated protein kinase kinase inhibitors in human leukemia cells that ectopically express Bcl-2 and Bcl-xL.
Leukemia, B-Cell
MAP3K11 is a tumor suppressor targeted by the oncomiR miR-125b in early B cells.
Leukemia, Lymphocytic, Chronic, B-Cell
Bayesian inference of MicroRNA targets from sequence and expression data.
Leukemia, Lymphoid
MEK/ERK pathway protects ionizing radiation-induced loss of mitochondrial membrane potential and cell death in lymphocytic leukemia cells.
Leukemia, Monocytic, Acute
Role of growth hormone signaling pathways in the development of atherosclerosis.
Leukemia, Myeloid
Cell-cycle-dependent activation of mitogen-activated protein kinase kinase (MEK-1/2) in myeloid leukemia cell lines and induction of growth inhibition and apoptosis by inhibitors of RAS signaling.
Leukemia, Myeloid
Epicatechin and a cocoa polyphenolic extract modulate gene expression in human Caco-2 cells.
Leukemia, Myeloid
Induction of differentiation-specific miRNAs in TPA-induced myeloid leukemia cells through MEK/ERK activation.
Leukemia, Myeloid
Modulation of anthracycline-induced cytotoxicity by targeting the prenylated proteome in myeloid leukemia cells.
Leukemia, Myeloid, Acute
An investigation of the MEK/ERK inhibitor U0126 in acute myeloid leukemia.
Leukemia, Myeloid, Acute
Chidamide Inhibits Acute Myeloid Leukemia Cell Proliferation by lncRNA VPS9D1-AS1 Downregulation via MEK/ERK Signaling Pathway.
Leukemia, Myeloid, Acute
Combinatorial targeting of XPO1 and FLT3 exerts synergistic anti-leukemia effects through induction of differentiation and apoptosis in FLT3-mutated acute myeloid leukemias: from concept to clinical trial.
Leukemia, Myeloid, Acute
Inhibition of MEK/ERK signaling induces apoptosis of acute myelogenous leukemia cells via inhibition of eukaryotic initiation factor 4E-binding protein 1 and down-regulation of Mcl-1.
Leukemia, Myeloid, Acute
Inhibition of MEK/ERK signaling synergistically potentiates histone deacetylase inhibitor-induced growth arrest, apoptosis and acetylation of histone H3 on p21waf1 promoter in acute myelogenous leukemia cell.
Leukemia, Myeloid, Acute
MEK blockade converts AML differentiating response to retinoids into extensive apoptosis.
Leukemia, Myeloid, Acute
MEK/ERK dependent activation of STAT1 mediates dasatinib-induced differentiation of acute myeloid leukemia.
Leukemia, Myeloid, Acute
Mitogen-activated protein kinase kinase inhibition enhances nuclear proapoptotic function of p53 in acute myelogenous leukemia cells.
Leukemia, Myeloid, Acute
PD98059 triggers G1 arrest and apoptosis in human leukemic U937 cells through downregulation of Akt signal pathway.
Leukemia, Myeloid, Acute
Quantitative single cell determination of ERK phosphorylation and regulation in relapsed and refractory primary acute myeloid leukemia.
Leukemia, Myeloid, Acute
The HER2 inhibitor TAK165 Sensitizes Human Acute Myeloid Leukemia Cells to Retinoic Acid-Induced Myeloid Differentiation by activating MEK/ERK mediated RAR?/STAT1 axis.
Leukemia, Promyelocytic, Acute
HMGB1 promotes differentiation syndrome by inducing hyperinflammation via MEK/ERK signaling in acute promyelocytic leukemia cells.
Leukemia, Promyelocytic, Acute
Lithium chloride antileukemic activity in acute promyelocytic leukemia is GSK-3 and MEK/ERK dependent.
Leukemia, Promyelocytic, Acute
MEK blockade converts AML differentiating response to retinoids into extensive apoptosis.
Leukemia, Promyelocytic, Acute
Metformin induces differentiation in acute promyelocytic leukemia by activating the MEK/ERK signaling pathway.
Leukemia, Promyelocytic, Acute
Pharmacologic inhibitors of extracellular signal-regulated kinase (ERKs) and c-Jun NH(2)-terminal kinase (JNK) decrease glutathione content and sensitize human promonocytic leukemia Cells to arsenic trioxide-induced apoptosis.
Leukemia, Promyelocytic, Acute
RAF-1/MEK/ERK pathway regulates ATRA-induced differentiation in acute promyelocytic leukemia cells through C/EBP?, C/EBP? and PU.1.
Leukemia, Promyelocytic, Acute
Sorafenib inhibited cell growth through the MEK/ERK signaling pathway in acute promyelocytic leukemia cells.
Leukemia, Promyelocytic, Acute
The combination of UCN-01 and ATRA triggers differentiation in ATRA resistant acute promyelocytic leukemia cell lines via RAF-1 independent activation of MEK/ERK.
Leukemia-Lymphoma, Adult T-Cell
Transcriptional regulation of parathyroid hormone-related protein promoter P3 by ETS-1 in adult T-cell leukemia/lymphoma.
Liver Neoplasms
Potentiation of the antitumor effects of both selective cyclooxygenase-1 and cyclooxygenase-2 inhibitors in human hepatic cancer cells by inhibition of the MEK/ERK pathway.
Liver Neoplasms
RNAi-mediated ERK2 knockdown inhibits growth of tumor cells in vitro and in vivo.
Liver Neoplasms
The role and mechanism of WEE1 on the cisplatin resistance reversal of the HepG2/DDP human hepatic cancer cell line.
Lung Injury
Reactive oxygen species (ROS) and reactive nitrogen species (RNS) generation by silica in inflammation and fibrosis.
Lung Injury
The effect of miR-21-5p on the MAP2K3 expressions and cellular apoptosis in the lung tissues of neonatal rats with hyperoxia-induced lung injuries.
Lung Neoplasms
A bombesin receptor subtype-3 peptide increases nuclear oncogene expression in a MEK-1 dependent manner in human lung cancer cells.
Lung Neoplasms
A Ferulic Acid Derivative FXS-3 Inhibits Proliferation and Metastasis of Human Lung Cancer A549 Cells via Positive JNK Signaling Pathway and Negative ERK/p38, AKT/mTOR and MEK/ERK Signaling Pathways.
Lung Neoplasms
AKR1B10 (Aldo-keto reductase family 1 B10) promotes brain metastasis of lung cancer cells in a multi-organ microfluidic chip model.
Lung Neoplasms
Aldehyde Dehydrogenase 1 (ALDH1) Promotes the Toxicity of TRAIL in Non-Small Cell Lung Cancer Cells via Post-Transcriptional Regulation of MEK-1 Expression.
Lung Neoplasms
An integrative pharmacogenomics analysis identifies therapeutic targets in KRAS-mutant lung cancer.
Lung Neoplasms
Anlotinib Exerts Anti-Cancer Effects on KRAS-Mutated Lung Cancer Cell Through Suppressing the MEK/ERK Pathway.
Lung Neoplasms
Apoptosis induced by depsipeptide FK228 coincides with inhibition of survival signaling in lung cancer cells.
Lung Neoplasms
Blockade of ?7 nicotinic acetylcholine receptors inhibit nicotine-induced tumor growth and vimentin expression in non-small cell lung cancer through MEK/ERK signaling way.
Lung Neoplasms
Blocking the PI3K/AKT and MEK/ERK signaling pathways can overcome gefitinib-resistance in non-small cell lung cancer cell lines.
Lung Neoplasms
BYL719, a selective inhibitor of phosphoinositide 3-Kinase ?, enhances the effect of selumetinib (AZD6244, ARRY-142886) in KRAS-mutant non-small cell lung cancer.
Lung Neoplasms
Cancer cell-intrinsic expression of MHC II in lung cancer cell lines is actively restricted by MEK/ERK signaling and epigenetic mechanisms.
Lung Neoplasms
Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium.
Lung Neoplasms
Combination therapies with mitogen-activated protein kinase kinase inhibitors and immune checkpoint inhibitors in non-small cell lung cancer.
Lung Neoplasms
Concurrent inhibition of ErbB family and MEK/ERK kinases to suppress non-small cell lung cancer proliferation.
Lung Neoplasms
Effects of 3-Tetrazolyl Methyl-3-Hydroxy-Oxindole Hybrid (THOH) on Cell Proliferation, Apoptosis, and G2/M Cell Cycle Arrest Occurs by Targeting Platelet-Derived Growth Factor D (PDGF-D) and the MEK/ERK Signaling Pathway in Human Lung Cell Lines SK-LU-1, A549, and A-427.
Lung Neoplasms
Enhanced G1 arrest and apoptosis via MDM4/MDM2 double knockdown and MEK inhibition in wild-type TP53 colon and gastric cancer cells with aberrant KRAS signaling.
Lung Neoplasms
Enhancing NK cell-mediated cytotoxicity to cisplatin-resistant lung cancer cells via MEK/Erk signaling inhibition.
Lung Neoplasms
Enhancing therapeutic efficacy of the MEK inhibitor, MEK162, by blocking autophagy or inhibiting PI3K/Akt signaling in human lung cancer cells.
Lung Neoplasms
Evidence that phosphatidylinositol 3-kinase- and mitogen-activated protein kinase kinase-4/c-Jun NH2-terminal kinase-dependent Pathways cooperate to maintain lung cancer cell survival.
Lung Neoplasms
Gastrointestinal perforation following dabrafenib and trametinib administration in non-small cell lung carcinoma with BRAF V600E mutation: a case report and literature review.
Lung Neoplasms
Gefitinib-Resistance Is Related to BIM Expression in Non-Small Cell Lung Cancer Cell Lines.
Lung Neoplasms
GINS2 facilitates epithelial-to-mesenchymal transition in non-small-cell lung cancer through modulating PI3K/Akt and MEK/ERK signaling.
Lung Neoplasms
HER2 induces cell proliferation and invasion of non-small-cell lung cancer by upregulating COX-2 expression via MEK/ERK signaling pathway.
Lung Neoplasms
High level of AKT activity is associated with resistance to MEK inhibitor AZD6244 (ARRY-142886).
Lung Neoplasms
Inhibition of histamine receptor H3 suppresses the growth and metastasis of human non-small cell lung cancer cells via inhibiting PI3K/Akt/mTOR and MEK/ERK signaling pathways and blocking EMT.
Lung Neoplasms
Inhibition of Mitogen-Activated Protein Kinase Kinase Alone and in Combination with Anaplastic Lymphoma Kinase (ALK) Inhibition Suppresses Tumor Growth in a Mouse Model of ALK-Positive Lung Cancer.
Lung Neoplasms
Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy.
Lung Neoplasms
Inhibitory effects of scutellarein on proliferation of human lung cancer A549 cells through ERK and NF?B mediated by the EGFR pathway.
Lung Neoplasms
Insulin-like growth factor-1 receptor induces immunosuppression in lung cancer by upregulating B7-H4 expression through the MEK/ERK signaling pathway.
Lung Neoplasms
Invasion inhibition by a MEK inhibitor correlates with the actin-based cytoskeleton in lung cancer A549 cells.
Lung Neoplasms
KRAS mutant lung cancer cells are differentially responsive to MEK inhibitor due to AKT or STAT3 activation: implication for combinatorial approach.
Lung Neoplasms
lncRNA SLC16A1-AS1 as a novel prognostic biomarker in non-small cell lung cancer.
Lung Neoplasms
Long non-coding RNA BC087858 induces non-T790M mutation acquired resistance to EGFR-TKIs by activating PI3K/AKT and MEK/ERK pathways and EMT in non-small-cell lung cancer.
Lung Neoplasms
MicroRNA-186 suppresses cell proliferation and metastasis through targeting MAP3K2 in non-small cell lung cancer.
Lung Neoplasms
MIG-7 and phosphorylated prohibitin coordinately regulate lung cancer invasion/metastasis.
Lung Neoplasms
miR-16 regulates proliferation and invasion of lung cancer cells via the ERK/MAPK signaling pathway by targeted inhibition of MAPK kinase 1 (MEK1).
Lung Neoplasms
Mitogen-activated protein kinase (MEK/ERK) inhibition sensitizes cancer cells to centromere-associated protein E (CENP-E) inhibition.
Lung Neoplasms
Mitogen-activated protein kinase kinase-4 promotes cell survival by decreasing PTEN expression through an NF kappa B-dependent pathway.
Lung Neoplasms
Mutation analysis of the coding sequences of MEK-1 and MEK-2 genes in human lung cancer cell lines.
Lung Neoplasms
Neuroendocrine differentiation contributes to radioresistance development and metastatic potential increase in non-small cell lung cancer.
Lung Neoplasms
Oestrogen receptor ?5 and epidermal growth factor receptor synergistically promote lung cancer progression.
Lung Neoplasms
PAQR3 suppresses the growth of non-small cell lung cancer cells via modulation of EGFR-mediated autophagy.
Lung Neoplasms
Phase I/II Trial of Immunotherapy With Durvalumab and Tremelimumab With Continuous or Intermittent MEK Inhibitor Selumetinib in NSCLC: Early Trial Report.
Lung Neoplasms
Population Pharmacokinetic and Exposure-Response Analysis of Selumetinib and Its N-desmethyl Metabolite in Patients With Non-Small Cell Lung Cancer.
Lung Neoplasms
RANKL increases migration of human lung cancer cells through intercellular adhesion molecule-1 up-regulation.
Lung Neoplasms
Rapid and dramatic responses to dabrafenib and trametinib in BRAF V600E-mutated lung adenocarcinoma.
Lung Neoplasms
Salidroside represses proliferation, migration and invasion of human lung cancer cells through AKT and MEK/ERK signal pathway.
Lung Neoplasms
STAT3 inhibitor sensitized KRAS-mutant lung cancers to RAF inhibitor by activating MEK/ERK signaling pathway.
Lung Neoplasms
The Akt/mTOR and mitogen-activated protein kinase pathways in lung cancer therapy.
Lung Neoplasms
The antitumor effect of hinesol, extract from Atractylodes lancea (Thunb.) DC. by proliferation, inhibition, and apoptosis induction via MEK/ERK and NF-?B pathway in non-small cell lung cancer cell lines A549 and NCI-H1299.
Lung Neoplasms
Transcriptional Activation of Gstp1 by MEK/ERK Signaling Confers Chemo-Resistance to Cisplatin in Lung Cancer Stem Cells.
Lupus Erythematosus, Systemic
Mesenchymal Stem Cells Activate the MEK/ERK Signaling Pathway and Enhance DNA Methylation via DNMT1 in PBMC from Systemic Lupus Erythematosus.
Lymphatic Metastasis
Comprehensive Analysis of 5-Methylcytosine Profiles of Messenger RNA in Human High-Grade Serous Ovarian Cancer by MeRIP Sequencing.
Lymphatic Metastasis
Impact of IFNalpha2b upon pSTAT3 and the MEK/ERK MAPK pathway in melanoma.
Lymphoma
B7-H1 expression is regulated by MEK/ERK signaling pathway in anaplastic large cell lymphoma and Hodgkin lymphoma.
Lymphoma
c-Jun NH2-terminal kinase activation leads to a FADD-dependent but Fas ligand-independent cell death in Jurkat T cells.
Lymphoma
Cell surface epidermal growth factor receptors increase Src and c-Cbl activity and receptor ubiquitylation.
Lymphoma
Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium.
Lymphoma
Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling.
Lymphoma
Downregulation of CKS1B restrains the proliferation, migration, invasion and angiogenesis of retinoblastoma cells through the MEK/ERK signaling pathway.
Lymphoma
EGF Mediates Survival of Rat Cochlear Sensory Cells via an NF-kappaB Dependent Mechanism In Vitro.
Lymphoma
IL-2- and IL-15-induced activation of the rapamycin-sensitive mTORC1 pathway in malignant CD4+ T lymphocytes.
Lymphoma
Inhibition of Mitogen-Activated Protein Kinase Kinase Alone and in Combination with Anaplastic Lymphoma Kinase (ALK) Inhibition Suppresses Tumor Growth in a Mouse Model of ALK-Positive Lung Cancer.
Lymphoma
The MAPK/ERK and PI3K pathways additively coordinate the transcription of recombination-activating genes in B lineage cells.
Lymphoma, B-Cell
A Sterol from Soft Coral Induces Apoptosis and Autophagy in MCF-7 Breast Cancer Cells.
Lymphoma, B-Cell
Combined gefitinib and pemetrexed overcome the acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
Lymphoma, B-Cell
Dietary vitamin C deficiency depresses the growth, head kidney and spleen immunity and structural integrity by regulating NF-?B, TOR, Nrf2, apoptosis and MLCK signaling in young grass carp (Ctenopharyngodon idella).
Lymphoma, B-Cell
EGF Mediates Survival of Rat Cochlear Sensory Cells via an NF-kappaB Dependent Mechanism In Vitro.
Lymphoma, B-Cell
Isobavachalcone inhibits the proliferation and invasion of tongue squamous cell carcinoma cells.
Lymphoma, B-Cell
miR-30d inhibits cell biological progression of Ewing's sarcoma by suppressing the MEK/ERK and PI3K/Akt pathways
Lymphoma, B-Cell
Mitogen-activated protein kinases mediate the production of B-cell lymphoma 2 protein by Mycobacterium tuberculosis in monocytes.
Lymphoma, B-Cell
Novel Insights of Lymphomagenesis of Helicobacter pylori-Dependent Gastric Mucosa-Associated Lymphoid Tissue Lymphoma.
Lymphoma, B-Cell
Pathogenicity and virulence of Japanese encephalitis virus: Neuroinflammation and neuronal cell damage.
Lymphoma, B-Cell
Rutin attenuates isoflurane-induced neuroapoptosis via modulating JNK and p38 MAPK pathways in the hippocampi of neonatal rats.
Lymphoma, B-Cell
The MAPK/ERK and PI3K pathways additively coordinate the transcription of recombination-activating genes in B lineage cells.
Lymphoma, B-Cell
The MEK/ERK pathway acts upstream of NF kappa B1 (p50) homodimer activity and Bcl-2 expression in a murine B-cell lymphoma cell line. MEK inhibition restores radiation-induced apoptosis.
Lymphoma, Large-Cell, Anaplastic
B7-H1 expression is regulated by MEK/ERK signaling pathway in anaplastic large cell lymphoma and Hodgkin lymphoma.
Medulloblastoma
Medulloblastoma sensitivity to 17-allylamino-17-demethoxygeldanamycin requires MEK/ERKM.
Medulloblastoma
The micro-RNA 199b-5p regulatory circuit involves Hes1, CD15, and epigenetic modifications in medulloblastoma.
Melanoma
17-AAG and 17-DMAG-induced inhibition of cell proliferation through B-Raf downregulation in WT B-Raf-expressing uveal melanoma cell lines.
Melanoma
A mitogen-activated protein kinase kinase inhibitor induced compound skin toxicity with oedema in metastatic malignant melanoma.
Melanoma
A novel BH3 mimetic reveals a mitogen-activated protein kinase-dependent mechanism of melanoma cell death controlled by p53 and reactive oxygen species.
Melanoma
A rare BRAF T599dup mutation conferring sensitivity to BRAF inhibitor in a patient with metastatic melanoma.
Melanoma
Adipocytes contribute to resistance of human melanoma cells to chemotherapy and targeted therapy.
Melanoma
Adjusting for treatment switching in the METRIC study shows further improved overall survival with trametinib compared with chemotherapy.
Melanoma
Apoptosis and melanogenesis in human melanoma cells induced by anthrax lethal factor inactivation of mitogen-activated protein kinase kinase.
Melanoma
Apoptosis induction in human melanoma cells by inhibition of MEK is caspase-independent and mediated by the Bcl-2 family members PUMA, Bim, and Mcl-1.
Melanoma
ARMS depletion facilitates UV irradiation induced apoptotic cell death in melanoma.
Melanoma
Bad Neighborhood: Fibrotic Stroma as a New Player in Melanoma Resistance to Targeted Therapies.
Melanoma
Baicalein restrains proliferation, migration, and invasion of human malignant melanoma cells by down-regulating colon cancer associated transcript-1.
Melanoma
Binimetinib, encorafenib and cetuximab (BEACON Trial) combination therapy for patients with BRAF V600E-mutant metastatic colorectal cancer.
Melanoma
Clinical responses to selumetinib (AZD6244; ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma.
Melanoma
Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma.
Melanoma
Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo.
Melanoma
Comparative safety of BRAF and MEK inhibitors (vemurafenib, dabrafenib and trametinib) in first-line therapy for BRAF-mutated metastatic melanoma.
Melanoma
Deltex-3-like (DTX3L) stimulates metastasis of melanoma through FAK/PI3K/AKT but not MEK/ERK pathway.
Melanoma
Design and Synthesis of Type-IV Inhibitors of BRAF Kinase That Block Dimerization and Overcome Paradoxical MEK/ERK Activation.
Melanoma
Direct targeting of MEK1/2 and RSK2 by silybin induces cell cycle arrest and inhibits melanoma cell growth.
Melanoma
DPS-2: A Novel Dual MEK/ERK and PI3K/AKT Pathway Inhibitor with Powerful Ex Vivo and In Vivo Anticancer Properties.
Melanoma
Efficient Suppression of NRAS-Driven Melanoma by Co-inhibition of ERK1/2 and ERK5 MAPK Pathways.
Melanoma
EphA2-Receptor Targeted PEGylated Nanoliposomes for the Treatment of BRAFV600E Mutated Parent- and Vemurafenib-Resistant Melanoma.
Melanoma
ER stress promotes antitumor effects in BRAFi/MEKi resistant human melanoma induced by natural compound 4-nerolidylcathecol (4-NC).
Melanoma
Expression of DNA Methyltransferase 1 Is a Hallmark of Melanoma, Correlating with Proliferation and Response to B-Raf and Mitogen-Activated Protein Kinase Inhibition in Melanocytic Tumors.
Melanoma
Functional consequences of mutations in a putative Akt phosphorylation motif of B-raf in human cancers.
Melanoma
Glycoprotein nonmetastatic melanoma protein B extracellular fragment shows neuroprotective effects and activates the PI3K/Akt and MEK/ERK pathways via the Na(+)/K(+)-ATPase.
Melanoma
Harnessing autophagy to overcome mitogen-activated protein kinase kinase inhibitor-induced resistance in metastatic melanoma.
Melanoma
Identification of direct transcriptional targets of BRAF/MEK signalling in melanoma.
Melanoma
Inhibition of constitutively activated nuclear factor-kappaB radiosensitizes human melanoma cells.
Melanoma
Inhibition of endoplasmic reticulum stress-induced apoptosis of melanoma cells by the ARC protein.
Melanoma
Inhibition of MEK sensitizes human melanoma cells to endoplasmic reticulum stress-induced apoptosis.
Melanoma
Inhibition of phosphatidylinositol-3-kinase and mitogen-activated protein kinase kinase 1/2 prevents melanoma development and promotes melanoma regression in the transgenic TPRas mouse model.
Melanoma
Keratoacanthoma, palmoplantar keratoderma developing in an advanced melanoma patient treated with vemurafenib regressed by blockade of mitogen-activated protein kinase kinase signaling.
Melanoma
Long-term survival as a treatment benchmark in melanoma: latest results and clinical implications.
Melanoma
Malignant transformation of melanocytes to melanoma by constitutive activation of mitogen-activated protein kinase kinase (MAPKK) signaling.
Melanoma
Mechanisms of Acquired BRAF Inhibitor Resistance in Melanoma: A Systematic Review.
Melanoma
MicroSCALE screening reveals genetic modifiers of therapeutic response in melanoma.
Melanoma
MKK6 increases the melanocyte dendricity through the regulation of Rho family GTPases.
Melanoma
Mortalin depletion induces MEK/ERK-dependent and ANT/CypD-mediated death in vemurafenib-resistant B-RafV600E melanoma cells.
Melanoma
Mutation of B-Raf in human choroidal melanoma cells mediates cell proliferation and transformation through the MEK/ERK pathway.
Melanoma
Neoadjuvant therapy for locally advanced melanoma: new strategies with targeted therapies.
Melanoma
Noxa upregulation by oncogenic activation of MEK/ERK through CREB promotes autophagy in human melanoma cells.
Melanoma
Ocular Changes in Metastatic Melanoma Patients Treated with MEK Inhibitor Cobimetinib and BRAF Inhibitor Vemurafenib.
Melanoma
Ocular Toxicity in Metastatic Melanoma Patients Treated With Mitogen-Activated Protein Kinase Kinase Inhibitors: A Case Series.
Melanoma
Oncogenic Activation of MEK/ERK Primes Melanoma Cells for Adaptation to Endoplasmic Reticulum Stress.
Melanoma
Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma.
Melanoma
Opposite long-term regulation of c-Myc and p27Kip1 through overactivation of Raf-1 and the MEK/ERK module in proliferating human choroidal melanoma cells.
Melanoma
Overexpression of collagenase 1 (MMP-1) is mediated by the ERK pathway in invasive melanoma cells: role of BRAF mutation and fibroblast growth factor signaling.
Melanoma
p38 MAP kinase is necessary for melanoma-mediated regulation of VE-cadherin disassembly.
Melanoma
P53 and MITF/Bcl-2 identified as key pathways in the acquired resistance of NRAS-mutant melanoma to MEK inhibition.
Melanoma
Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma.
Melanoma
Pharmacogenomics of metabotropic glutamate receptor subtype 1 and in vivo malignant melanoma formation.
Melanoma
Platelet-derived growth factor-receptor alpha strongly inhibits melanoma growth in vitro and in vivo.
Melanoma
POU4F1 promotes the resistance of melanoma to BRAF inhibitors through MEK/ERK pathway activation and MITF up-regulation.
Melanoma
Preliminary results from a prospective trial of preoperative combined BRAF and MEK-targeted therapy in advanced BRAF mutation-positive melanoma.
Melanoma
Ras mediates the cAMP-dependent activation of extracellular signal-regulated kinases (ERKs) in melanocytes.
Melanoma
Reactivation of Mitogen-activated Protein Kinase (MAPK) Pathway by FGF Receptor 3 (FGFR3)/Ras Mediates Resistance to Vemurafenib in Human B-RAF V600E Mutant Melanoma.
Melanoma
Relative bioavailability of pediatric oral solution and tablet formulations of trametinib in adult patients with solid tumors.
Melanoma
Repression of microRNA-768-3p by MEK/ERK signalling contributes to enhanced mRNA translation in human melanoma.
Melanoma
Resveratrol inhibits proliferation, promotes differentiation and melanogenesis in HT-144 melanoma cells through inhibition of MEK/ERK kinase pathway.
Melanoma
Serous Retinopathy Associated with Mitogen-Activated Protein Kinase Kinase Inhibition (Binimetinib) for Metastatic Cutaneous and Uveal Melanoma.
Melanoma
Serum 5-S-cysteinyl-dopa levels as a predictive marker for the efficacy of nivolumab in advanced malignant melanoma.
Melanoma
Signaling networks in cutaneous melanoma metastasis identified by complementary DNA microarrays.
Melanoma
Specific amino acid deficiency alters the expression of genes in human melanoma and other tumor cell lines.
Melanoma
Sustained IRE1 and ATF6 signaling is important for survival of melanoma cells undergoing ER stress.
Melanoma
Targeted-gene silencing of BRAF to interrupt BRAF/MEK/ERK pathway synergized photothermal therapeutics for melanoma using a novel FA-GNR-siBRAF nanosystem.
Melanoma
Targeting BRAF-Mutant Non-Small Cell Lung Cancer: From Molecular Profiling to Rationally Designed Therapy.
Melanoma
The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma.
Melanoma
Treatment of metastatic melanoma with an orally available inhibitor of the Ras-Raf-MAPK cascade.
Melanoma
Triplet combination of BRAF, MEK and PD-1/PD-L1 blockade in melanoma: the more the better?
Melanoma
U0126, a mitogen-activated protein kinase kinase inhibitor, inhibits the invasion of human A375 melanoma cells.
Melanoma
Usefulness of serum 5-S-cysteinyl-dopa as a biomarker for predicting prognosis and detecting relapse in patients with advanced stage malignant melanoma.
Melanoma
WNT1-inducible signaling pathway protein 1 (WISP1/CCN4) stimulates melanoma invasion and metastasis by promoting the epithelial - mesenchymal transition.
Melanoma, Experimental
Mechanism of pigmentation by minocycline in murine B16 melanoma cells.
Memory Disorders
Activation of Glycogen Synthase Kinase-3 Mediates the Olfactory Deficit-Induced Hippocampal Impairments.
Memory Disorders
Extracellular signal-regulated kinase activity in the entorhinal cortex is necessary for long-term spatial memory.
Meningioma
CXCR4 and SDF1 expression in human meningiomas: a proliferative role in tumoral meningothelial cells in vitro.
mitogen-activated protein kinase kinase deficiency
Mitogen-activated protein kinase kinase 4 deficiency in cardiomyocytes causes connexin 43 reduction and couples hypertrophic signals to ventricular arrhythmogenesis.
Mouth Neoplasms
Areca nut components stimulate ADAM17, IL-1?, PGE2 and 8-isoprostane production in oral keratinocyte: role of reactive oxygen species, EGF and JAK signaling.
Mouth Neoplasms
Benzo (a) pyrene induced tumorigenesity of human immortalized oral epithelial cells: transcription profiling.
Mouth Neoplasms
Duchesnea indica extract attenuates oral cancer cells metastatic potential through the inhibition of the matrix metalloproteinase-2 activity by down-regulating the MEK/ERK pathway.
Mouth Neoplasms
MicroRNA-1179 suppresses the proliferation and enhances vincristine sensitivity of oral cancer cells via induction of apoptosis and modulation of MEK/ERK and PI3K/AKT signalling pathways.
Mouth Neoplasms
Xanthoxyletin Inhibits Proliferation of Human Oral Squamous Carcinoma Cells and Induces Apoptosis, Autophagy, and Cell Cycle Arrest by Modulation of the MEK/ERK Signaling Pathway.
Mucositis
Efficacy of Azatyrosine-Phenylbutyric Hydroxamides, a Histone Deacetylase Inhibitor, on Chemotherapy-Induced Gastrointestinal Mucositis.
Multiple Myeloma
Circular RNA Protein Tyrosine Kinase 2 Promotes Cell Proliferation, Migration and Suppresses Apoptosis via Activating MicroRNA-638 Mediated MEK/ERK, WNT/?-Catenin Signaling Pathways in Multiple Myeloma.
Multiple Myeloma
Combined disruption of both the MEK/ERK and the IL-6R/STAT3 pathways is required to induce apoptosis of multiple myeloma cells in the presence of bone marrow stromal cells.
Multiple Myeloma
Combined targeting of MEK/MAPK and PI3K/Akt signalling in multiple myeloma.
Multiple Myeloma
Dissecting the roles of checkpoint kinase 1/CDC2 and mitogen-activated protein kinase kinase 1/2/extracellular signal-regulated kinase 1/2 in relation to 7-hydroxystaurosporine-induced apoptosis in human multiple myeloma cells.
Multiple Myeloma
Exon-4 Mutations in KRAS Affect MEK/ERK and PI3K/AKT Signaling in Human Multiple Myeloma Cell Lines.
Multiple Myeloma
Molecular signaling in multiple myeloma: association of RAS/RAF mutations and MEK/ERK pathway activation.
Multiple Myeloma
Optimizing immunotherapy in multiple myeloma: Restoring the function of patients' monocyte-derived dendritic cells by inhibiting p38 or activating MEK/ERK MAPK and neutralizing interleukin-6 in progenitor cells.
Multiple Myeloma
Targeting MEK/MAPK signal transduction module potentiates ATO-induced apoptosis in multiple myeloma cells through multiple signaling pathways.
Multiple Myeloma
The increased expression of receptor activator of nuclear-kappaB ligand (RANKL) of multiple myeloma bone marrow stromal cells is inhibited by the bisphosphonate ibandronate.
Muscular Dystrophies
P38? MAPK underlies muscular dystrophy and myofiber death through a Bax-dependent mechanism.
Myocardial Infarction
Overexpression of mitogen-activated protein kinase kinase 6 in the heart improves functional recovery from ischemia in vitro and protects against myocardial infarction in vivo.
Myocardial Infarction
Post-infarction remodeling is independent of mitogen-activated protein kinase kinase 3 (MKK3).
Myocardial Infarction
Qishen capsule safely boosts cardiac function and angiogenesis via the MEK/ERK pathway in a rat myocardial infarction model.
Myocardial Infarction
Rosuvastatin enhances the therapeutic efficacy of adipose-derived mesenchymal stem cells for myocardial infarction via PI3K/Akt and MEK/ERK pathways.
Myocarditis
CVB3 Nonstructural 2A Protein Modulates SREBP1a Signaling via the MEK/ERK Pathway.
Nasopharyngeal Carcinoma
MiR-101 promotes nasopharyngeal carcinoma cell apoptosis through inhibiting Ras/Raf/MEK/ERK signaling pathway.
Nasopharyngeal Carcinoma
Overexpression of BPIFB1 promotes apoptosis and inhibits proliferation via the MEK/ERK signal pathway in nasopharyngeal carcinoma.
Nasopharyngeal Carcinoma
Tetrandrine sensitizes nasopharyngeal carcinoma cells to irradiation by inducing autophagy and inhibiting MEK/ERK pathway.
Nasopharyngeal Neoplasms
Activity of the MEK inhibitor selumetinib (AZD6244; ARRY-142886) in nasopharyngeal cancer cell lines.
Nasopharyngeal Neoplasms
Eriodictyol inhibits the growth of CNE1 human nasopharyngeal cancer growth by targeting MEK/ERK signalling pathway, inducing cellular autophagy and inhibition of cell migration and invasion.
Neoplasm Metastasis
"MKK4 suppresses metastatic colonization by multiple highly metastatic prostate cancer cell lines through a transient impairment in cell cycle progression"
Neoplasm Metastasis
(-)-Epigallocatechin-3-gallate inhibits osteosarcoma cell invasiveness by inhibiting the MEK/ERK signaling pathway in human osteosarcoma cells.
Neoplasm Metastasis
3-Hydroxyflavone inhibits human osteosarcoma U2OS and 143B cells metastasis by affecting EMT and repressing u-PA/MMP-2 via FAK-Src to MEK/ERK and RhoA/MLC2 pathways and reduces 143B tumor growth in vivo.
Neoplasm Metastasis
A Ferulic Acid Derivative FXS-3 Inhibits Proliferation and Metastasis of Human Lung Cancer A549 Cells via Positive JNK Signaling Pathway and Negative ERK/p38, AKT/mTOR and MEK/ERK Signaling Pathways.
Neoplasm Metastasis
Alpha-Mangostin Suppresses the Metastasis of Human Renal Carcinoma Cells by Targeting MEK/ERK Expression and MMP-9 Transcription Activity.
Neoplasm Metastasis
Analysis of the mitogen-activated protein kinase kinase 4 (MAP2K4) tumor suppressor gene in ovarian cancer.
Neoplasm Metastasis
Bone morphogenetic protein 2 mediates epithelial-mesenchymal transition via AKT and ERK signaling pathways in gastric cancer.
Neoplasm Metastasis
Building on the foundation of daring hypotheses: using the MKK4 metastasis suppressor to develop models of dormancy and metastatic colonization.
Neoplasm Metastasis
Cellular mechanisms of hepatocyte growth factor-mediated urokinase plasminogen activator secretion by MAPK signaling in hepatocellular carcinoma.
Neoplasm Metastasis
CircRNA CDR1as/miR-1287/Raf1 Axis Modulates Hepatocellular Carcinoma Progression Through MEK/ERK Pathway.
Neoplasm Metastasis
Comprehensive Analysis of 5-Methylcytosine Profiles of Messenger RNA in Human High-Grade Serous Ovarian Cancer by MeRIP Sequencing.
Neoplasm Metastasis
CSE1L silence inhibits the growth and metastasis in gastric cancer by repressing GPNMB via positively regulating transcription factor MITF.
Neoplasm Metastasis
Deltex-3-like (DTX3L) stimulates metastasis of melanoma through FAK/PI3K/AKT but not MEK/ERK pathway.
Neoplasm Metastasis
Downregulation of phosphorylated MKK4 is associated with a poor prognosis in colorectal cancer patients.
Neoplasm Metastasis
Entelon® (Vitis vinifera Seed Extract) Prevents Cancer Metastasis via the Downregulation of Interleukin-1 Alpha in Triple-Negative Breast Cancer Cells.
Neoplasm Metastasis
Fisetin Suppresses the Proliferation and Metastasis of Renal Cell Carcinoma through Upregulation of MEK/ERK-Targeting CTSS and ADAM9.
Neoplasm Metastasis
Friedelin inhibits the growth and metastasis of human leukemia cells via modulation of MEK/ERK and PI3K/AKT signalling pathways.
Neoplasm Metastasis
Hematopoietic cell kinase enhances osteosarcoma development via the MEK/ERK pathway.
Neoplasm Metastasis
Hypoxic tumor-derived exosomal miR-31-5p promotes lung adenocarcinoma metastasis by negatively regulating SATB2-reversed EMT and activating MEK/ERK signaling.
Neoplasm Metastasis
Impact of IFNalpha2b upon pSTAT3 and the MEK/ERK MAPK pathway in melanoma.
Neoplasm Metastasis
Inhibition of histamine receptor H3 suppresses the growth and metastasis of human non-small cell lung cancer cells via inhibiting PI3K/Akt/mTOR and MEK/ERK signaling pathways and blocking EMT.
Neoplasm Metastasis
Insulin promotes proliferation, survival, and invasion in endometrial carcinoma by activating the MEK/ERK pathway.
Neoplasm Metastasis
Invasion inhibition by a MEK inhibitor correlates with the actin-based cytoskeleton in lung cancer A549 cells.
Neoplasm Metastasis
Kinesin family member 2C promotes hepatocellular carcinoma growth and metastasis via activating MEK/ERK pathway.
Neoplasm Metastasis
LDLR inhibition promotes hepatocellular carcinoma proliferation and metastasis by elevating intracellular cholesterol synthesis through the MEK/ERK signaling pathway.
Neoplasm Metastasis
LncRNA HOXA-AS3 Sponges miR-29c to Facilitate Cell Proliferation, Metastasis, and EMT Process and Activate the MEK/ERK Signaling Pathway in Hepatocellular Carcinoma.
Neoplasm Metastasis
Long non-coding RNA AL139002.1 promotes gastric cancer development by sponging microRNA-490-3p to regulate Hepatitis A Virus Cellular Receptor 1 expression.
Neoplasm Metastasis
MCM6 promotes metastasis of hepatocellular carcinoma via MEK/ERK pathway and serves as a novel serum biomarker for early recurrence.
Neoplasm Metastasis
Methylation-dependent MCM6 repression induced by LINC00472 inhibits triple-negative breast cancer metastasis by disturbing the MEK/ERK signaling pathway.
Neoplasm Metastasis
MicroRNA-335 targets the MEK/ERK pathway to regulate the proliferation and metastasis of colon cancer.
Neoplasm Metastasis
MicroRNA-338-3p suppresses ovarian cancer cells growth and metastasis: implication of Wnt/catenin beta and MEK/ERK signaling pathways.
Neoplasm Metastasis
miR-665 expression predicts poor survival and promotes tumor metastasis by targeting NR4A3 in breast cancer.
Neoplasm Metastasis
Mitogen-activated protein kinase kinase 4 (MAP2K4) promotes human prostate cancer metastasis.
Neoplasm Metastasis
Mitogen-activated protein kinase kinase 4 (MKK4) acts as a metastasis suppressor gene in human ovarian carcinoma.
Neoplasm Metastasis
Mitogen-activated protein kinase kinase 4 metastasis suppressor gene expression is inversely related to histological pattern in advancing human prostatic cancers.
Neoplasm Metastasis
Mitogen-activated protein kinase kinase 4/stress-activated protein/Erk kinase 1 (MKK4/SEK1), a prostate cancer metastasis suppressor gene encoded by human chromosome 17.
Neoplasm Metastasis
Modeling MEK4 Kinase Inhibitors through Perturbed Electrostatic Potential Charges.
Neoplasm Metastasis
Neferine inhibits MDA-MB-231?cells growth and metastasis by regulating miR-374a/FGFR-2.
Neoplasm Metastasis
Nitric Oxide (NO) and NO Synthases (NOS)-Based Targeted Therapy for Colon Cancer.
Neoplasm Metastasis
Possible involvement of RUNX3 silencing in the peritoneal metastases of gastric cancers.
Neoplasm Metastasis
Puerarin inhibits M2 polarization and metastasis of tumor-associated macrophages from NSCLC xenograft model via inactivating MEK/ERK 1/2 pathway.
Neoplasm Metastasis
Reduction of metastasis, cell invasion, and adhesion in mouse osteosarcoma by YM529/ONO-5920-induced blockade of the Ras/MEK/ERK and Ras/PI3K/Akt pathway.
Neoplasm Metastasis
Serine protease inhibitor Kazal type 1 (SPINK1) downregulates E-cadherin and induces EMT of hepatoma cells to promote hepatocellular carcinoma metastasis via the MEK/ERK signaling pathway.
Neoplasm Metastasis
SERPINA11 Inhibits Metastasis in Hepatocellular Carcinoma by Suppressing MEK/ERK Signaling Pathway.
Neoplasm Metastasis
Signaling networks in cutaneous melanoma metastasis identified by complementary DNA microarrays.
Neoplasm Metastasis
Specific amino acid deficiency alters the expression of genes in human melanoma and other tumor cell lines.
Neoplasm Metastasis
STYK1 promotes epithelial-mesenchymal transition and tumor metastasis in human hepatocellular carcinoma through MEK/ERK and PI3K/AKT signaling.
Neoplasm Metastasis
Targeting Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Kinase in the Mutant (V600E) B-Raf Signaling Cascade Effectively Inhibits Melanoma Lung Metastases.
Neoplasm Metastasis
The novel long noncoding RNA AU021063, induced by IL-6/Arid5a signaling, exacerbates breast cancer invasion and metastasis by stabilizing Trib3 and activating the Mek/Erk pathway.
Neoplasm Metastasis
Time-dependent transcriptional profiling links gene expression to mitogen-activated protein kinase kinase 4 (MKK4)-mediated suppression of omental metastatic colonization.
Neoplasm Metastasis
Treatment of metastatic melanoma with an orally available inhibitor of the Ras-Raf-MAPK cascade.
Neoplasm Metastasis
Upregulation of lncRNA ADAMTS9-AS2 Promotes Salivary Adenoid Cystic Carcinoma Metastasis via PI3K/Akt and MEK/Erk Signaling.
Neoplasm Metastasis
[Expression of MEK/ERK signal pathways in renal cell carcinoma with bone metastasis].
Neoplasm Metastasis
[The relationship between expression of mitogen-activated protein kinase kinase 4 and metastasis in oral squamous cell carcinoma].
Neoplasms
(18)F-FLT-PET for Response Evaluation of MEK Inhibitor Selumetinib (AZD6244, ARRY-142886) in Patients with Solid Tumors.
Neoplasms
3-Hydroxyflavone inhibits human osteosarcoma U2OS and 143B cells metastasis by affecting EMT and repressing u-PA/MMP-2 via FAK-Src to MEK/ERK and RhoA/MLC2 pathways and reduces 143B tumor growth in vivo.
Neoplasms
3D-QSAR and molecular docking studies on substituted isothiazole analogs as inhibitors against MEK-1 kinase.
Neoplasms
?-Chaconine isolated from a Solanum tuberosum L. cv Jayoung suppresses lipopolysaccharide-induced pro-inflammatory mediators via AP-1 inactivation in RAW 264.7 macrophages and protects mice from endotoxin shock.
Neoplasms
A chemical biology approach identifies a beta-2 adrenergic receptor agonist that causes human tumor regression by blocking the Raf-1/Mek-1/Erk1/2 pathway.
Neoplasms
A long-term surviving patient with recurrent low-grade serous ovarian carcinoma treated with the MEK1/2 inhibitor, selumetinib.
Neoplasms
A Mortalin/HSPA9-Mediated Switch in Tumor-Suppressive Signaling of Raf/MEK/Extracellular Signal-Regulated Kinase.
Neoplasms
A new prognosis prediction model combining TNM stage with MAP2K4 and JNK in postoperative pancreatic cancer patients.
Neoplasms
A Novel Ribonuclease from Rana Chensinensis and Its Potential for the Treatment of Human Breast Cancer.
Neoplasms
A phase 1b study of trametinib, an oral Mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumours.
Neoplasms
A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours.
Neoplasms
A plate-based assay to measure cellular ERK substrate phosphorylation: utility for drug discovery of the MAPK-signaling cascade.
Neoplasms
A precisely regulated gene expression cassette potently modulates metastasis and survival in multiple solid cancers.
Neoplasms
A tumor-associated splice-isoform of MAP2K7 drives dedifferentiation in MBNL1-low cancers via JNK activation.
Neoplasms
Activated MEK/ERK Pathway Drives Widespread and Coordinated Overexpression of UHRF1 and DNMT1 in Cancer cells.
Neoplasms
Activation of integrin alpha(V)beta(3) regulates cell adhesion and migration to bone sialoprotein.
Neoplasms
Activation of signal transducers and activators of transcription 3 and focal adhesion kinase by stromal cell-derived factor 1 is required for migration of human mesenchymal stem cells in response to tumor cell-conditioned medium.
Neoplasms
Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies.
Neoplasms
ADP-ribosylation factor 6 regulates tumor cell invasion through the activation of the MEK/ERK signaling pathway.
Neoplasms
AlphaB-crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer.
Neoplasms
Analysis of invasion-metastasis mechanism in pancreatic cancer: involvement of tight junction transmembrane protein occludin and MEK/ERK signal transduction pathway in cancer cell dissociation.
Neoplasms
Analysis of the mitogen-activated protein kinase kinase 4 (MAP2K4) tumor suppressor gene in ovarian cancer.
Neoplasms
Analytical approach to characterize the intratumoral pharmacokinetics and pharmacodynamics of gefitinib in a glioblastoma model.
Neoplasms
Androgen-induced miR-27A acted as a tumor suppressor by targeting MAP2K4 and mediated prostate cancer progression.
Neoplasms
Anethole blocks both early and late cellular responses transduced by tumor necrosis factor: effect on NF-kappaB, AP-1, JNK, MAPKK and apoptosis.
Neoplasms
Anthrax lethal factor causes proteolytic inactivation of mitogen-activated protein kinase kinase.
Neoplasms
Anti-inflammatory action of herbal medicine comprised of Scutellaria baicalensis and Chrysanthemum morifolium.
Neoplasms
Anti-inflammatory Effects of Oxymatrine Through Inhibition of Nuclear Factor-kappa B and Mitogen-activated Protein Kinase Activation in Lipopolysaccharide-induced BV2 Microglia Cells.
Neoplasms
Antitumor activity of the MEK inhibitor trametinib on intestinal polyp formation in Apc(?716) mice involves stromal COX-2.
Neoplasms
Arrangement of expression and distribution of tight junction protein claudin-1 in cell dissociation of pancreatic cancer cells.
Neoplasms
Artesunate induces apoptosis and inhibits the proliferation, stemness, and tumorigenesis of leukemia.
Neoplasms
Atypical protein kinase C iota expression and aurothiomalate sensitivity in human lung cancer cells.
Neoplasms
Baicalin Suppresses Bilirubin-Induced Apoptosis and Inflammation by Regulating p38 Mitogen-Activated Protein Kinases (MAPK) Signaling in Neonatal Neurons.
Neoplasms
Bcl-2 and Bcl-xL mediate resistance to receptor tyrosine kinase-targeted therapy in lung and gastric cancer.
Neoplasms
Bcl-2-mediated cell survival promotes metastasis of EpH4 betaMEKDD mammary epithelial cells.
Neoplasms
Bidirectional signals transduced by TOPK-ERK interaction increase tumorigenesis of HCT116 colorectal cancer cells.
Neoplasms
Bioactive compounds in plant materials for the prevention of diabetesand obesity.
Neoplasms
Biological Rationale for Targeting MEK/ERK Pathways in Anti-Cancer Therapy and to Potentiate Tumour Responses to Radiation.
Neoplasms
Blockade of ?7 nicotinic acetylcholine receptors inhibit nicotine-induced tumor growth and vimentin expression in non-small cell lung cancer through MEK/ERK signaling way.
Neoplasms
Blockage of progesterone receptor effectively protects pancreatic islet beta cell viability.
Neoplasms
Bone morphogenetic protein 2 mediates epithelial-mesenchymal transition via AKT and ERK signaling pathways in gastric cancer.
Neoplasms
Bovine lactoferrin protects RSC96 Schwann cells from tumor necrosis factor-alpha-induced growth arrest via extracellular-signal-regulated kinase 1/2.
Neoplasms
Building on the foundation of daring hypotheses: using the MKK4 metastasis suppressor to develop models of dormancy and metastatic colonization.
Neoplasms
C6orf106 accelerates pancreatic cancer cell invasion and proliferation via activating ERK signaling pathway.
Neoplasms
Ca(2+)/calmodulin-dependent protein kinase II promotes cell cycle progression by directly activating MEK1 and subsequently modulating p27 phosphorylation.
Neoplasms
Cancer cell-intrinsic expression of MHC II in lung cancer cell lines is actively restricted by MEK/ERK signaling and epigenetic mechanisms.
Neoplasms
CD40 signaling of monocyte inflammatory cytokine synthesis through an ERK1/2-dependent pathway. A target of interleukin (il)-4 and il-10 anti-inflammatory action.
Neoplasms
Characterization of a novel mitogen-activated protein kinase kinase 1/2 inhibitor with a unique mechanism of action for cancer therapy.
Neoplasms
Characterization of Activating Mutations of the MEK1 Gene in Papillary Thyroid Carcinomas.
Neoplasms
Cinobufotalin powerfully reversed EBV-miR-BART22-induced cisplatin resistance via stimulating MAP2K4 to antagonize non-muscle myosin heavy chain IIA/glycogen synthase 3?/?-catenin signaling pathway.
Neoplasms
CInQ-03, a novel allosteric MEK inhibitor, suppresses cancer growth in vitro and in vivo.
Neoplasms
Claudin-4, mitogen-activated protein kinase kinase 4, and stratifin are markers of gastric adenocarcinoma precursor lesions.
Neoplasms
Clinicopathologic and prognostic significance of MKK4 and MKK7 in resectable pancreatic ductal adenocarcinoma.
Neoplasms
Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium.
Neoplasms
Close correlation between MEK/ERK and Aurora-B signaling pathways in sustaining tumorigenic potential and radioresistance of gynecological cancer cell lines.
Neoplasms
Combination of SB431542, CHIR99021 and PD0325901 has a synergic effect on abrogating valproic acid?induced epithelial?mesenchymal transition and stemness in HeLa, 5637 and SCC?15 cells.
Neoplasms
Combined MEK and PI3K/p110? Inhibition as a Novel Targeted Therapy for Malignant Mesothelioma Displaying Sarcomatoid Features.
Neoplasms
Combined targeting of JAK2 and Bcl-2/Bcl-xL to cure mutant JAK2-driven malignancies and overcome acquired resistance to JAK2 inhibitors.
Neoplasms
Commentary on Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model Kinkade CW, Castillo-Martin M, Puzio-Kuter A, Yan J, Foster TH, Gao H, Sun Y, Ouyang X, Gerald WL, Cordon-Cardo C, Abate-Shen C, Department of Urology, Columbia University College of Physicians and Surgeons, New York, NY.
Neoplasms
Comparative proteomics of human embryonic stem cells and embryonal carcinoma cells.
Neoplasms
Comprehensive Analysis of 5-Methylcytosine Profiles of Messenger RNA in Human High-Grade Serous Ovarian Cancer by MeRIP Sequencing.
Neoplasms
Concomitant activation of MEK-1 and Rac-1 increases the proliferative potential of thyroid epithelial cells, without affecting their differentiation.
Neoplasms
Concurrent inhibition of ErbB family and MEK/ERK kinases to suppress non-small cell lung cancer proliferation.
Neoplasms
Constitutive Activation of Mitogen-activated Protein Kinase Kinase (MEK1) in Ileal Enterocytes Leads to Dysplasia and a Predisposition to Cancer.
Neoplasms
Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation.
Neoplasms
Control of PD-L1 expression by miR-140/142/340/383 and oncogenic activation of the OCT4-miR-18a pathway in cervical cancer.
Neoplasms
Cooperation of BRAF(F595L) and mutant HRAS in histiocytic sarcoma provides new insights into oncogenic BRAF signaling.
Neoplasms
Cotargeting signaling pathways driving survival and cell cycle circumvents resistance to Kit inhibitors in leukemia.
Neoplasms
Critical signaling pathways in bone sarcoma: candidates for therapeutic interventions.
Neoplasms
CSE1L silence inhibits the growth and metastasis in gastric cancer by repressing GPNMB via positively regulating transcription factor MITF.
Neoplasms
Cytokine-activated p42/p44 MAP kinase is involved in inducible nitric oxide synthase gene expression independent from NF-kappaB activation in vascular smooth muscle cells.
Neoplasms
Dasatinib sensitises KRAS-mutant cancer cells to mitogen-activated protein kinase kinase inhibitor via inhibition of TAZ activity.
Neoplasms
DC120, a novel and potent inhibitor of AKT kinase, induces tumor cell apoptosis and suppresses tumor growth.
Neoplasms
Decrease in K-ras p21 and increase in Raf1 and activated Erk 1 and 2 in murine lung tumors initiated by N-nitrosodimethylamine and promoted by 2,3,7,8-tetrachlorodibenzo-p-dioxin.
Neoplasms
Delphinidin attenuates neoplastic transformation in JB6 Cl41 mouse epidermal cells by blocking Raf/mitogen-activated protein kinase kinase/extracellular signal-regulated kinase signaling.
Neoplasms
Desacetyluvaricin induces S phase arrest in SW480 colorectal cancer cells through superoxide overproduction.
Neoplasms
Differential Activation of ERK Signaling in HPV-Related Oropharyngeal Squamous Cell Carcinoma.
Neoplasms
Dimerization of the kinase ARAF promotes MAPK pathway activation and cell migration.
Neoplasms
Discovery of the SMYD3 Inhibitor BAY-6035 Using Thermal Shift Assay (TSA)-Based High-Throughput Screening.
Neoplasms
Distinct genetic alterations in the mitogen-activated protein kinase pathway dictate sensitivity of thyroid cancer cells to mitogen-activated protein kinase kinase 1/2 inhibition.
Neoplasms
DNMT3B in vitro knocking-down is able to reverse embryonal rhabdomyosarcoma cell phenotype through inhibition of proliferation and induction of myogenic differentiation.
Neoplasms
Down-regulation of Aquaporin-1 mediates a microglial phenotype switch affecting glioma growth.
Neoplasms
Down-regulation of c-Myc following MEK/ERK inhibition halts the expression of malignant phenotype in rhabdomyosarcoma and in non muscle-derived human tumors.
Neoplasms
Downregulation of uPAR inhibits migration, invasion, proliferation, FAK/PI3K/Akt signaling and induces senescence in papillary thyroid carcinoma cells.
Neoplasms
Drug-induced RAF dimerization is independent of RAS mutation status and does not lead to universal MEK dependence for cell survival in head and neck cancers.
Neoplasms
Dual Activity of Ginsenoside Rb1 in Hypertrophic Cardiomyocytes and Activated Macrophages: Implications for the Therapeutic Intervention of Cardiac Hypertrophy.
Neoplasms
Editorial comment on: Von Hippel-Lindau tumor suppressor gene loss in renal cell carcinoma promotes oncogenic epidermal growth factor receptor signaling via Akt-1 and MEK-1.
Neoplasms
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.
Neoplasms
Efficacy of the EGFr inhibitor Iressa on development of chemically-induced urinary bladder cancers: Dose dependency and modulation of biomarkers.
Neoplasms
Efficient Suppression of NRAS-Driven Melanoma by Co-inhibition of ERK1/2 and ERK5 MAPK Pathways.
Neoplasms
Eicosapentaenoic acid and docosahexaenoic acid inhibit macrophage-induced gastric cancer cell migration by attenuating the expression of matrix metalloproteinase 10.
Neoplasms
Elevated expression of ERK 2 in human tumor cells chronically treated with PD98059.
Neoplasms
Elevated hydrostatic pressure enhances the motility and enlarges the size of the lung cancer cells through aquaporin upregulation mediated by caveolin-1 and ERK1/2 signaling.
Neoplasms
Eliminating animal facility light-at-night contamination and its effect on circadian regulation of rodent physiology, tumor growth, and metabolism: a challenge in the relocation of a cancer research laboratory.
Neoplasms
Enhancement of the antitumor effect of HER2-directed CAR-T cells through blocking epithelial-mesenchymal transition in tumor cells.
Neoplasms
Enhancement of the therapeutic efficacy of taxol by the mitogen-activated protein kinase kinase inhibitor CI-1040 in nude mice bearing human heterotransplants.
Neoplasms
Epigenetic silencing of tumor suppressor miR-3151 contributes to Chinese chronic lymphocytic leukemia by constitutive activation of MADD/ERK and PIK3R2/AKT signaling pathways.
Neoplasms
ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor.
Neoplasms
Erythropoietin inhibits gluconeogenesis and inflammation in the liver and improves glucose intolerance in high-fat diet-fed mice.
Neoplasms
Essential genes shape cancer genomes through linear limitation of homozygous deletions.
Neoplasms
Essential, non-redundant roles of B-Raf and Raf-1 in Ras-driven skin tumorigenesis.
Neoplasms
Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%.
Neoplasms
Evaluation of kinase inhibitors as potential therapeutics for flavivirus infections.
Neoplasms
Exosomes Released by Gastric Cancer Cells Induce Transition of Pericytes Into Cancer-Associated Fibroblasts.
Neoplasms
Expression and mutation analyses of MKK4, a candidate tumour suppressor gene encoded by chromosome 17p, in human gastric adenocarcinoma.
Neoplasms
Expression and prognostic role of MEKK3 and pERK in patients with renal clear cell carcinoma.
Neoplasms
Expression of DNA Methyltransferase 1 Is a Hallmark of Melanoma, Correlating with Proliferation and Response to B-Raf and Mitogen-Activated Protein Kinase Inhibition in Melanocytic Tumors.
Neoplasms
Favourable prognosis in medulloblastoma with extensive nodularity is associated with mitogen-activated protein kinase upregulation.
Neoplasms
Fc gamma R-dependent mitogen-activated protein kinase activation in leukocytes: a common signal transduction event necessary for expression of TNF-alpha and early activation genes.
Neoplasms
FGF-1/-3/FGFR4 signaling in cancer-associated fibroblasts promotes tumor progression in colon cancer through Erk and MMP-7.
Neoplasms
FGFR3 Deficiency Causes Multiple Chondroma-like Lesions by Upregulating Hedgehog Signaling.
Neoplasms
Fluorinated thiazolidinol drives autophagic cell death in pancreatic cancer cells via AMPK activation and perturbation of critical sentinels of oncogenic signaling.
Neoplasms
FOXO3a from the Nucleus to the Mitochondria: A Round Trip in Cellular Stress Response.
Neoplasms
Gene expression profiles in liver of mouse after chronic exposure to drinking water.
Neoplasms
Genetic and molecular alterations in rhabdomyosarcoma: mRNA overexpression of MCL1 and MAP2K4 genes.
Neoplasms
Genetic heterogeneity and actionable mutations in HER2-positive primary breast cancers and their brain metastases.
Neoplasms
Genistein-induced differentiation of breast cancer stem/progenitor cells through a paracrine mechanism.
Neoplasms
Globularifolin exerts anticancer effects on glioma U87 cells through inhibition of Akt/mTOR and MEK/ERK signaling pathways in vitro and inhibits tumor growth in vivo.
Neoplasms
Glucocorticoids Suppress Selected Components of the Senescence-Associated Secretory Phenotype.
Neoplasms
Glycyrrhizic Acid Modulates Apoptosis through Extrinsic/Intrinsic Pathways and Inhibits Protein Kinase B- and Extracellular Signal-Regulated Kinase-Mediated Metastatic Potential in Hepatocellular Carcinoma In Vitro and In Vivo.
Neoplasms
GPR30-mediated HMGB1 upregulation in CAFs induces autophagy and tamoxifen resistance in ER?-positive breast cancer cells.
Neoplasms
HAVCR1 Affects the MEK/ERK Pathway in Gastric Adenocarcinomas and Influences Tumor Progression and Patient Outcome.
Neoplasms
Hepatitis B virus core protein sensitizes hepatocytes to tumor necrosis factor-induced apoptosis by suppression of the phosphorylation of mitogen-activated protein kinase kinase 7.
Neoplasms
Hit identification of SMYD3 enzyme inhibitors using structure-based pharmacophore modeling.
Neoplasms
Hotspot Mutations Detectable by Next-generation Sequencing in Exhaled Breath Condensates from Patients with Lung Cancer.
Neoplasms
HSP70 inhibitor VER155008 suppresses pheochromocytoma cell and xenograft growth by inhibition of PI3K/AKT/mTOR and MEK/ERK pathways.
Neoplasms
Hypoxia-induced acetylation of PAK1 enhances autophagy and promotes brain tumorigenesis via phosphorylating ATG5.
Neoplasms
Hypoxia-Induced S100A8 Expression Activates Microglial Inflammation and Promotes Neuronal Apoptosis.
Neoplasms
Hypoxic tumor-derived exosomal miR-31-5p promotes lung adenocarcinoma metastasis by negatively regulating SATB2-reversed EMT and activating MEK/ERK signaling.
Neoplasms
IL-6 Mediates Cross-Talk between Tumor Cells and Activated Fibroblasts in the Tumor Microenvironment.
Neoplasms
Immune Responses to BRAF-Targeted Therapy in Melanoma: Is Targeted Therapy Immunotherapy?
Neoplasms
Immunohistochemical detection of Ki67 in breast cancer correlates with transcriptional regulation of genes related to apoptosis and cell death.
Neoplasms
In silico investigation of new binding pocket for mitogen activated kinase kinase (MEK): Development of new promising inhibitors.
Neoplasms
In vivo effect of alpha-bisabolol, a nontoxic sesquiterpene alcohol, on the induction of spontaneous mammary tumors in HER-2/neu transgenic mice.
Neoplasms
Increased Adipose Tissue Expression of Proinflammatory CD40, MKK4 and JNK in Patients with Very Severe Chronic Obstructive Pulmonary Disease.
Neoplasms
Increased STAT-3 and synchronous activation of Raf-1-MEK-1-MAPK, and phosphatidylinositol 3-Kinase-Akt-mTOR pathways in atypical and anaplastic meningiomas.
Neoplasms
Induction of integrin ?3 by sustained ERK activity promotes the invasiveness of TGF?-induced mesenchymal tumor cells.
Neoplasms
Infrequent but high-level amplification of 17p11.2 approximately p12 in human glioma.
Neoplasms
Inhibition of Apolipoprotein AI Gene Expression by Tumor Necrosis Factor alpha: Roles for MEK/ERK and JNK Signaling.
Neoplasms
Inhibition of c-Myc down-regulation by sustained extracellular signal-regulated kinase activation prevents the antimetabolite methotrexate- and gemcitabine-induced differentiation in non-small-cell lung cancer cells.
Neoplasms
Inhibition of conjugated linoleic acid on mouse forestomach neoplasia induced by benzo (a) pyrene and chemopreventive mechanisms.
Neoplasms
Inhibition of Doxorubicin-induced autophagy in hepatocellular carcinoma Hep3B cells by Sorafenib: the role of extracellular signal-regulated kinase counteraction.
Neoplasms
Inhibition of either phosphatidylinositol 3-kinase/Akt or the mitogen/extracellular-regulated kinase, MEK/ERK, signaling pathways suppress growth of breast cancer cell lines, but MEK/ERK signaling is critical for cell survival.
Neoplasms
Inhibition of fatty acid transport and proliferative activity in tissue-isolated human squamous cell cancer xenografts perfused in situ with melatonin or eicosapentaenoic or conjugated linoleic acids.
Neoplasms
Inhibition of MAP kinase kinase causes morphological reversion and dissociation between soft agar growth and in vivo tumorigenesis in angiosarcoma cells.
Neoplasms
Inhibition of Mitogen-Activated Protein Kinase Kinase Alone and in Combination with Anaplastic Lymphoma Kinase (ALK) Inhibition Suppresses Tumor Growth in a Mouse Model of ALK-Positive Lung Cancer.
Neoplasms
Inhibitory effects of the mitogen-activated protein kinase kinase inhibitor CI-1040 on the proliferation and tumor growth of thyroid cancer cells with BRAF or RAS mutations.
Neoplasms
Insulin receptor, insulin receptor substrate-1, Raf-1, and Mek-1 during hormonal hepatocarcinogenesis by intrahepatic pancreatic islet transplantation in diabetic rats.
Neoplasms
Integrative pan-cancer analysis of MEK1 aberrations and the potential clinical implications.
Neoplasms
Interplay of T-cell receptor and interleukin-2 signalling in Vgamma2Vdelta2 T-cell cytotoxicity.
Neoplasms
Intestinal epithelial cancer cell anoikis resistance: EGFR-mediated sustained activation of Src overrides Fak-dependent signaling to MEK/Erk and/or PI3-K/Akt-1.
Neoplasms
Intrinsic FAK activity and Y925 phosphorylation facilitate an angiogenic switch in tumors.
Neoplasms
JNKK1 organizes a MAP kinase module through specific and sequential interactions with upstream and downstream components mediated by its amino-terminal extension.
Neoplasms
Key role of MEK/ERK pathway in sustaining tumorigenicity and in vitro radioresistance of embryonal rhabdomyosarcoma stem-like cell population.
Neoplasms
KrasG12D mutation contributes to regulatory T cell conversion through activation of the MEK/ERK pathway in pancreatic cancer.
Neoplasms
KRASG12D- and BRAFV600E-Induced Transformation of Murine Pancreatic Epithelial Cells Requires MEK/ERK-Stimulated IGF1R Signaling.
Neoplasms
Krüppel-like factor 5 promotes apoptosis triggered by tumor necrosis factor ? in LNCaP prostate cancer cells via up-regulation of mitogen-activated protein kinase kinase 7.
Neoplasms
LIM and SH3 protein 1 knockdown suppresses proliferation and metastasis of colorectal carcinoma cells via inhibition of the mitogen-activated protein kinase signaling pathway.
Neoplasms
Mammary Precancerous Stem and Non-Stem Cells Evolve into Cancers of Distinct Subtypes.
Neoplasms
Map2k4 functions as a tumor suppressor in lung adenocarcinoma and inhibits tumor cell invasion by decreasing peroxisome proliferator-activated receptor ?2 expression.
Neoplasms
Map2k4? - Identification and functional characterization of a novel Map2k4 splice variant.
Neoplasms
MAP3K1 and MAP2K4 mutations are associated with sensitivity to MEK inhibitors in multiple cancer models.
Neoplasms
MAPK pathway alterations correlate with poor survival and drive resistance to therapy in patients with lung cancers driven by ROS1 fusions.
Neoplasms
Mass spectrometry-based proteomics reveals potential roles of NEK9 and MAP2K4 in resistance to PI3K inhibitors in triple negative breast cancers.
Neoplasms
Mechanism of lapatinib-mediated radiosensitization of breast cancer cells is primarily by inhibition of the Raf>MEK>ERK mitogen-activated protein kinase cascade and radiosensitization of lapatinib-resistant cells restored by direct inhibition of MEK.
Neoplasms
MED12 controls the response to multiple cancer drugs through regulation of TGF-? receptor signaling.
Neoplasms
Medulloblastoma sensitivity to 17-allylamino-17-demethoxygeldanamycin requires MEK/ERKM.
Neoplasms
MEK inhibition induces caspases activation, differentiation blockade and PML/RARalpha degradation in acute promyelocytic leukaemia.
Neoplasms
MEK inhibition prevents tumour-shed transforming growth factor-?-induced T-regulatory cell augmentation in tumour milieu.
Neoplasms
MEK inhibitors induce Akt activation and drug resistance by suppressing negative feedback ERK-mediated HER2 phosphorylation at Thr701.
Neoplasms
MEK inhibitors: a therapeutic approach to targeting the Ras-MAP kinase pathway in tumors.
Neoplasms
MEK/ERK inhibitor U0126 affects in vitro and in vivo growth of embryonal rhabdomyosarcoma.
Neoplasms
MEK/ERK signaling is a critical regulator of high-risk human papillomavirus oncogene expression revealing therapeutic targets for HPV-induced tumors.
Neoplasms
MEK/ERK signaling pathway in apoptosis of SW620 cell line and inhibition effect of resveratrol.
Neoplasms
MEK/ERK-dependent uPAR expression is required for motility via phosphorylation of P70S6K in human hepatocarcinoma cells.
Neoplasms
MEK2 is a prognostic marker and potential chemo-sensitizing target for glioma patients undergoing temozolomide treatment.
Neoplasms
MEKKs, GCKs, MLKs, PAKs, TAKs, and tpls: upstream regulators of the c-Jun amino-terminal kinases?
Neoplasms
Metalloprotease-dependent activation of EGFR modulates CD44(+)/CD24(-) populations in triple negative breast cancer cells through the MEK/ERK pathway.
Neoplasms
microRNA-124-3p inhibits tumourigenesis by targeting mitogen-activated protein kinase 4 in papillary thyroid carcinoma.
Neoplasms
MicroRNA-216a-3p promotes sorafenib sensitivity in hepatocellular carcinoma by downregulating MAPK14 expression.
Neoplasms
microRNA-363 plays a tumor suppressive role in osteosarcoma by directly targeting MAP2K4.
Neoplasms
MicroRNA-802 plays a tumour suppressive role in tongue squamous cell carcinoma through directly targeting MAP2K4.
Neoplasms
MicroRNA?136 inhibits prostate cancer cell proliferation and invasion by directly targeting mitogen?activated protein kinase kinase 4.
Neoplasms
miR-125b inhibited epithelial-mesenchymal transition of triple-negative breast cancer by targeting MAP2K7.
Neoplasms
miR-199a Regulates the Tumor Suppressor Mitogen-Activated Protein Kinase Kinase Kinase 11 in Gastric Cancer.
Neoplasms
MiR-744-5p inducing cell death by directly targeting HNRNPC and NFIX in ovarian cancer cells.
Neoplasms
MiR-92b-3p ameliorates inflammation and autophagy by targeting TRAF3 and suppressing MKK3-p38 pathway in caerulein-induced AR42J cells.
Neoplasms
Mitogen-activated protein kinase (MEK/ERK) inhibition sensitizes cancer cells to centromere-associated protein E (CENP-E) inhibition.
Neoplasms
Mitogen-activated protein kinase kinase 1/2 inhibitors and 17-allylamino-17-demethoxygeldanamycin synergize to kill human gastrointestinal tumor cells in vitro via suppression of c-FLIP-s levels and activation of CD95.
Neoplasms
Mitogen-activated protein kinase kinase 3 induces cell cycle arrest via p38 activation mediated Bmi-1 downregulation in hepatocellular carcinoma.
Neoplasms
Mitogen-activated protein kinase kinase 4 (MAP2K4) promotes human prostate cancer metastasis.
Neoplasms
Mitogen-activated protein kinase kinase 4 metastasis suppressor gene expression is inversely related to histological pattern in advancing human prostatic cancers.
Neoplasms
Mitogen-activated protein kinases mediate the production of B-cell lymphoma 2 protein by Mycobacterium tuberculosis in monocytes.
Neoplasms
Mobile element insertions and associated structural variants in longitudinal breast cancer samples.
Neoplasms
Modulation of expression of 17-Hydroxylase/17,20 lyase (CYP17) and P450 aromatase (CYP19) by inhibition of MEK1 in a human ovarian granulosa-like tumor cell line.
Neoplasms
Molecular mechanisms for the p38-induced cellular senescence in normal human fibroblast.
Neoplasms
mTOR-targeted cancer therapy: great target but disappointing clinical outcomes, why?
Neoplasms
Mutant p53-induced up-regulation of mitogen-activated protein kinase kinase 3 contributes to gain of function.
Neoplasms
Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models.
Neoplasms
Mycobacterium tuberculosis Lipoprotein and Lipoglycan Binding to Toll-Like Receptor 2 Correlates with Agonist Activity and Functional Outcomes.
Neoplasms
Myricetin is a novel natural inhibitor of neoplastic cell transformation and MEK1.
Neoplasms
Nanosized Modification Strategies for Improving the Antitumor Efficacy of MEK Inhibitors.
Neoplasms
Network analysis of skin tumor progression identifies a rewired genetic architecture affecting inflammation and tumor susceptibility.
Neoplasms
Neuroendocrine differentiation contributes to radioresistance development and metastatic potential increase in non-small cell lung cancer.
Neoplasms
Nitric Oxide (NO) and NO Synthases (NOS)-Based Targeted Therapy for Colon Cancer.
Neoplasms
Non-autonomous regulation of germline stem cell proliferation by somatic MPK-1/MAPK activity in C. elegans.
Neoplasms
Notch Pathway Inhibition Using PF-03084014, a ?-Secretase Inhibitor (GSI), Enhances the Antitumor Effect of Docetaxel in Prostate Cancer.
Neoplasms
Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.
Neoplasms
Nuclear receptor CAR represses TNFalpha-induced cell death by interacting with the anti-apoptotic GADD45B.
Neoplasms
O-GlcNAcylation of MEK2 promotes the proliferation and migration of breast cancer cells.
Neoplasms
Obatoclax overcomes resistance to cell death in aggressive thyroid carcinomas by countering Bcl2a1 and Mcl1 overexpression.
Neoplasms
Oncogenic K-Ras Regulates Bioactive Sphingolipids in a Sphingosine Kinase 1-dependent Manner.
Neoplasms
Oncogenic NRAS, required for pathogenesis of embryonic rhabdomyosarcoma, relies upon the HMGA2-IGF2BP2 pathway.
Neoplasms
Oncogenic tyrosine kinase NPM/ALK induces activation of the MEK/ERK signaling pathway independently of c-Raf.
Neoplasms
Overactivation of Akt Contributes to MEK Inhibitor Primary and Acquired Resistance in Colorectal Cancer Cells.
Neoplasms
Overactivation of the MEK/ERK pathway in liver tumor cells confers resistance to TGF-{beta}-induced cell death through impairing up-regulation of the NADPH oxidase NOX4.
Neoplasms
Overcoming mTOR inhibition-induced paradoxical activation of survival signaling pathways enhances mTOR inhibitors' anticancer efficacy.
Neoplasms
Overexpressed microRNA-136 works as a cancer suppressor in gallbladder cancer through suppression of JNK signaling pathway via inhibition of MAP2K4.
Neoplasms
Overexpression of miR-199a-5p decreases esophageal cancer cell proliferation through repression of mitogen-activated protein kinase kinase kinase-11 (MAP3K11).
Neoplasms
Oxidative Stress in Malignant Melanoma Enhances Tumor Necrosis Factor-? Secretion of Tumor-Associated Macrophages That Promote Cancer Cell Invasion.
Neoplasms
P-REX1 creates a positive feedback loop to activate growth factor receptor, PI3K/AKT and MEK/ERK signaling in breast cancer.
Neoplasms
p38 MAP kinase and MKK-1 co-operate in the generation of GM-CSF from LPS-stimulated human monocytes by an NF-kappa B-independent mechanism.
Neoplasms
p38 MAPK signaling in M1 macrophages results in selective elimination of M2 macrophages by MEK inhibition.
Neoplasms
PAC exhibits potent anti-colon cancer properties through targeting cyclin D1 and suppressing epithelial-to-mesenchymal transition.
Neoplasms
PAK1 confers chemoresistance and poor outcome in non-small cell lung cancer via ?-catenin-mediated stemness.
Neoplasms
Pancreatic tumor cells with mutant K-ras suppress ERK activity by MEK-dependent induction of MAP kinase phosphatase-2.
Neoplasms
Paradoxical activation of MEK/ERK signaling induced by B-Raf inhibition enhances DR5 expression and DR5 activation-induced apoptosis in Ras-mutant cancer cells.
Neoplasms
Pathogenicity and virulence of Japanese encephalitis virus: Neuroinflammation and neuronal cell damage.
Neoplasms
PD0325901, a mitogen-activated protein kinase kinase inhibitor, produces ocular toxicity in a rabbit animal model of retinal vein occlusion.
Neoplasms
PD98059 triggers G1 arrest and apoptosis in human leukemic U937 cells through downregulation of Akt signal pathway.
Neoplasms
Peptides derived from the extracellular domain of the somatostatin receptor splicing variant SST5TMD4 increase malignancy in multiple cancer cell types.
Neoplasms
Peroxisome proliferators activate extracellular signal-regulated kinases in immortalized mouse liver cells.
Neoplasms
Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers.
Neoplasms
Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers.
Neoplasms
Phosphatidylinositol 3-kinase pathway genomic alterations in 60,991 diverse solid tumors informs targeted therapy opportunities.
Neoplasms
Phosphorylation of myofibrillogenesis regulator-1 activates the MAPK signaling pathway and induces proliferation and migration in human breast cancer MCF7 cells.
Neoplasms
PI3K-driven HER2 expression is a potential therapeutic target in colorectal cancer stem cells.
Neoplasms
PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling.
Neoplasms
Polymeric immunoglobulin receptor promotes tumor growth in hepatocellular carcinoma.
Neoplasms
Preliminary results from a prospective trial of preoperative combined BRAF and MEK-targeted therapy in advanced BRAF mutation-positive melanoma.
Neoplasms
Pro-Renin Receptor Overexpression Promotes Angiotensin II-Induced Abdominal Aortic Aneurysm Formation in Apolipoprotein E-Knockout Mice.
Neoplasms
Prolonged survival and delayed progression of pancreatic intraepithelial neoplasia in LSL-KrasG12D/+;Pdx-1-Cre mice by vitamin E ?-tocotrienol.
Neoplasms
Purification and cDNA cloning of SAPKK3, the major activator of RK/p38 in stress- and cytokine-stimulated monocytes and epithelial cells.
Neoplasms
Purification and identification of a major activator for p38 from osmotically shocked cells. Activation of mitogen-activated protein kinase kinase 6 by osmotic shock, tumor necrosis factor-alpha, and H2O2.
Neoplasms
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth.
Neoplasms
Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma.
Neoplasms
RAS/MAPK signaling functions in oxidative stress, DNA damage response and cancer progression.
Neoplasms
Reactivation of Mitogen-activated Protein Kinase (MAPK) Pathway by FGF Receptor 3 (FGFR3)/Ras Mediates Resistance to Vemurafenib in Human B-RAF V600E Mutant Melanoma.
Neoplasms
Reactive oxygen species (ROS) and reactive nitrogen species (RNS) generation by silica in inflammation and fibrosis.
Neoplasms
Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers.
Neoplasms
Regorafenib: Antitumor Activity upon Mono and Combination Therapy in Preclinical Pediatric Malignancy Models.
Neoplasms
Regulation of type I plasminogen activator inhibitor in human gingival fibroblasts with cyclosporine A.
Neoplasms
Relationship between the expression of extracellular signal-regulated kinase 1/2 and the dissociation of pancreatic cancer cells: Involvement of ERK1/2 in the dissociation status of cancer cells.
Neoplasms
Requirement of mitogen-activated protein kinase kinase 3 (MKK3) for tumor necrosis factor-induced cytokine expression.
Neoplasms
Response and resistance to MEK inhibition in leukaemias initiated by hyperactive Ras.
Neoplasms
REX-1 Represses RASSF1a and Activates the MEK/ERK Pathway to Promote Tumorigenesis in Prostate Cancer.
Neoplasms
RNAi-mediated ERK2 knockdown inhibits growth of tumor cells in vitro and in vivo.
Neoplasms
RNAi-mediated MEK1 knock-down prevents ERK1/2 activation and abolishes human hepatocarcinoma growth in vitro and in vivo.
Neoplasms
Role of MEK partner-1 in cancer stemness through MEK/ERK pathway in cancerous neural stem cells, expressing EGFRviii.
Neoplasms
Role of MEK/ERK pathway in the MAD2-mediated cisplatin sensitivity in testicular germ cell tumour cells.
Neoplasms
Selected polyphenols potentiate the apoptotic efficacy of glycolytic inhibitors in human acute myeloid leukemia cell lines. Regulation by protein kinase activities.
Neoplasms
Selective potentiation of paclitaxel (taxol)-induced cell death by mitogen-activated protein kinase kinase inhibition in human cancer cell lines.
Neoplasms
Selumetinib attenuate skeletal muscle wasting in murine cachexia model through ERK inhibition and AKT activation.
Neoplasms
Serine protease inhibitor Kazal type 1 (SPINK1) downregulates E-cadherin and induces EMT of hepatoma cells to promote hepatocellular carcinoma metastasis via the MEK/ERK signaling pathway.
Neoplasms
SGK1 inhibits cellular apoptosis and promotes proliferation via the MEK/ERK/p53 pathway in colitis.
Neoplasms
Signal transduction pathways activated and required for mammary carcinogenesis in response to specific oncogenes.
Neoplasms
Silencing of long noncoding RNA HOXD-AS1 inhibits proliferation, cell cycle progression, migration and invasion of hepatocellular carcinoma cells through MEK/ERK pathway.
Neoplasms
Sodium butyrate improved intestinal immune function associated with NF-?B and p38MAPK signalling pathways in young grass carp (Ctenopharyngodon idella).
Neoplasms
Sophocarpine prevents cigarette smoke-induced restenosis in rat carotid arteries after angioplasty.
Neoplasms
Sp1 regulates Raf/MEK/ERK-induced p21(CIP1) transcription in TP53-mutated cancer cells.
Neoplasms
Specific amino acid deficiency alters the expression of genes in human melanoma and other tumor cell lines.
Neoplasms
Steady-State Levels of Phosphorylated Mitogen-Activated Protein Kinase Kinase 1/2 Determined by Mortalin/HSPA9 and Protein Phosphatase 1 Alpha in KRAS and BRAF Tumor Cells.
Neoplasms
Structure-Based Design of a Novel SMYD3 Inhibitor that Bridges the SAM-and MEKK2-Binding Pockets.
Neoplasms
Structure-guided cancer blockade between bioactive bursehernin and proteins: Molecular docking and molecular dynamics study.
Neoplasms
STYK1 promotes epithelial-mesenchymal transition and tumor metastasis in human hepatocellular carcinoma through MEK/ERK and PI3K/AKT signaling.
Neoplasms
Sulforaphane enhances the therapeutic potential of TRAIL in prostate cancer orthotopic model through regulation of apoptosis, metastasis, and angiogenesis.
Neoplasms
Suppression of mitochondrial biogenesis through toll-like receptor 4-dependent mitogen-activated protein kinase kinase/extracellular signal-regulated kinase signaling in endotoxin-induced acute kidney injury.
Neoplasms
Synergistic anti-angiogenic treatment effects by dual FGFR1 and VEGFR1 inhibition in FGFR1-amplified breast cancer.
Neoplasms
Synergistic interactions between MEK1/2 and histone deacetylase inhibitors in BCR/ABL+ human leukemia cells.
Neoplasms
Synthesis and structure-activity relationships of 3-cyano-4-(phenoxyanilino)quinolines as MEK (MAPKK) inhibitors.
Neoplasms
t10,c12-Conjugated linoleic acid stimulates mammary tumor progression in Her2/ErbB2 mice through activation of both proliferative and survival pathways.
Neoplasms
Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model.
Neoplasms
Targeting compensatory MEK/ERK activation increases JAK inhibitor efficacy in myeloproliferative neoplasms.
Neoplasms
Targeting MEK/MAPK signal transduction module potentiates ATO-induced apoptosis in multiple myeloma cells through multiple signaling pathways.
Neoplasms
Targeting Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Kinase in the Mutant (V600E) B-Raf Signaling Cascade Effectively Inhibits Melanoma Lung Metastases.
Neoplasms
The Association of Modifiable Breast Cancer Risk Factors and Somatic Genomic Alterations in Breast Tumors: The Cancer Genome Atlas Network.
Neoplasms
The D Domain of LRRC4 anchors ERK1/2 in the cytoplasm and competitively inhibits MEK/ERK activation in glioma cells.
Neoplasms
The eukaryotic initiation factor 5A is involved in the regulation of proliferation and apoptosis induced by interferon-alpha and EGF in human cancer cells.
Neoplasms
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups.
Neoplasms
The important roles of RET, VEGFR2 and the RAF/MEK/ERK pathway in cancer treatment with sorafenib.
Neoplasms
The induction of prostaglandin E2 production, interleukin-6 production, cell cycle arrest, and cytotoxicity in primary oral keratinocytes and KB cancer cells by areca nut ingredients is differentially regulated by MEK/ERK activation.
Neoplasms
The interaction of SV40 small tumor antigen with protein phosphatase 2A stimulates the map kinase pathway and induces cell proliferation.
Neoplasms
The intermediate-activity L597VBRAF mutant acts as an epistatic modifier of oncogenic RAS by enhancing signaling through the RAF/MEK/ERK pathway.
Neoplasms
The landscape of candidate driver genes differs between male and female breast cancer.
Neoplasms
The long non-coding RNA PVT1/miR-145-5p/ITGB8 axis regulates cell proliferation, apoptosis, migration and invasion in non-small cell lung cancer cells.
Neoplasms
The MEK/ERK pathway acts upstream of NF kappa B1 (p50) homodimer activity and Bcl-2 expression in a murine B-cell lymphoma cell line. MEK inhibition restores radiation-induced apoptosis.
Neoplasms
The membrane immunoglobulin receptor utilizes a Shc/Grb2/hSOS complex for activation of the mitogen-activated protein kinase cascade in a B-cell line.
Neoplasms
The miR-19b-3p-MAP2K3-STAT3 feedback loop regulates cell proliferation and invasion in esophageal squamous cell carcinoma.
Neoplasms
The monoclonal antibody CH12 enhances the sorafenib-mediated growth inhibition of hepatocellular carcinoma xenografts expressing epidermal growth factor receptor variant III.
Neoplasms
The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner.
Neoplasms
The Similar Effects of miR-512-3p and miR-519a-2-5p on the Promotion of Hepatocellular Carcinoma: Different Tunes Sung With Equal Skill.
Neoplasms
The small molecule inhibitor YK-4-279 disrupts mitotic progression of neuroblastoma cells, overcomes drug resistance and synergizes with inhibitors of mitosis.
Neoplasms
The Use of MEK Inhibitors in Neurofibromatosis Type 1-Associated Tumors and Management of Toxicities.
Neoplasms
TIMP-2 binding with cellular MT1-MMP stimulates invasion-promoting MEK/ERK signaling in cancer cells.
Neoplasms
TOPK modulates tumour-specific radiosensitivity and correlates with recurrence after prostate radiotherapy.
Neoplasms
Transforming growth factor {beta}1-mediated activation of the smooth muscle {alpha}-actin gene in human pulmonary myofibroblasts is inhibited by tumor necrosis factor-{alpha} via mitogen-activated protein kinase kinase 1-dependent Induction of the Egr-1 transcriptional repressor.
Neoplasms
Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic.
Neoplasms
Truncation- and motif-based pan-cancer analysis reveals tumor-suppressing kinases.
Neoplasms
Tuberous sclerosis-associated neoplasms express activated p42/44 mitogen-activated protein (MAP) kinase, and inhibition of MAP kinase signaling results in decreased in vivo tumor growth.
Neoplasms
Tumor microenvironment confers mTOR inhibitor resistance in invasive intestinal adenocarcinoma.
Neoplasms
Tumor necrosis factor receptor 1/c-Jun-NH2-kinase signaling promotes human neoplasia.
Neoplasms
Tumor necrosis factor signaling to stress-activated protein kinase (SAPK)/Jun NH2-terminal kinase (JNK) and p38. Germinal center kinase couples TRAF2 to mitogen-activated protein kinase/ERK kinase kinase 1 and SAPK while receptor interacting protein associates with a mitogen-activated protein kinase kinase kinase upstream of MKK6 and p38.
Neoplasms
Tumor necrosis factor-alpha regulates inflammatory and mesenchymal responses via mitogen-activated protein kinase kinase, p38, and nuclear factor kappaB in human endometriotic epithelial cells.
Neoplasms
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) promotes mitochondrial dysfunction and apoptosis induced by 7-hydroxystaurosporine and mitogen-activated protein kinase kinase inhibitors in human leukemia cells that ectopically express Bcl-2 and Bcl-xL.
Neoplasms
Tumor- and cytokine-primed human natural killer cells exhibit distinct phenotypic and transcriptional signatures.
Neoplasms
Tumor-Associated Macrophages Suppress the Cytotoxic Activity of Antimitotic Agents.
Neoplasms
Tumour necrosis factor alpha and interleukin 1 signalling: do MAPKK kinases connect it all?
Neoplasms
Unbiased Proteomic and Phosphoproteomic Analysis Identifies Response Signatures and Novel Susceptibilities After Combined MEK and mTOR Inhibition in BRAFV600E Mutant Glioma.
Neoplasms
Uncoupling FoxO3A mitochondrial and nuclear functions in cancer cells undergoing metabolic stress and chemotherapy.
Neoplasms
Unmet needs in ovarian cancer: dividing histologic subtypes to exploit novel targets and pathways.
Neoplasms
Upregulation of lactate dehydrogenase a by 14-3-3? leads to increased glycolysis critical for breast cancer initiation and progression.
Neoplasms
Validation of a multiparameter flow cytometry method for the determination of phosphorylated extracellular-signal-regulated kinase and DNA in circulating tumor cells.
Neoplasms
Variable apoptotic response of NSCLC cells to inhibition of the MEK/ERK pathway by small molecules or dominant negative mutants.
Neoplasms
Von Hippel-Lindau tumor suppressor gene loss in renal cell carcinoma promotes oncogenic epidermal growth factor receptor signaling via Akt-1 and MEK-1.
Neoplasms
Wogonoside promotes apoptosis and ER stress in human gastric cancer cells by regulating the IRE1? pathway.
Neoplasms
Zonula occludens-1 (ZO-1) redistribution is involved in the regulation of cell dissociation in pancreatic cancer cells.
Neoplasms
[18 F]FDG-PET imaging is an early non-invasive pharmacodynamic biomarker for a first-in-class dual MEK/Raf inhibitor, RO5126766 (CH5126766), in preclinical xenograft models.
Neoplasms
[Angiotensin II and aldosterone stimulate alpha1-(I) procollagen mRNA expression in hepatic stellate cells via activation of ERK1/2 and AP-1]
Neoplasms
[Coexpression of MAP2K4 and vimentin proteins in human endometrial carcinoma and its clinicopathological significance].
Neoplasms
[Effects of angiotensin II and aldosterone on NF-kappaB binding activity in hepatic stellate cells]
Neoplasms
[Future targeting of the RAS/RAF/MEK/ERK signaling pathway in oncology: the example of melanoma].
Neoplasms
[Retracted] Anticancer activity of caffeic acid n?butyl ester against A431 skin carcinoma cell line occurs via induction of apoptosis and inhibition of the mTOR/PI3K/AKT signaling pathway.
Neoplasms, Germ Cell and Embryonal
Role of MEK/ERK pathway in the MAD2-mediated cisplatin sensitivity in testicular germ cell tumour cells.
Neoplastic Cells, Circulating
Mitogen-activated protein kinase kinase 4 (MAP2K4) promotes human prostate cancer metastasis.
Neoplastic Cells, Circulating
Validation of a multiparameter flow cytometry method for the determination of phosphorylated extracellular-signal-regulated kinase and DNA in circulating tumor cells.
Neuralgia
Following nerve injury neuregulin-1 drives microglial proliferation and neuropathic pain via the MEK/ERK pathway.
Neuralgia
Neurosteroid Allopregnanolone Suppresses Median Nerve Injury-induced Mechanical Hypersensitivity and Glial Extracellular Signal-regulated Kinase Activation through ?-Aminobutyric Acid Type A Receptor Modulation in the Rat Cuneate Nucleus.
Neuralgia
Overexpression of miR-206 ameliorates chronic constriction injury-induced neuropathic pain in rats via the MEK/ERK pathway by targeting brain-derived neurotrophic factor.
Neurilemmoma
Activation of ERK, AKT and JNK signalling pathways in human schwannomas in situ.
Neurilemmoma
Nilotinib alone or in combination with selumetinib is a drug candidate for neurofibromatosis type 2.
Neurobehavioral Manifestations
Map2k7 Haploinsufficiency Induces Brain Imaging Endophenotypes and Behavioral Phenotypes Relevant to Schizophrenia.
Neuroblastoma
All-trans retinoic acid induces COX-2 and prostaglandin E2 synthesis in SH-SY5Y human neuroblastoma cells: involvement of retinoic acid receptors and extracellular-regulated kinase 1/2.
Neuroblastoma
Binimetinib inhibits MEK and is effective against neuroblastoma tumor cells with low NF1 expression.
Neuroblastoma
Clinical responses to selumetinib (AZD6244; ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma.
Neuroblastoma
Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium.
Neuroblastoma
Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling.
Neuroblastoma
Correction: LGR5 regulates pro-survival MEK/ERK and proliferative Wnt/?-catenin signalling in neuroblastoma.
Neuroblastoma
Detecting the spectrum of multigene mutations in non-small cell lung cancer by Snapshot assay.
Neuroblastoma
Effect of retinoic acid and delta-like 1 homologue (DLK1) on differentiation in neuroblastoma.
Neuroblastoma
Growth Inhibition and Apoptosis of Neuroblastoma Cells Through ROS-Independent MEK/ERK Activation by Sulforaphane.
Neuroblastoma
Hotspot Mutations Detectable by Next-generation Sequencing in Exhaled Breath Condensates from Patients with Lung Cancer.
Neuroblastoma
Immunohistochemical staining of phosphorylated-ERK in post-chemotherapeutic samples is a potential predictor of the prognosis of neuroblastoma.
Neuroblastoma
Induction of cyclin-dependent kinase 5 and its activator p35 through the extracellular-signal-regulated kinase and protein kinase A pathways during retinoic-acid mediated neuronal differentiation in human neuroblastoma SK-N-BE(2)C cells.
Neuroblastoma
Induction of MEK/ERK activity by AZD8055 confers acquired resistance in neuroblastoma.
Neuroblastoma
LGR5 regulates pro-survival MEK/ERK and proliferative Wnt/?-catenin signalling in neuroblastoma.
Neuroblastoma
Mechanisms of Acquired BRAF Inhibitor Resistance in Melanoma: A Systematic Review.
Neuroblastoma
Modulation of extracellular signal-regulated kinase (ERK) by opioid and cannabinoid receptors that are expressed in the same cell.
Neuroblastoma
Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma.
Neuroblastoma
Phospholipase D2 activation by p38 MAP kinase is involved in neurite outgrowth.
Neuroblastoma
Rapid membrane effects of steroids in neuroblastoma cells: effects of estrogen on mitogen activated protein kinase signalling cascade and c-fos immediate early gene transcription.
Neuroblastoma
The proliferative response of NB69 human neuroblastoma cells to a 50 Hz magnetic field is mediated by ERK1/2 signaling.
Neurofibroma, Plexiform
Physiologically Based Pharmacokinetic Modeling for Selumetinib to Evaluate Drug-Drug Interactions and Pediatric Dose Regimens.
Neurofibroma, Plexiform
The Use of MEK Inhibitors in Neurofibromatosis Type 1-Associated Tumors and Management of Toxicities.
Neurofibromatoses
Heat shock factor 1 (HSF1)-targeted anticancer therapeutics: overview of current preclinical progress.
Neurofibromatoses
Physiologically Based Pharmacokinetic Modeling for Selumetinib to Evaluate Drug-Drug Interactions and Pediatric Dose Regimens.
Neurofibromatoses
The Use of MEK Inhibitors in Neurofibromatosis Type 1-Associated Tumors and Management of Toxicities.
Neurofibromatosis 1
Heat shock factor 1 (HSF1)-targeted anticancer therapeutics: overview of current preclinical progress.
Neurofibromatosis 1
Physiologically Based Pharmacokinetic Modeling for Selumetinib to Evaluate Drug-Drug Interactions and Pediatric Dose Regimens.
Neurofibromatosis 1
The Use of MEK Inhibitors in Neurofibromatosis Type 1-Associated Tumors and Management of Toxicities.
Newcastle Disease
Newcastle Disease Virus Nonstructural V Protein Upregulates SOCS3 Expression to Facilitate Viral Replication Depending on the MEK/ERK Pathway.
Newcastle Disease
Newcastle Disease Virus V Protein Promotes Viral Replication in HeLa Cells through the Activation of MEK/ERK Signaling.
Noonan Syndrome
Inducible Pluripotent Stem Cell-Derived Cardiomyocytes Reveal Aberrant Extracellular Regulated Kinase 5 and Mitogen-Activated Protein Kinase Kinase 1/2 Signaling Concomitantly Promote Hypertrophic Cardiomyopathy in RAF1-Associated Noonan Syndrome.
Obesity
MAP2K3 is associated with body mass index in American Indians and Caucasians and may mediate hypothalamic inflammation.
Obesity
MiR-21a-5p suppresses bisphenol A-induced pre-adipocyte differentiation by targeting map2k3 through MKK3/p38/MAPK.
Optic Nerve Injuries
PI3K/akt, JAK/STAT and MEK/ERK pathway inhibition protects retinal ganglion cells via different mechanisms after optic nerve injury.
Osteoarthritis
Egr-1 inhibits the expression of extracellular matrix genes in chondrocytes by TNFalpha-induced MEK/ERK signalling.
Osteoarthritis
In vivo selective inhibition of mitogen-activated protein kinase kinase 1/2 in rabbit experimental osteoarthritis is associated with a reduction in the development of structural changes.
Osteoarthritis
Inhibition of interleukin-1beta-induced activation of MEK/ERK pathway and DNA binding of NF-kappaB and AP-1: Potential mechanism for Diacerein effects in osteoarthritis.
Osteoarthritis
Rhein inhibits interleukin-1 beta-induced activation of MEK/ERK pathway and DNA binding of NF-kappa B and AP-1 in chondrocytes cultured in hypoxia: a potential mechanism for its disease-modifying effect in osteoarthritis.
Osteoarthritis, Knee
Activation of the extracellular-signal-regulated kinase (ERK)/c-Jun N-terminal kinase (JNK) signal pathway and osteogenic factors in subchondral bone of patients with knee osteoarthritis.
Osteoporosis, Postmenopausal
Disturbed MEK/ERK signaling increases osteoclast activity via the Hedgehog-Gli pathway in postmenopausal osteoporosis.
Osteoporosis, Postmenopausal
QingYan formula extracts protect against postmenopausal osteoporosis in ovariectomized rat model via active ER-dependent MEK/ERK and PI3K/Akt signal pathways.
Osteosarcoma
(-)-Epigallocatechin-3-gallate inhibits osteosarcoma cell invasiveness by inhibiting the MEK/ERK signaling pathway in human osteosarcoma cells.
Osteosarcoma
3-Hydroxyflavone inhibits human osteosarcoma U2OS and 143B cells metastasis by affecting EMT and repressing u-PA/MMP-2 via FAK-Src to MEK/ERK and RhoA/MLC2 pathways and reduces 143B tumor growth in vivo.
Osteosarcoma
Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against osteosarcoma.
Osteosarcoma
Association of RDM1 with osteosarcoma progression via cell cycle and MEK/ERK signalling pathway regulation.
Osteosarcoma
ERK1/2 activation mediated by the nutlin?3?induced mitochondrial translocation of p53.
Osteosarcoma
Factors Associated with Promoted Proliferation of Osteosarcoma by Peptidylarginine Deiminase 4.
Osteosarcoma
Hematopoietic cell kinase enhances osteosarcoma development via the MEK/ERK pathway.
Osteosarcoma
Increased expression of ecotropic viral integration site 2A indicates a poor prognosis and promotes osteosarcoma evolution through activating MEK/ERK pathway.
Osteosarcoma
MicroRNA-27a promotes proliferation, migration and invasion by targeting MAP2K4 in human osteosarcoma cells.
Osteosarcoma
microRNA-363 plays a tumor suppressive role in osteosarcoma by directly targeting MAP2K4.
Osteosarcoma
p16(INK4A) inhibits the pro-metastatic potentials of osteosarcoma cells through targeting the ERK pathway and TGF-?1.
Osteosarcoma
RRAS2 knockdown suppresses osteosarcoma progression by inactivating the MEK/ERK signaling pathway.
Osteosarcoma
Signal transduction pathways involved in the stimulation of tissue type plasminogen activator by interleukin-1alpha and Porphyromonas gingivalis in human osteosarcoma cells.
Osteosarcoma
Specific inhibitor of MEK-mediated cross-talk between ERK and p38 MAPK during differentiation of human osteosarcoma cells.
Osteosarcoma
Targeted MEK inhibition by cobimetinib enhances doxorubicin's efficacy in osteosarcoma models.
Ovarian Neoplasms
Analysis of the mitogen-activated protein kinase kinase 4 (MAP2K4) tumor suppressor gene in ovarian cancer.
Ovarian Neoplasms
Down-regulation of TRIB3 inhibits the progression of ovarian cancer via MEK/ERK signaling pathway.
Ovarian Neoplasms
E-cadherin promotes proliferation of human ovarian cancer cells in vitro via activating MEK/ERK pathway.
Ovarian Neoplasms
Gallic acid sensitizes paclitaxel-resistant human ovarian carcinoma cells through an increase in reactive oxygen species and subsequent downregulation of ERK activation.
Ovarian Neoplasms
Kaempferol exerts anti-proliferative effects on human ovarian cancer cells by inducing apoptosis, G0/G1 cell cycle arrest and modulation of MEK/ERK and STAT3 pathways.
Ovarian Neoplasms
KRAS Genomic Status Predicts the Sensitivity of Ovarian Cancer Cells to Decitabine.
Ovarian Neoplasms
LncRNA HOTTIP promotes the proliferation and invasion of ovarian cancer cells by activating the MEK/ERK pathway.
Ovarian Neoplasms
Low-grade epithelial ovarian cancer: a number of distinct clinical entities?
Ovarian Neoplasms
Lysophosphatidic Acid Stimulates Ovarian Cancer Cell Migration via a Ras-MEK Kinase 1 Pathway.
Ovarian Neoplasms
MicroRNA-338-3p suppresses ovarian cancer cells growth and metastasis: implication of Wnt/catenin beta and MEK/ERK signaling pathways.
Ovarian Neoplasms
Mitogen-activated Protein Kinase Kinase 6-fusion Protein (MAP2K6-FP) Potentiates the Anti-tumor effects of Paclitaxel in Ovarian Cancer.
Ovarian Neoplasms
Novel functions for 2-phenylbenzimidazole-5-sulphonic acid: Inhibition of ovarian cancer cell responses and tumour angiogenesis.
Ovarian Neoplasms
p21-Activated kinase 4 regulates ovarian cancer cell proliferation, migration, and invasion and contributes to poor prognosis in patients.
Ovarian Neoplasms
Propofol suppresses cell viability, cell cycle progression and motility and induces cell apoptosis of ovarian cancer cells through suppressing MEK/ERK signaling via targeting circVPS13C/miR-145 axis.
Ovarian Neoplasms
SPARCL1 suppresses the proliferation and migration of human ovarian cancer cells via the MEK/ERK signaling.
Ovarian Neoplasms
Transactivation of the epidermal growth factor receptor in endothelin-1-induced mitogenic signaling in human ovarian carcinoma cells.
Ovarian Neoplasms
Using MKK4's metastasis suppressor function to identify and dissect cancer cell-microenvironment interactions during metastatic colonization.
Ovarian Neoplasms
[Combined inhibition of PI3K and MEK has synergistic inhibitory effect on the proliferation of cisplatin-resistant ovarian cancer cells].
Overnutrition
A Maternal High-Fat Diet Induces DNA Methylation Changes That Contribute to Glucose Intolerance in Offspring.
Pancreatic Neoplasms
A FAM83A Positive Feed-back Loop Drives Survival and Tumorigenicity of Pancreatic Ductal Adenocarcinomas.
Pancreatic Neoplasms
A new prognosis prediction model combining TNM stage with MAP2K4 and JNK in postoperative pancreatic cancer patients.
Pancreatic Neoplasms
Analysis of invasion-metastasis mechanism in pancreatic cancer: involvement of tight junction transmembrane protein occludin and MEK/ERK signal transduction pathway in cancer cell dissociation.
Pancreatic Neoplasms
Antitumor activity and mechanism of resistance of the novel HDAC and PI3K dual inhibitor CUDC-907 in pancreatic cancer.
Pancreatic Neoplasms
Arrangement of expression and distribution of tight junction protein claudin-1 in cell dissociation of pancreatic cancer cells.
Pancreatic Neoplasms
Benzophenone Compounds, from a Marine-Derived Strain of the Fungus Pestalotiopsis neglecta, Inhibit Proliferation of Pancreatic Cancer Cells by Targeting the MEK/ERK Pathway.
Pancreatic Neoplasms
C6orf106 accelerates pancreatic cancer cell invasion and proliferation via activating ERK signaling pathway.
Pancreatic Neoplasms
Correction to Benzophenone Compounds, from a Marine-Derived Strain of the Fungus Pestalotiopsis neglecta, Inhibit Proliferation of Pancreatic Cancer Cells by Targeting the MEK/ERK Pathway.
Pancreatic Neoplasms
Direct TGF-?1 signaling between activated platelets and pancreatic cancer cells primes cisplatin insensitivity.
Pancreatic Neoplasms
Dual PI3K/mTOR inhibitors induce rapid over-activation of the MEK/ERK pathway in human pancreatic cancer cells through suppression of mTORC2.
Pancreatic Neoplasms
ERR? promotes pancreatic cancer progression by enhancing the transcription of PAI1 and activating the MEK/ERK pathway.
Pancreatic Neoplasms
Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%.
Pancreatic Neoplasms
Expression of connective tissue growth factor in pancreatic cancer cell lines.
Pancreatic Neoplasms
Growth factor-dependent activation of the MAPK pathway in human pancreatic cancer: MEK/ERK and p38 MAP kinase interaction in uPA synthesis.
Pancreatic Neoplasms
Identification of common variants in BRCA2 and MAP2K4 for susceptibility to sporadic pancreatic cancer.
Pancreatic Neoplasms
Inhibition of the MEK/ERK pathway augments nab-paclitaxel-based chemotherapy effects in preclinical models of pancreatic cancer.
Pancreatic Neoplasms
Involvement of matrix metalloproteinase-7 in invasion-metastasis through induction of cell dissociation in pancreatic cancer.
Pancreatic Neoplasms
Involvement of MMP-7 in invasion of pancreatic cancer cells through activation of the EGFR mediated MEK-ERK signal transduction pathway.
Pancreatic Neoplasms
Involvement of the mitogen-activated protein kinase kinase 2 in the induction of cell dissociation in pancreatic cancer.
Pancreatic Neoplasms
KrasG12D mutation contributes to regulatory T cell conversion through activation of the MEK/ERK pathway in pancreatic cancer.
Pancreatic Neoplasms
LIM-only protein FHL2 critically determines survival and radioresistance of pancreatic cancer cells.
Pancreatic Neoplasms
LPS Induced miR-181a Promotes Pancreatic Cancer Cell Migration via Targeting PTEN and MAP2K4.
Pancreatic Neoplasms
LTB4 stimulates growth of human pancreatic cancer cells via MAPK and PI-3 kinase pathways.
Pancreatic Neoplasms
MEK Inhibition Potentiates the Activity of Hsp90 Inhibitor 17-AAG against Pancreatic Cancer Cells.
Pancreatic Neoplasms
MEK Inhibitor Suppresses Expression of the miR-17-92 Cluster with G1-Phase Arrest in HT-29 Human Colon Cancer Cells and MIA PaCa-2 Pancreatic Cancer Cells.
Pancreatic Neoplasms
MEK/ERK signaling pathway regulates the expression of Bcl-2, Bcl-X(L), and Mcl-1 and promotes survival of human pancreatic cancer cells.
Pancreatic Neoplasms
MEK/ERK-mediated proliferation is negatively regulated by P38 map kinase in the human pancreatic cancer cell line, PANC-1.
Pancreatic Neoplasms
Multiple signal pathways are involved in the mitogenic effect of 5(S)-HETE in human pancreatic cancer.
Pancreatic Neoplasms
Netrin-1 suppresses the MEK/ERK pathway and ITGB4 in pancreatic cancer.
Pancreatic Neoplasms
Novel Agents in the Management of Pancreatic Adenocarcinoma: Phase I Studies. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011.
Pancreatic Neoplasms
Relationship between activation of epidermal growth factor receptor and cell dissociation in pancreatic cancer.
Pancreatic Neoplasms
Synergistic effect between erlotinib and MEK inhibitors in KRAS wildtype human pancreatic cancer cells.
Pancreatic Neoplasms
The glucosylceramide synthase inhibitor PDMP sensitizes pancreatic cancer cells to MEK/ERK inhibitor AZD-6244.
Pancreatic Neoplasms
The MEK/ERK pathway promotes NOTCH signalling in pancreatic cancer cells.
Pancreatic Neoplasms
Zonula occludens-1 (ZO-1) redistribution is involved in the regulation of cell dissociation in pancreatic cancer cells.
Pancreatitis
Mitogen-activated Protein Kinase Kinase Activity Maintains Acinar-to-Ductal Metaplasia and Is Required for Organ Regeneration in Pancreatitis.
Parkinson Disease
A chemical genomics-aggrephagy integrated method studying functional analysis of autophagy inducers.
Parkinson Disease
Neuroprotective properties of icariin in MPTP-induced mouse model of Parkinson's disease: Involvement of PI3K/Akt and MEK/ERK signaling pathways.
Peritoneal Fibrosis
MicroRNA-21 contributes to high glucose-induced fibrosis in peritoneal mesothelial cells in rat models by activation of the Ras-MAPK signaling pathway via Sprouty-1.
Pheochromocytoma
Constitutively active mutant of the mitogen-activated protein kinase kinase MEK1 induces epithelial dedifferentiation and growth inhibition in madin-darby canine kidney-C7 cells.
Pheochromocytoma
GDNF-induced leukemia inhibitory factor can mediate differentiation via the MEK/ERK pathway in pheochromocytoma cells derived from nf1-heterozygous knockout mice.
Pheochromocytoma
HSP70 inhibitor VER155008 suppresses pheochromocytoma cell and xenograft growth by inhibition of PI3K/AKT/mTOR and MEK/ERK pathways.
Pheochromocytoma
Inhibition of MAP kinase kinase blocks the differentiation of PC-12 cells induced by nerve growth factor.
Pheochromocytoma
Signaling pathways for PC12 cell differentiation: making the right connections.
Pheochromocytoma
Specific regulation of JNK signalling by the novel rat MKK7gamma1 isoform.
phosphatidylinositol-3,4,5-trisphosphate 5-phosphatase deficiency
Lipid phosphatase SHIP-1 regulates chondrocyte hypertrophy and skeletal development.
Pneumonia
MAPK kinase 3 potentiates Chlamydia HSP60-induced inflammatory response through distinct activation of NF-?B.
Polycystic Kidney Diseases
?-catenin ablation exacerbates polycystic kidney disease progression.
Polycystic Kidney, Autosomal Dominant
Cyclic AMP activates B-Raf and ERK in cyst epithelial cells from autosomal-dominant polycystic kidneys.
Polycystic Ovary Syndrome
Alterations in mitogen-activated protein kinase kinase and extracellular regulated kinase signaling in theca cells contribute to excessive androgen production in polycystic ovary syndrome.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Central role of Fas-associated death domain protein in apoptosis induction by the mitogen-activated protein kinase kinase inhibitor CI-1040 (PD184352) in acute lymphocytic leukemia cells in vitro.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Inactivation of KLF4 promotes T-cell acute lymphoblastic leukemia and activates the MAP2K7 pathway.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Inhibition of the NEDD8 conjugation pathway induces calcium-dependent compensatory activation of the pro-survival MEK/ERK pathway in acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Mitogen-activated protein kinase is required for bryostatin 1-induced differentiation of the human acute lymphoblastic leukemia cell line Reh.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
PI3K/AKT/mTORC1 and MEK/ERK signaling in T-cell acute lymphoblastic leukemia: New options for targeted therapy.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
The autophagy induced by curcumin via MEK/ERK pathway plays an early anti-leukemia role in human Philadelphia chromosome-positive acute lymphoblastic leukemia SUP-B15 cells.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
The histone demethylase PHF8 promotes adult acute lymphoblastic leukemia through interaction with the MEK/ERK signaling pathway.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Combined targeting of JAK2 and Bcl-2/Bcl-xL to cure mutant JAK2-driven malignancies and overcome acquired resistance to JAK2 inhibitors.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Inactivation of KLF4 promotes T-cell acute lymphoblastic leukemia and activates the MAP2K7 pathway.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Inhibition of the MAP2K7-JNK pathway with 5Z-7-oxozeaenol induces apoptosis in T-cell acute lymphoblastic leukemia.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Interleukin-7 in T-cell acute lymphoblastic leukemia: an extrinsic factor supporting leukemogenesis?
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Novel tumor-suppressor function of KLF4 in pediatric T-cell acute lymphoblastic leukemia.
Prostatic Neoplasms
"MKK4 suppresses metastatic colonization by multiple highly metastatic prostate cancer cell lines through a transient impairment in cell cycle progression"
Prostatic Neoplasms
Androgen-induced miR-27A acted as a tumor suppressor by targeting MAP2K4 and mediated prostate cancer progression.
Prostatic Neoplasms
Commentary on Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model Kinkade CW, Castillo-Martin M, Puzio-Kuter A, Yan J, Foster TH, Gao H, Sun Y, Ouyang X, Gerald WL, Cordon-Cardo C, Abate-Shen C, Department of Urology, Columbia University College of Physicians and Surgeons, New York, NY.
Prostatic Neoplasms
Counteracting the activation of pAkt by inhibition of MEK/Erk inhibition reduces actin disruption-mediated apoptosis in PTEN-null PC3M prostate cancer cell lines.
Prostatic Neoplasms
Evolving therapeutic concepts in prostate cancer based on genome-wide analyses (review).
Prostatic Neoplasms
Identification of Genes Required for Enzalutamide Resistance in Castration-Resistant Prostate Cancer Cells In Vitro.
Prostatic Neoplasms
Identification of kinases regulating prostate cancer cell growth using an RNAi phenotypic screen.
Prostatic Neoplasms
Insulin exacerbated high glucose-induced epithelial-mesenchymal transition in prostatic epithelial cells BPH-1 and prostate cancer cells PC-3 via MEK/ERK signaling pathway.
Prostatic Neoplasms
Krüppel-like factor 5 promotes apoptosis triggered by tumor necrosis factor ? in LNCaP prostate cancer cells via up-regulation of mitogen-activated protein kinase kinase 7.
Prostatic Neoplasms
Loss of scinderin decreased expression of epidermal growth factor receptor and promoted apoptosis of castration-resistant prostate cancer cells.
Prostatic Neoplasms
Lysyl oxidase propeptide inhibits prostate cancer cell growth by mechanisms that target FGF-2-cell binding and signaling.
Prostatic Neoplasms
MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer.
Prostatic Neoplasms
MiR-203 over-expression promotes prostate cancer cell apoptosis and reduces ADM resistance.
Prostatic Neoplasms
Mitogen-activated protein kinase kinase 4 (MAP2K4) promotes human prostate cancer metastasis.
Prostatic Neoplasms
Mitogen-activated protein kinase kinase 4 metastasis suppressor gene expression is inversely related to histological pattern in advancing human prostatic cancers.
Prostatic Neoplasms
Mitogen-Activated Protein Kinase Kinase 4/c-Jun NH2-Terminal Kinase Kinase 1 Protein Expression Is Subject to Translational Regulation in Prostate Cancer Cell Lines.
Prostatic Neoplasms
Mitogen-activated protein kinase kinase 4/stress-activated protein/Erk kinase 1 (MKK4/SEK1), a prostate cancer metastasis suppressor gene encoded by human chromosome 17.
Prostatic Neoplasms
Modeling MEK4 Kinase Inhibitors through Perturbed Electrostatic Potential Charges.
Prostatic Neoplasms
Novel roles for class II Phosphoinositide 3-Kinase C2? in signalling pathways involved in prostate cancer cell invasion.
Prostatic Neoplasms
PAGE4 promotes prostate cancer cells survive under oxidative stress through modulating MAPK/JNK/ERK pathway.
Prostatic Neoplasms
Requirement for direct cross-talk between B1 and B2 kinin receptors for the proliferation of androgen-insensitive prostate cancer PC3 cells.
Prostatic Neoplasms
REX-1 Represses RASSF1a and Activates the MEK/ERK Pathway to Promote Tumorigenesis in Prostate Cancer.
Prostatic Neoplasms
Signal transduction pathways in androgen-dependent and -independent prostate cancer cell proliferation.
Prostatic Neoplasms
Specific amino acid deficiency alters the expression of genes in human melanoma and other tumor cell lines.
Prostatic Neoplasms
Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model.
Prostatic Neoplasms
The PPAR Gamma Agonist Troglitazone Regulates Erk 1/2 Phosphorylation via a PPAR?-Independent, MEK-Dependent Pathway in Human Prostate Cancer Cells.
Prostatic Neoplasms
Transforming growth factor-beta1 (TGF-beta)-induced apoptosis of prostate cancer cells involves Smad7-dependent activation of p38 by TGF-beta-activated kinase 1 and mitogen-activated protein kinase kinase 3.
Prostatic Neoplasms
[Effects of P2Y receptor activation on prostatic cancer cells requiring ERK1/2 or p38 cascade]
Prostatic Neoplasms
[SHP2 and MKP5 in P2Y purinergic receptor-mediated prostate cancer invasion]
Pulmonary Arterial Hypertension
TRPM7 channel inhibition exacerbates pulmonary arterial hypertension through MEK/ERK pathway.
Pulmonary Disease, Chronic Obstructive
Anti-inflammatory action of herbal medicine comprised of Scutellaria baicalensis and Chrysanthemum morifolium.
Pulmonary Disease, Chronic Obstructive
Dual Role For A MEK Inhibitor As A Modulator Of Inflammation And Host Defense Mechanisms With Potential Therapeutic Application In COPD.
Pulmonary Disease, Chronic Obstructive
Rare variant of MAP2K7 is associated with increased risk of COPD in southern and eastern Chinese.
Pulmonary Fibrosis
A novel lnc-PCF promotes the proliferation of TGF-?1-activated epithelial cells by targeting miR-344a-5p to regulate map3k11 in pulmonary fibrosis.
Pulmonary Fibrosis
Danshensu alleviates bleomycin-induced pulmonary fibrosis by inhibiting lung fibroblast-to-myofibroblast transition via the MEK/ERK signaling pathway.
Pulmonary Fibrosis
MEK-ERK Pathway Modulation Ameliorates Pulmonary Fibrosis Associated with Epidermal Growth Factor Receptor Activation.
Purpura
Circulating IgA from acute stage of childhood Henoch-Schönlein purpura can enhance endothelial interleukin (IL)-8 production through MEK/ERK signalling pathway.
Reperfusion Injury
Activation of the ERK1/2 pathway by the CaMEK gene via adeno-associated virus serotype 9 in cardiomyocytes.
Reperfusion Injury
Evidence that the MEK/ERK but not the PI3K/Akt pathway is required for protection from myocardial ischemia-reperfusion injury by 3',4'-dihydroxyflavonol.
Reperfusion Injury
The role of 1,25-dyhydroxyvitamin D3 in mouse liver ischemia reperfusion injury: regulation of autophagy through activation of MEK/ERK signaling and PTEN/PI3K/Akt/mTORC1 signaling.
Restless Legs Syndrome
The effects of a MAP2K5 microRNA target site SNP on risk for anxiety and depressive disorders.
Retinal Vein Occlusion
PD0325901, a mitogen-activated protein kinase kinase inhibitor, produces ocular toxicity in a rabbit animal model of retinal vein occlusion.
Retinoblastoma
ANRIL acts as onco-lncRNA by regulation of microRNA-24/c-Myc, MEK/ERK and Wnt/?-catenin pathway in retinoblastoma.
Retinoblastoma
Downregulation of CKS1B restrains the proliferation, migration, invasion and angiogenesis of retinoblastoma cells through the MEK/ERK signaling pathway.
Retinoblastoma
Increased expression of FGF1-mediated signaling molecules in adipose tissue of obese mice.
Retinoblastoma
Neurotrophin Receptors TrkA and TrkB in Retinoblastoma Are Differentially Expressed Depending on Cellular Differentiation.
Retinoblastoma
pRb phosphorylation regulates the proliferation of supporting cells in gentamicin-damaged neonatal avian utricle.
Retinoblastoma
ZD1839 induces p15INK4b and causes G1 arrest by inhibiting the mitogen-activated protein kinase/extracellular signal-regulated kinase pathway.
Retinopathy of Prematurity
Persistent inhibition of oxygen-induced retinal neovascularization by anthrax lethal toxin.
Rhabdomyosarcoma
Down-regulation of c-Myc following MEK/ERK inhibition halts the expression of malignant phenotype in rhabdomyosarcoma and in non muscle-derived human tumors.
Rhabdomyosarcoma
Genetic and molecular alterations in rhabdomyosarcoma: mRNA overexpression of MCL1 and MAP2K4 genes.
Rhabdomyosarcoma
MEK/ERK inhibitor U0126 increases the radiosensitivity of rhabdomyosarcoma cells in vitro and in vivo by downregulating growth and DNA repair signals.
Rhabdomyosarcoma
p21WAF1 expression induced by MEK/ERK pathway activation or inhibition correlates with growth arrest, myogenic differentiation and onco-phenotype reversal in rhabdomyosarcoma cells.
Rhabdomyosarcoma, Embryonal
c-Myc Sustains Transformed Phenotype and Promotes Radioresistance of Embryonal Rhabdomyosarcoma Cell Lines.
Rhabdomyosarcoma, Embryonal
Key role of MEK/ERK pathway in sustaining tumorigenicity and in vitro radioresistance of embryonal rhabdomyosarcoma stem-like cell population.
Rhabdomyosarcoma, Embryonal
MEK/ERK inhibitor U0126 affects in vitro and in vivo growth of embryonal rhabdomyosarcoma.
Rhabdomyosarcoma, Embryonal
MEK/ERK inhibitor U0126 increases the radiosensitivity of rhabdomyosarcoma cells in vitro and in vivo by downregulating growth and DNA repair signals.
Sarcoma
Clinical responses to selumetinib (AZD6244; ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma.
Sarcoma
Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium.
Sarcoma
Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling.
Sarcoma
Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo.
Sarcoma
Detecting the spectrum of multigene mutations in non-small cell lung cancer by Snapshot assay.
Sarcoma
Differentially expressed kinase genes associated with trypsinogen activation in rat pancreatic acinar cells treated with taurolithocholic acid 3-sulfate.
Sarcoma
ER stress promotes antitumor effects in BRAFi/MEKi resistant human melanoma induced by natural compound 4-nerolidylcathecol (4-NC).
Sarcoma
Factors influencing the CNS distribution of a novel MEK-1/2 inhibitor: implications for combination therapy for melanoma brain metastases.
Sarcoma
Hotspot Mutations Detectable by Next-generation Sequencing in Exhaled Breath Condensates from Patients with Lung Cancer.
Sarcoma
Ocular Changes in Metastatic Melanoma Patients Treated with MEK Inhibitor Cobimetinib and BRAF Inhibitor Vemurafenib.
Sarcoma
Ocular Toxicity in Metastatic Melanoma Patients Treated With Mitogen-Activated Protein Kinase Kinase Inhibitors: A Case Series.
Sarcoma
Phase I/II Trial of Immunotherapy With Durvalumab and Tremelimumab With Continuous or Intermittent MEK Inhibitor Selumetinib in NSCLC: Early Trial Report.
Sarcoma
Quercetin inhibits migration and invasion of SAS human oral cancer cells through inhibition of NF-?B and matrix metalloproteinase-2/-9 signaling pathways.
Sarcoma
Ras/ERK signaling pathway is involved in curcumin-induced cell cycle arrest and apoptosis in human gastric carcinoma AGS cells.
Sarcoma
Triiodothyronine stimulates steroid and VEGF production in murine Leydig cells via cAMP-PKA pathway.
Sarcoma
Triplet combination of BRAF, MEK and PD-1/PD-L1 blockade in melanoma: the more the better?
Sarcoma, Ewing
Erratum: miR-30d inhibits cell biological progression of Ewing's sarcoma by suppressing the MEK/ERK and PI3K/Akt pathways in vitro.
Sarcoma, Ewing
miR-30d inhibits cell biological progression of Ewing's sarcoma by suppressing the MEK/ERK and PI3K/Akt pathways
Scleroderma, Systemic
Erratum to: Thrombospondin 1 is a key mediator of transforming growth factor b-mediated cell contractility in systemic sclerosis via a mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK)-dependent mechanism.
Scleroderma, Systemic
Thrombospondin 1 is a key mediator of transforming growth factor beta-mediated cell contractility in systemic sclerosis via a mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK)-dependent mechanism.
Seizures
Formation of a tumour necrosis factor receptor 1 molecular scaffolding complex and activation of apoptosis signal-regulating kinase 1 during seizure-induced neuronal death.
Sepsis
Endothelial MKK3 is a critical mediator of lethal murine endotoxemia and acute lung injury.
Sepsis
Phosphorylation of Extracellular Signal-Regulated Kinase (ERK)-1/2 Is Associated with the Downregulation of Peroxisome Proliferator-Activated Receptor (PPAR)-? during Polymicrobial Sepsis.
Skin Neoplasms
3-Deoxysappanchalcone Inhibits Skin Cancer Proliferation by Regulating T-Lymphokine-Activated Killer Cell-Originated Protein Kinase in vitro and in vivo.
Skin Neoplasms
The mitogen-activated protein kinase kinase 4 has a pro-oncogenic role in skin cancer.
Sleep Deprivation
Influence of sleep deprivation on expression of MKK4 and c-fos in the mandibular condylar cartilage of rats.
Small Cell Lung Carcinoma
Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy.
Spinal Cord Injuries
Age-dependent autophagy induction after injury promotes axon regeneration by limiting NOTCH.
Spinal Cord Injuries
An injectable, self-healing, electroconductive extracellular matrix-based hydrogel for enhancing tissue repair after traumatic spinal cord injury.
Spinal Cord Injuries
Type I Interferon Inhibits Astrocytic Gliosis and Promotes Functional Recovery after Spinal Cord Injury by Deactivation of the MEK/ERK Pathway.
Squamous Cell Carcinoma of Head and Neck
Development and validation of a novel survival model for head and neck squamous cell carcinoma based on autophagy-related genes.
Squamous Cell Carcinoma of Head and Neck
Fibroblast growth factor receptor 3-mediated reactivation of ERK signaling promotes head and neck squamous cancer cell insensitivity to MEK inhibition.
Squamous Cell Carcinoma of Head and Neck
Kinin b2 receptor mediates induction of cyclooxygenase-2 and is overexpressed in head and neck squamous cell carcinomas.
Squamous Cell Carcinoma of Head and Neck
MEK Inhibitor PD-0325901 Overcomes Resistance to PI3K/mTOR Inhibitor PF-5212384 and Potentiates Antitumor Effects in Human Head and Neck Squamous Cell Carcinoma.
Squamous Cell Carcinoma of Head and Neck
Overexpression of integrin ?v facilitates proliferation and invasion of oral squamous cell carcinoma cells via MEK/ERK signaling pathway that is activated by interaction of integrin ?v?8 with type ? collagen.
Squamous Cell Carcinoma of Head and Neck
Overexpression of mitogen-activated protein kinase kinase 4 and nuclear factor-kappaB in laryngeal squamous cell carcinoma: a potential indicator for poor prognosis.
Squamous Cell Carcinoma of Head and Neck
Regulation of cisplatin-resistant head and neck squamous cell carcinoma by the SRC/ETS-1 signaling pathway.
Squamous Cell Carcinoma of Head and Neck
[The relationship between expression of mitogen-activated protein kinase kinase 4 and metastasis in oral squamous cell carcinoma].
Starvation
A Caenorhabditis elegans MAP kinase kinase, MEK-1, is involved in stress responses.
Starvation
A phosphatidylinositol 3-kinase inhibitor induces a senescent-like growth arrest in human diploid fibroblasts.
Starvation
Colorectal cancer-related mutant KRAS alleles function as positive regulators of autophagy.
Starvation
Inhibition of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase enhances chemotherapeutic effects on H460 human non-small cell lung cancer cells through activation of apoptosis.
Starvation
LIN-35/Rb causes starvation-induced germ cell apoptosis via CED-9/Bcl2 downregulation in Caenorhabditis elegans.
Starvation
Noxa upregulation by oncogenic activation of MEK/ERK through CREB promotes autophagy in human melanoma cells.
Starvation
Onset of gluconate-H+ symport in Schizosaccharomyces pombe is regulated by the kinases Wis1 and Pka1, and requires the gti1+ gene product.
Starvation
PI3K/Akt and MAPK pathways evoke activation of FoxO transcription factor to undergo neuronal apoptosis in brain of the silkworm Bombyx mori (Lepidoptera: Bombycidae).
Starvation
The fission yeast stress-responsive MAPK pathway promotes meiosis via the phosphorylation of Pol II CTD in response to environmental and feedback cues.
Status Epilepticus
Peroxisome Proliferator-Activated Receptor ? Coactivator 1? Activates Vascular Endothelial Growth Factor That Protects Against Neuronal Cell Death Following Status Epilepticus through PI3K/AKT and MEK/ERK Signaling.
Stomach Diseases
Helicobacter pylori cytotoxin-associated gene A protein upregulates ?-enolase expression via Src/MEK/ERK pathway: implication for progression of gastric cancer.
Stomach Neoplasms
ALOX5-5-HETE promotes gastric cancer growth and alleviates chemotherapy toxicity via MEK/ERK activation.
Stomach Neoplasms
Bone morphogenetic protein 2 mediates epithelial-mesenchymal transition via AKT and ERK signaling pathways in gastric cancer.
Stomach Neoplasms
Cellular prion protein promotes invasion and metastasis of gastric cancer.
Stomach Neoplasms
Dynamic reprogramming of signaling upon met inhibition reveals a mechanism of drug resistance in gastric cancer.
Stomach Neoplasms
ERK inhibition enhances TSA-induced gastric cancer cell apoptosis via NF-?B-dependent and Notch-independent mechanism.
Stomach Neoplasms
Exosomes Released by Gastric Cancer Cells Induce Transition of Pericytes Into Cancer-Associated Fibroblasts.
Stomach Neoplasms
G protein subunit ? q regulates gastric cancer growth via the p53/p21 and MEK/ERK pathways.
Stomach Neoplasms
Helicobacter pylori induces Snail expression through ROS-mediated activation of Erk and inactivation of GSK-3? in human gastric cancer cells.
Stomach Neoplasms
Human gastrin mRNA expression up-regulated by Helicobacter pylori CagA through MEK/ERK and JAK2-signaling pathways in gastric cancer cells.
Stomach Neoplasms
Hyperactivation of MEK/ERK pathway by Ca2+ /calmodulin-dependent protein kinase kinase 2 promotes cellular proliferation by activating cyclin-dependent kinases and minichromosome maintenance protein in gastric cancer cells.
Stomach Neoplasms
Increased expression of mitogen-activated protein kinase and its upstream regulating signal in human gastric cancer.
Stomach Neoplasms
Inhibition of MEK blocks GRP78 up-regulation and enhances apoptosis induced by ER stress in gastric cancer cells.
Stomach Neoplasms
LAMC1 is related to the poor prognosis of patients with gastric cancer and facilitates cancer cell malignancies.
Stomach Neoplasms
Low expression of SPARC in gastric cancer-associated fibroblasts leads to stemness transformation and 5-fluorouracil resistance in gastric cancer.
Stomach Neoplasms
miR-199a Regulates the Tumor Suppressor Mitogen-Activated Protein Kinase Kinase Kinase 11 in Gastric Cancer.
Stomach Neoplasms
Pro-apoptotic role of the MEK/ERK pathway in ursodeoxycholic acid-induced apoptosis in SNU601 gastric cancer cells.
Stomach Neoplasms
Regulation of hepatocyte growth factor-mediated urokinase plasminogen activator secretion by MEK/ERK activation in human stomach cancer cell lines.
Stomach Neoplasms
Silibinin suppresses TNF-alpha-induced MMP-9 expression in gastric cancer cells through inhibition of the MAPK pathway.
Stomach Neoplasms
Stromal interaction molecule 1 plays an important role in gastric cancer progression.
Stomach Neoplasms
Truncation- and motif-based pan-cancer analysis reveals tumor-suppressing kinases.
Stroke
Activation of neuronal Ras-related C3 botulinum toxin substrate 1 (Rac1) improves post-stroke recovery and axonal plasticity in mice.
Stroke
Combination treatment with U0126 and rt-PA prevents adverse effects of the delayed rt-PA treatment after acute ischemic stroke.
Stroke
Ras-Related C3 Botulinum Toxin Substrate 1 Promotes Axonal Regeneration after Stroke in Mice.
Subarachnoid Hemorrhage
Blockade of the MEK/ERK pathway with a raf inhibitor prevents activation of pro-inflammatory mediators in cerebral arteries and reduction in cerebral blood flow after subarachnoid hemorrhage in a rat model.
Subarachnoid Hemorrhage
Improvement in neurological outcome and abolition of cerebrovascular endothelin B and 5-hydroxytryptamine 1B receptor upregulation through mitogen-activated protein kinase kinase 1/2 inhibition after subarachnoid hemorrhage in rats.
Tachycardia
Cilostazol Prevents Atrial Structural Remodeling through the MEK/ERK Pathway in a Canine Model of Atrial Tachycardia.
Tetanus
C-terminal fragment of tetanus toxin heavy chain activates Akt and MEK/ERK signalling pathways in a Trk receptor-dependent manner in cultured cortical neurons.
Thanatophoric Dysplasia
C-type natriuretic Peptide plasma levels are elevated in subjects with achondroplasia, hypochondroplasia, and thanatophoric dysplasia.
Thymoma
Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling.
Thymoma
Distinct roles for p42/p44 and p38 mitogen-activated protein kinases in the induction of IL-2 by IL-1.
Thymoma
Dual Inhibition of AKT and MEK Pathways Potentiates the Anti-Cancer Effect of Gefitinib in Triple-Negative Breast Cancer Cells.
Thymoma
Effects of phorbol ester on mitogen-activated protein kinase kinase activity in wild-type and phorbol ester-resistant EL4 thymoma cells.
Thymoma
PAQR3 suppresses the growth of non-small cell lung cancer cells via modulation of EGFR-mediated autophagy.
Thymoma
Protein phosphatase 3 differentially modulates vascular endothelial growth factor- and fibroblast growth factor 2-stimulated cell proliferation and signaling in ovine fetoplacental artery endothelial cells.
Thymoma
The Anti-Melanogenesis Effect of 3,4-Dihydroxybenzalacetone through Downregulation of Melanosome Maturation and Transportation in B16F10 and Human Epidermal Melanocytes.
Thymoma
Unmet needs in ovarian cancer: dividing histologic subtypes to exploit novel targets and pathways.
Thyroid Cancer, Papillary
Differential responses of human papillary thyroid cancer cell lines carrying the RET/PTC1 rearrangement or a BRAF mutation to MEK1/2 inhibitors.
Thyroid Cancer, Papillary
Downregulation of uPAR inhibits migration, invasion, proliferation, FAK/PI3K/Akt signaling and induces senescence in papillary thyroid carcinoma cells.
Thyroid Cancer, Papillary
Dual specificity phosphatase 6 as a predictor of invasiveness in papillary thyroid cancer.
Thyroid Cancer, Papillary
Leptin enhances migration of human papillary thyroid cancer cells through the PI3K/AKT and MEK/ERK signaling pathways.
Thyroid Cancer, Papillary
Sunitinib inhibits MEK/ERK and SAPK/JNK pathways and increases sodium/iodide symporter expression in papillary thyroid cancer.
Thyroid Cancer, Papillary
Synergistic inhibition of MEK/ERK and BRAF V600E with PD98059 and PLX4032 induces sodium/iodide symporter (NIS) expression and radioiodine uptake in BRAF mutated papillary thyroid cancer cells.
Thyroid Carcinoma, Anaplastic
Dual inhibition of mitogen-activated protein kinase kinase and mammalian target of rapamycin in differentiated and anaplastic thyroid cancer.
Thyroid Neoplasms
BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines.
Thyroid Neoplasms
Distinct genetic alterations in the mitogen-activated protein kinase pathway dictate sensitivity of thyroid cancer cells to mitogen-activated protein kinase kinase 1/2 inhibition.
Thyroid Neoplasms
Inhibitory effects of the mitogen-activated protein kinase kinase inhibitor CI-1040 on the proliferation and tumor growth of thyroid cancer cells with BRAF or RAS mutations.
Thyroid Neoplasms
Radioiodine-Refractory Thyroid Cancer: Molecular Basis of Redifferentiation Therapies, Management, and Novel Therapies.
Thyroid Neoplasms
Selective growth inhibition in BRAF mutant thyroid cancer by the mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244.
Thyroid Neoplasms
Synergistic inhibition of thyroid cancer by suppressing MAPK/PI3K/AKT pathways.
Toxemia
Highly predictive support vector machine (SVM) models for anthrax toxin lethal factor (LF) inhibitors.
Toxic Optic Neuropathy
Ocular Toxicity in Metastatic Melanoma Patients Treated With Mitogen-Activated Protein Kinase Kinase Inhibitors: A Case Series.
Toxic Optic Neuropathy
PD0325901, a mitogen-activated protein kinase kinase inhibitor, produces ocular toxicity in a rabbit animal model of retinal vein occlusion.
Triple Negative Breast Neoplasms
DHEA inhibits proliferation, migration and alters mesenchymal-epithelial transition proteins through the PI3K/Akt pathway in MDA-MB-231 cells.
Triple Negative Breast Neoplasms
High expression of MKK3 is associated with worse clinical outcomes in African American breast cancer patients.
Triple Negative Breast Neoplasms
Metalloprotease-dependent activation of EGFR modulates CD44(+)/CD24(-) populations in triple negative breast cancer cells through the MEK/ERK pathway.
Triple Negative Breast Neoplasms
Methylation-dependent MCM6 repression induced by LINC00472 inhibits triple-negative breast cancer metastasis by disturbing the MEK/ERK signaling pathway.
Triple Negative Breast Neoplasms
miR-125b inhibited epithelial-mesenchymal transition of triple-negative breast cancer by targeting MAP2K7.
Tuberculosis
Mitogen-activated protein kinases mediate Mycobacterium tuberculosis-induced CD44 surface expression in monocytes.
Tuberculosis
Mitogen-activated protein kinases mediate the production of B-cell lymphoma 2 protein by Mycobacterium tuberculosis in monocytes.
Tuberculosis
Mycobacterium tuberculosis H37Rv induces monocytic release of interleukin-6 via activation of mitogen-activated protein kinases: inhibition by N-acetyl-L-cysteine.
Tuberculosis
Role of mitogen-activated protein kinase pathways in the production of tumor necrosis factor-alpha, interleukin-10, and monocyte chemotactic protein-1 by Mycobacterium tuberculosis H37Rv-infected human monocytes.
Tuberculosis
Targeting Tuberculosis and HIV Infection-Specific Regulatory T Cells with MEK/ERK Signaling Pathway Inhibitors.
Tuberous Sclerosis
A non-canonical MEK/ERK signaling pathway regulates autophagy via regulating Beclin 1.
Tuberous Sclerosis
A subset of metastatic pancreatic ductal adenocarcinomas depends quantitatively on oncogenic Kras/Mek/Erk-induced hyperactive mTOR signalling.
Urinary Bladder Neoplasms
Inhibition of TPL2 by interferon-? suppresses bladder cancer through activation of PDE4D.
Urinary Bladder Neoplasms
MEK1 and MEK2 differentially regulate human insulin- and insulin glargine-induced human bladder cancer T24 cell proliferation.
Urinary Bladder Neoplasms
Stress-activated kinase pathway alteration is a frequent event in bladder cancer.
Urinary Bladder Neoplasms
The tumor-suppressor gene Nkx2.8 suppresses bladder cancer proliferation through upregulation of FOXO3a and inhibition of the MEK/ERK signaling pathway.
Uterine Cervical Neoplasms
Carvacrol induces cytotoxicity in human cervical cancer cells but causes cisplatin resistance: Involvement of MEK-ERK activation.
Uterine Cervical Neoplasms
LncRNA SNHG20 promotes cell proliferation and invasion via miR-140-5p-ADAM10 axis in cervical cancer.
Uterine Cervical Neoplasms
RACK1 promotes the invasive activities and lymph node metastasis of cervical cancer via galectin-1.
Uterine Cervical Neoplasms
SLP-2 inhibits cisplatin-induced apoptosis through MEK/ERK signaling and mitochondrial apoptosis pathway in cervical cancer cells.
Uterine Cervical Neoplasms
The Association Between -1304T>G Polymorphism in the Promoter of Mitogen-Activated Protein Kinase Kinase 4 Gene and the Risk of Cervical Cancer in Chinese Population.
Vaccinia
A mitogenic signal triggered at an early stage of vaccinia virus infection: implication of MEK/ERK and protein kinase A in virus multiplication.
Vaccinia
c-Jun integrates signals from both MEK/ERK and MKK/JNK pathways upon vaccinia virus infection.
Vaccinia
Viral exploitation of the MEK/ERK pathway - A tale of vaccinia virus and other viruses.
Vascular System Injuries
In vivo gene transfer: prevention of neointima formation by inhibition of mitogen-activated protein kinase kinase.
Virus Diseases
A mitogenic signal triggered at an early stage of vaccinia virus infection: implication of MEK/ERK and protein kinase A in virus multiplication.
Virus Diseases
c-Jun integrates signals from both MEK/ERK and MKK/JNK pathways upon vaccinia virus infection.
Virus Diseases
Investigation on the partial resistance of Cpkk2 knock out strain of Cryphonectria parasitica to Cryphonectria hypovirus 1 infection in presence of Geneticin and Geneticin resistance gene.
Virus Diseases
Isolation and expression analysis of an MAPKK gene from Fenneropenaeus chinensis in response to white spot syndrome virus infection.
Vitamin E Deficiency
Vitamin E deficiency impairs the somatostatinergic receptor-effector system and leads to phosphotyrosine phosphatase overactivation and cell death in the rat hippocampus.
Whooping Cough
A neuroactive steroid inhibits guinea pig airway sensory nerves via Maxi-K channel activation.
Whooping Cough
A role of protein kinase C mu in signalling from the human adenosine A1 receptor to the nucleus.
Whooping Cough
Activation of rat frizzled-1 promotes Wnt signaling and differentiation of mouse F9 teratocarcinoma cells via pathways that require Galpha(q) and Galpha(o) function.
Whooping Cough
Alpha2-adrenoceptors in opossum kidney cells couple to stimulation of mitogen-activated protein kinase independently of adenylyl cyclase inhibition.
Whooping Cough
beta-Migrating very low density lipoprotein (beta VLDL) activates smooth muscle cell mitogen-activated protein (MAP) kinase via G protein-coupled receptor-mediated transactivation of the epidermal growth factor (EGF) receptor: effect of MAP kinase activation on beta VLDL plus EGF-induced cell proliferation.
Whooping Cough
Biphasic modulation of intracellular Ca2+ concentration by interleukin-1beta in cortical synaptosomes: involvement of a pertussis toxin-sensitive G-protein and mitogen-activated protein kinase.
Whooping Cough
Conjugated linoleic acid induces human adipocyte delipidation: autocrine/paracrine regulation of MEK/ERK signaling by adipocytokines.
Whooping Cough
Coupling of serotonin 5-HT1B receptors to activation of mitogen-activated protein kinase (ERK-2) and p70 S6 kinase signaling systems.
Whooping Cough
Dual mechanisms for lysophospholipid induction of proliferation of human breast carcinoma cells.
Whooping Cough
Functional coupling of SSTR4, a major hippocampal somatostatin receptor, to adenylate cyclase inhibition, arachidonate release and activation of the mitogen-activated protein kinase cascade.
Whooping Cough
Human adenosine A1 receptor and P2Y2-purinoceptor-mediated activation of the mitogen-activated protein kinase cascade in transfected CHO cells.
Whooping Cough
Human Salivary Histatin-1 Promotes Osteogenic Cell Spreading on Both Bio-Inert Substrates and Titanium SLA Surfaces.
Whooping Cough
Idiopathic pulmonary fibrosis fibroblasts migrate and proliferate to CC chemokine ligand 21.
Whooping Cough
Nerve growth factor stimulation of p42/p44 mitogen-activated protein kinase in PC12 cells: role of G(i/o), G protein-coupled receptor kinase 2, beta-arrestin I, and endocytic processing.
Whooping Cough
P2Y receptor-mediated inhibition of tumor necrosis factor alpha -stimulated stress-activated protein kinase activity in EAhy926 endothelial cells.
Whooping Cough
PAR1 and PAR2 couple to overlapping and distinct sets of G proteins and linked signaling pathways to differentially regulate cell physiology.
Whooping Cough
Prosaptide activates the MAPK pathway by a G-protein-dependent mechanism essential for enhanced sulfatide synthesis by Schwann cells.
Whooping Cough
Prostaglandin D2 induces the production of human beta-defensin-3 in human keratinocytes.
Whooping Cough
Regulation of p42/p44 mitogen-activated protein kinase by the human adenosine A3 receptor in transfected CHO cells.
Whooping Cough
Regulation of Ras.GTP loading and Ras-Raf association in neonatal rat ventricular myocytes by G protein-coupled receptor agonists and phorbol ester. Activation of the extracellular signal-regulated kinase cascade by phorbol ester is mediated by Ras.
Whooping Cough
Stimulation of mitogen activated protein kinase by LDL and oxLDL in human U-937 macrophage-like cells.
Whooping Cough
The beta1-adrenergic receptor mediates extracellular signal-regulated kinase activation via Galphas.
Whooping Cough
The high mobility group (HMG) boxes of the nuclear protein HMG1 induce chemotaxis and cytoskeleton reorganization in rat smooth muscle cells.
Whooping Cough
Xaliproden (SR57746A) induces 5-HT1A receptor-mediated MAP kinase activation in PC12 cells.
Wiskott-Aldrich Syndrome
Gene expression pattern in human brain endothelial cells in response to Neisseria meningitidis.
Yellow Fever
MEK/ERK activation plays a decisive role in yellow fever virus replication: implication as an antiviral therapeutic target.
Yellow Fever
The small molecule AZD6244 inhibits dengue virus replication in vitro and protects against lethal challenge in a mouse model.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
ORGANISM
COMMENTARY
LITERATURE
UNIPROT
SEQUENCE DB
SOURCE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SOURCE TISSUE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
SOURCE
high expression level of MKK4, expression in adult and fetal brain
brenda
high expression level of MKK4, expression in adult and fetal liver
brenda
human pancreatic, lung, breast, testicle, and colorectal cancer cell lines
brenda
additional information
additional information
ubiquitous expression of MKK4 in adult tissues
brenda
additional information
ubiquitous expression of MKK4 in adult tissues
brenda
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
LOCALIZATION
ORGANISM
UNIPROT
COMMENTARY
GeneOntology No.
LITERATURE
SOURCE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
GENERAL INFORMATION
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
malfunction
MKK4 is highly mutated and has a pro-oncogenic role in cancers of pancreatic, breast, colon, prostate, skin, and laryngeal squamous cell. Strong association between -1304T>G (rs3826392) polymorphism in the promoter of MKK4 gene and a decreased risk of sporadic colorectal cancer in a southern Chinese population, overview
metabolism
MKK4 belongs to MAPK pathways known to have involvement in the regulation of apoptosis, inflammation, and tumorigenesis
physiological function
additional information
the transient state of apo npMAP2K4 exists between the canonical kinase fold and the aggregation state. The ATP molecule under physiological conditions allows the transient conformation to rapidly assume the canonical kinase fold but the depletion of ATP under conditions of low levels of bioactivity perhaps enhances the transition to the aggregation state
physiological function
mitogen-activated protein kinase kinase 4 (MAP2K4) plays a crucial role in the stress-activated signal cascade and is enzymatically regulated by ligand or substrate binding, and/or post-translational modification
physiological function
the enzyme plays a key role in multiple physiologic and pathophysiologic processes such as inflammation and tumor suppression
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
UNIPROT
ENTRY NAME
ORGANISM
NO. OF AA
NO. OF TRANSM. HELICES
MOLECULAR WEIGHT[Da]
SOURCE
SEQUENCE
LOCALIZATION PREDICTION
The reliability class of the localization prediction ranges from 1 (very reliable) to 5 (not reliable).
The reliability class of the localization prediction ranges from 1 (very reliable) to 5 (not reliable). MP2K4_HUMAN
399
0
44288
Swiss-Prot
other Location (Reliability: 2)
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
PDB
SCOP
CATH
UNIPROT
ORGANISM
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
MOLECULAR WEIGHT
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SUBUNIT
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
?
x * 37419 , apo npMAP2K4, sequence calculation, x * 37950, npMAP2K4/ANP complex, sequence calculation, x * 39000 , apo npMAP2K4, light scattering, x * 40000, npMAP2K4/ANP complex, light scattering
additional information
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
POSTTRANSLATIONAL MODIFICATION
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
phosphoprotein
MKKs are activated by phopshorylation through MKKKs, e.g. MEKK, MLK, TAK1, Ask1, or TPL2, MKK4 is phopshorylated at serine and threonine residues in the SIAKT motif
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
CRYSTALLIZATION (Commentary)
ORGANISM
UNIPROT
LITERATURE
molecular dynamics simulation of inhibitors ZINC06091752-MKK4 and ZINC00391412-MKK4 complexes reveals stable and potential binding modes. Residues Lys 231 and Ser 233 show hydrogen bonding between ligand and receptor whereas Lys 131 and Lys 231 making ionic interactions between ligand and MKK4
purified recombinant apo MAP2K4-KD or in complex with ANP, 15 mg/ml protein in a solution containing 20 mM Tris-HCl, pH 7.5, 100 mM NaCl, 10% glycerol and 10 mM DTT for the apoenzyme, and 2 mM ANP and MgCl2 additional for the npMAP2K4/ANP complex, mixing with reservoir solution containing 0.2 M ammonium acetate, 22-25% w/v PEG 3350 and 0.1 M HEPESNaOH, pH 7.0, 20°C, X-ray diffraction structure determination and analysis at 3.5 A resolution
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
PROTEIN VARIANTS
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
additional information
association between -1304T>G (rs3826392) polymorphism in the promoter of MKK4 gene and the risk of sporadic colorectal cancer in a southern Chinese population
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
CLONED (Commentary)
ORGANISM
UNIPROT
LITERATURE
gene MKK4, maps to chromosome 17p11.2 and encodes a 399-amino acid protein in humans spans over 120 kb and consists of 11 exons, for identification of the genetic effects of the -1304T>G polymorphism on cancer risk, a meta-analysis composed of the publications evaluating the association between the -1304T>G polymorphism and risk of cancer is performed, overview
MKK4, DNA and amino acid sequence determination, the gene is located on chromosome 17
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
REF.
AUTHORS
TITLE
JOURNAL
VOL.
PAGES
YEAR
ORGANISM (UNIPROT)
PUBMED ID
SOURCE
Derijard, B.; Raingeaud, J.; Barrett, T.; Wu, I.H.; Han, J.; Ulevitch, R.J.; Davis, R.J.
Independent human MAP-kinase signal transduction pathways defined by MEK and MKK isoforms
Science
267
682-685
1995
Homo sapiens (P45985), Homo sapiens (P46734)
brenda
Vitale, G.; Bernardi, L.; Napolitani, G.; Mock, M.; Montecucco, C.
Susceptibility of mitogen-activated protein kinase kinase family members to proteolysis by anthrax lethal factor
Biochem. J.
352
739-745
2000
Homo sapiens (O14733), Homo sapiens (P36507), Homo sapiens (P45985), Homo sapiens (P52564), Homo sapiens (Q02750)
brenda
Lin, A.; Minden, A.; Martinetto, H.; Claret, F.X.; Lange-Carter, C.; Mercurio, F.; Johnson, G.L.; Karin, M.
Identification of a dual specificity kinase that activates the Jun kinases and p38-Mpk2
Science
268
286-290
1995
Homo sapiens (P45985)
brenda
Su, G.H.; Hilgers, W.; Shekher, M.C.; Tang, D.J.; Yeo, C.J.; Hruban, R.H.; Kern, S.E.
Alterations in pancreatic, biliary, and breast carcinomas support MKK4 as a genetically targeted tumor suppressor gene
Cancer Res.
58
2339-2342
1998
Homo sapiens (P45985)
brenda
Whitmarsh, A.J.; Davis, R.J.
Role of mitogen-activated protein kinase kinase 4 in cancer
Oncogene
26
3172-3184
2007
Drosophila melanogaster, Homo sapiens, Homo sapiens (O14733), Homo sapiens (P45985), Mus musculus, Mus musculus (P47809), Mus musculus (Q8CE90), Rattus norvegicus, Xenopus laevis
brenda
Matsumoto, T.; Kinoshita, T.; Kirii, Y.; Tada, T.; Yamano, A.
Crystal and solution structures disclose a putative transient state of mitogen-activated protein kinase kinase 4
Biochem. Biophys. Res. Commun.
425
195-200
2012
Homo sapiens (P45985)
brenda
Geng, P.; Ou, J.; Xie, G.; Li, J.; Zhao, X.; Xiang, L.; Liao, Y.; Wang, N.; Liang, H.
Mitogen-activated protein kinase kinase 4 gene polymorphism and cancer risk
Medicine (Baltimore)
94
e0938
2015
Homo sapiens (P45985)
brenda
Khanam, U.; Malik, B.; Mathur, P.; Rathi, B.
Identification of novel inhibitors for mitogen-activated protein kinase kinase 4 by virtual screening and molecular dynamics simulation techniques
Int. J. Pharm. Pharm. Sci.
8
262-268
2016
Homo sapiens (P45985)
-
brenda
EXTERNAL LINKS (specific for EC-Number 2.7.12.2)
Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.
Release 2023.1 (January 2023)
About BRENDA
Social media
Help
Survey
Download
Contribution
Legal
Curated at
Member of
